Compositions and methods for inhibiting gene expression of factor XII

ABSTRACT

RNA interference (RNAi) triggers for inhibiting the expression of Factor XII (F12) gene through the mechanism of RNA interference are described. Pharmaceutical compositions comprising one or more F12 RNAi triggers together with one or more excipients capable of delivering the RNAi trigger(s) to a liver cell in vivo are also described. Delivery of the F12 RNAi trigger(s) to liver cells in vivo provides for inhibition of F12 gene expression and treatment of angioedema, including hereditary angioedema (HAE) and venous thromboembolism (VTE), and diseases associated with angioedema.

PRIORITY

The present application is a divisional of U.S. patent application Ser. No. 15/071,634, filed Mar. 16, 2016, now U.S. Pat. No. 9,803,205, which claims the benefit of U.S. Provisional Patent Application No. 62/134,186, filed Mar. 17, 2015, the contents of each of which are incorporated herein in their entirety.

BACKGROUND

Factor XII, a serine protease expressed predominantly in the liver and found in blood, has dual functions in both the intrinsic coagulation pathway and the kinin-kallikrein system. The kinin-kallikrein system plays a role in inflammation, blood pressure control, coagulation and pain. The active form of Factor XII (also referred to as FXII, F12, or Hageman factor) binds and cleaves both Factor XI in the coagulation cascade and prekallikrein in the kinin-kininogen system, yielding the active forms FXI and kallikrein, respectively.

Patients with complete loss of F12 do not present with a bleeding disorder. Further, mice lacking F12 by gene knockout are protected from thrombosis (Renne et al JEM 2005, 202:271-281). The thrombo-protective effect of F12 depletion was also observed in F12-inhibitory antibody treated mice, rabbits and primates (Larsson et al. ScienceTransMed, 2014 6:22ra17). Current treatments for thromboembolic events target enzymes downstream in the coagulation pathway that are critical for controlling injury-related blood loss through fibrin formation, and therefore, treatment with these agents have the downside of potential life-threatening hemorrhage.

Hereditary angioedema (HAE) is a rare disease characterized by recurrent episodes of severe swelling. The most common areas of the body to develop swelling are the limbs, face, intestinal tract, and airway. Episodes may be spontaneous or be induced by physical trauma or stress. Laryngeal (airway) edema can be life-threatening, as it can lead to death by asphyxiation.

The majority of HAE treatment options are for administration at the time of attack, focusing on either C1INH replacement, inhibiting kallikrein, or signaling through the bradykinin 2 receptor. Currently, the only long-term prophylactic treatment is C1INH replacement therapy. Because both thrombosis (including venous thromboembolism, VTE) and angioedema are thought to occur through overactive signaling of their respective pathways, inhibition of F12 gene expression would be useful in preventing both types of disorders.

SUMMARY

Described herein are F12 RNA interference (RNAi) triggers and compositions thereof for inhibiting expression of the F12 gene in vivo. The F12 RNAi triggers described herein can be used for treating diseases caused by over-activation of the kinin-kallikrein and intrinsic coagulation pathways, such as HAE and thrombosis.

Described herein are Factor XII (also termed Factor 12, F12, or Hageman factor) gene-specific RNA interference (RNAi) trigger molecules (also termed RNAi agent, RNAi trigger, or trigger) able to selectively and efficiently decrease expression of F12. Use of the described. F12 RNAi triggers can be used in methods for therapeutic treatment of diseases associated with angioedema, including but not limited to: hereditary angioedema (HAE), acquired angioedema (AAE), ACE inhibitor associated angioedema, allergic angioedema, nonhistaminergic angioedema (INAE), idiopathic angioedema, thrombosis, venous thromboembolism (VTE), thrombotic occlusive disease, pen-operative venous occlusive disease prophylaxis. Use of the described F12 RNAi triggers further provides methods for the treatment and prevention of venous occlusive disease such as deep venous thrombosis or pulmonary embolism, and treatment or prevention of arterial thromboembolic disease. Such methods comprise administration of an F12 RNAi trigger as described herein to a subject, e.g., a human or animal subject.

RNAi triggers for inhibiting expression of the human F12 gene (F12 RNAi triggers) are described herein. Each RNAi trigger includes at least a sense strand and an antisense strand. The sense strand and the antisense strand can be partially, substantially, or fully complementary to each other. The length of the RNAi trigger sense and antisense strands described herein each can be 16 to 30 nucleotides in length. In some embodiments, the sense and antisense strands each can be 17 to 26 nucleotides in length. The sense and antisense strands can be either the same length or different lengths. In some embodiments, both the sense and antisense strands each can be 26 nucleotides in length. In other embodiments, the sense strand is about 23 nucleotides in length while the antisense strand is about 21 nucleotides in length. In some embodiments, the sense and antisense strands are 17 nucleotides in length. The RNAi triggers described herein, upon delivery to a cell expressing the F12 gene, inhibit the expression of the F12 gene in vitro or in vivo.

A sense strand of the F12 RNAi triggers described herein contains a nucleotide sequence having at least 90% identity to a sequence in an F12 mRNA. In some embodiments, the nucleotide sequence having at least 90% identity to a sequence in an F12 mRNA is 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26 nucleotides in length. An antisense strand of the F12 RNAi triggers described herein contains a nucleotide sequence having at least 90% complementary to a sequence in an F12 mRNA. In some embodiments, the nucleotide sequence having at least 90% complementarity to a sequence in an F12 mRNA is 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26 nucleotides in length. Examples of F12 RNAi trigger sense strands and antisense strands that can be used in a F12 RNAi trigger are provided in Tables 1-3.

In some embodiments, one or more F12 RNAi triggers are delivered to target cells or tissues using any oligonucleotide delivery technology known in the art. Nucleic acid delivery methods include, but are not limited to, by encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres, proteinaceous vectors or DPCs (see, for example WO 2000/053722, WO 2008/0022309, WO 2011/104169, and WO 2012/083185, each of which is incorporated herein by reference). In some embodiments, an F12 RNAi trigger is covalently linked to a targeting group. The targeting group can include a cell receptor ligand, such as a galactose cluster, including a galactose cluster comprised of an N-acetyl-galactosamine trimer, or a hydrophobic group, such as a cholesterol. In some embodiments, an F12 RNAi trigger is provided with an in vivo delivery compound or vehicle. The delivery compound or vehicle can include a polymer, such as a melittin-like peptide (MLP) delivery polymer or copolymer. In some embodiments, an F12 RNAi trigger can be covalently linked to a delivery compound or vehicle.

The F12 RNAi triggers or pharmaceutical compositions containing one or more F12 RNAi triggers can be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. In some embodiments, administration is topical (e.g., by a transdermal patch), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer: intratracheal, intranasal, epidermal and transdermal, oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; subdermal, e.g., via an implanted device; or intracranial, e.g., by intraparenchymal, intrathecal or intraventricular, administration.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1. Graphs showing: A. Serum F12 protein levels in wild-type mice following administration of 2 mg/kg RNAi trigger with 2 mg/kg MLP delivery polymer, and B. Serum F12 protein levels in wild-type mice following administration of 4 mg/kg RNAi trigger with 4 mg/kg MLP delivery polymer. mF12 levels were normalized to day 1 and saline control.

FIG. 2. Graph showing serum F12 protein levels in wild-type mice following administration of 1, 2, or 4 mg/kg F12 RNAi trigger dosed 1:1 wt./wt. with MLP delivery polymer. mF12 levels were normalized to day 1 and saline control.

FIG. 3. Graph showing serum F12 protein levels in wild-type mice following a single subcutaneous (SQ) administration of 1, 3, or 10 mg/kg RNAi trigger on day 1. mF12 levels were normalized to day 1 and saline control.

FIG. 4. Graph showing serum F12 protein levels in wild-type mice following SQ administration of 1 or 2 mg/kg RNAi trigger on days 1, 8 and 15. mF12 levels were normalized to day 1 and saline control.

FIG. 5. Graph showing serum F12 protein levels in cynomolgus monkeys following administration of a single 2 mg/kg RNAi trigger dosed 1:1 wt./wt. with MLP delivery polymer on day 1. cF12 levels were normalized to day 1. F12 RNAi trigger AD01001 is shown in black circles, F12 RNAi trigger AD01520 is shown in gray squares. Standard Deviation is displayed as error bars graphed above the mean.

FIG. 6. Graph showing serum F12 protein levels in cynomolgus monkeys following administration of 2 mg/kg RNAi trigger dosed 1:1 with MLP delivery polymer on day 1, 29, 57, and 85. cF12 levels were normalized to day 1. F12 RNAi trigger AD01001 is shown in black circles, F12 RNAi trigger AD01520 is shown in gray squares. Standard deviation is displayed as error bars graphed above the mean.

FIG. 7. Graph showing serum F12 protein levels in cynomolgus monkeys following administration of 4 mg/kg F12 RNAi trigger AD01520 dosed 1:1 with MLP delivery polymer on day 1, 29, 57, 85, and 121. cF12 levels were normalized to day 1. cF12 levels are graphed in gray squares, aPTT is shown in black circles. Standard deviation is displayed as error bars graphed above the mean.

FIG. 8. Graph showing serum F12 protein levels in cynomolgus monkeys following single subcutaneous administration of 3 mg/kg or 10 mpg of F12 RNAi trigger AD02562 on day 1. cF12 levels were normalized to day 1.3 mg/kg dose is shown in gray squares, 10 mg/kg dose is shown in black circles. Standard deviation is displayed as error bars graphed above the mean.

FIG. 9. Graph showing change in rat paw volume after carrageenan injection in rats treated seven days prior to carrageenan injection with either saline, or 8 mg/kg F12 RNAi trigger AD01520 with 8 mg/kg MLP delivery polymer. A. Shows change in paw volume in treated vs. saline animals. B. Shows level of knockdown in treated vs. saline animals.

FIG. 10. Graph showing: A. Time to occlusion after ferric chloride challenge in mice treated seven days prior to ferric chloride challenge with either saline, or 8 mg/kg F12 RNAi trigger AD01520 with 8 mg/kg MLP delivery polymer. All animals in the RNAi trigger-treated group did not occlude during the time of the experiment (30 minutes, noted by dashed line). B. Knockdown in animals treated with F12 RNAi trigger AD01520 with MLP delivery polymer, compared to animals treated with saline.

FIG. 11. Graphs showing: A. Bleeding times of mice treated with either saline, 8 mg/kg F7-targeted RNAi trigger with 8 mg/kg MLP delivery polymer, or 8 mg/kg F12 RNAi trigger AD01520 with 8 mg/kg MLP delivery polymer. B. F12 protein levels. C. F7 protein levels.

DETAILED DESCRIPTION

Described herein are RNAi triggers for inhibiting expression of the Factor XII gene (referred to herein as F12 RNAi triggers). An F12 RNAi triggers each comprise a sense strand and an antisense strand. The sense strand and the antisense strand are partially, substantially, or fully complementary to each other. In some embodiments, the length of the herein described RNAi trigger sense and antisense strands are independently 16 to 30 nucleotides in length. In some embodiments, the length of the herein described RNAi trigger sense and antisense strands are independently 17 to 26 nucleotides in length. In some embodiments, the herein described RNAi trigger sense and antisense strands are independently 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26 nucleotides in length. The sense and antisense strands can be either the same length or they can be different lengths. In some embodiments, both the sense and antisense strands are each 26 nucleotides in length. In other embodiments, the sense strand is about 23 nucleotides in length while the antisense strand is about 21 nucleotides in length. In other embodiments, the sense and antisense strands are independently 17-21 nucleotides in length. Examples of nucleotide sequences used in forming F12 RNAi trigger molecules are provided in Tables 1-3.

RNAi triggers include, but are not limited to: short interfering RNAs (siRNAs), double-strand RNAs (dsRNA), micro RNAs (miRNAs), short hairpin RNAs (shRNA), and dicer substrates (U.S. Pat. No. 8,084,599 8,349,809 and 8,513,207). The RNAi triggers described herein, upon delivery to a cell expressing the F12 gene, inhibit or knockdown expression of F12 gene in vitro or in vivo through the biological process of RNA interference (RNAi).

An F12 RNAi trigger comprises a sense strand and an antisense strand each containing a core sequence of 16-23 nucleobases in length. An antisense strand core sequence is 100% (perfectly) complementary or at least 90% (substantially) complementary to a nucleotide sequence (sometimes referred to, e.g. as a target sequence) present in the F12 mRNA. A sense strand core sequence is 100% (perfectly) complementary or at least 90% (substantially) complementary to a sequence in the antisense strand and thus the sense strand core sequence is perfectly identical or at least 90% identical to a nucleotide sequence (target sequence) present in the F12 mRNA. A sense strand core sequence can be the same length as a corresponding antisense core sequence or it can be a different length. In some embodiments, the antisense strand core sequence is 17, 18, 19, 20, 21, 22, or 23 nucleotides in length. In some embodiments, the sense strand core sequence is 17, 18, 19, 20, 21, 22, or 23 nucleotides in length.

The F12 RNAi trigger sense and antisense strands typically anneal to form a duplex. Within the complementary duplex region, the sense strand core sequence is at least 90% complementary or 100% complementary to the antisense core sequence. In some embodiments, the sense strand core sequence contains a sequence of at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21 nucleotides that is at least 90% or 100% complementary to a corresponding 16, 17, 18, 19, 20, or 21 nucleotide sequence of the antisense strand core sequence (i.e., the sense strand and antisense core sequences of an F12 RNAi trigger have a region of at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21 nucleotides that is at least 90% base paired or 100% base paired.)

The sense strand and/or the antisense strand may optionally and independently contain an additional 1, 2, 3, 4, 5, or 6 nucleotides (extension) at the 3′ end, the 5′ end, or both the 3′ and 5′ ends of the core sequences. The antisense strand additional nucleotides, if present, may or may not be complementary to the corresponding sequence in the F12 mRNA. The sense strand additional nucleotides, if present, may or may not be identical to the corresponding sequence in the F12 mRNA. The antisense strand additional nucleotides, if present, may or may not be complementary to the corresponding sense strands additional nucleotides, if present.

As used herein, an extension comprises 1, 2, 3, 4, 5, or 6 nucleotides at the 5′ and/or 3′ end of the sense strand core sequence and/or antisense strand core sequence. The extension nucleotides on a sense strand may or may not be complementary to nucleotides, either core sequence nucleotides or extension nucleotides, in the corresponding antisense strand. Conversely, the extension nucleotides on an antisense strand may or may not be complementary to nucleotides, either core sequence nucleotides or extension nucleotides, in the corresponding sense strand. In some embodiments, both the sense strand and the antisense strand of an RNAi trigger contain 3′ and 5′ extensions. In some embodiments, one or more of the 3′ extension nucleotides of one strand base pairs with one or more 5′ extension nucleotides of the other strand. In other embodiments, one or more of 3′ extension nucleotides of one strand do not base pair with one or more 5′ extension nucleotides of the other strand. In some embodiments, an F12 RNAi trigger has an antisense strand having a 3′ extension and a sense strand having a 5′ extension.

In some embodiments an F12 RNAi trigger molecule comprises an antisense strand having a 3′ extension of 1, 2, 3, 4, 5, or 6 nucleotides in length. In other embodiments, an F12 RNAi trigger molecule comprises an antisense strand having a 3′ extension of 1, 2, or 3 nucleotides in length. In some embodiments, one or more of the antisense strand extension nucleotides comprise uracil or thymidine nucleotides or nucleotides which are complementary to the corresponding F12 mRNA sequence. In some embodiments, the antisense strand extension can be, but is not limited to: uAu, uGu, udTsdT, usdTsdT, UfAu, Aua, Afsusa, UAU, uAfu, uau, udAu, uscu, usgu, uscsu, cAu, aUa, aua, u(invdA)u, cag, agu, gcg, caa, usasu, uAMTM, usTMsAM (each listed 5′ to 3′, notation is the same as for Tables 2 and 3).

In some embodiments, an F12 RNAi trigger molecule comprises an antisense strand having a 5′ extension of 1, 2, 3, 4, or 5 nucleotides in length. In other embodiments, an F12 RNAi trigger molecule comprises an antisense strand having a 5′ extension of 1 or 2 nucleotides in length.

In some embodiments, one or more of the antisense strand extension nucleotides comprises uracil or thymidine nucleotides or nucleotides which are complementary to the corresponding F12 mRNA sequence. In other embodiments, the antisense strand extension includes or consists of dA, dT, pdT, vpdT, or u, wherein dA and di represent deoxyadenosine and deoxythimidine nucleotides respectively, pdT represents a deoxythimidine nucleotide having a 5′ phosphosphate, vpdT represents a vinylphosphonate deoxythimidine nucleotide, and u represents a 2′-OMe modified uracil nucleotide. An antisense strand may have any of the 3′ extensions described above in combination with any of the 5′ antisense strand extensions described, if present.

In some embodiments, an F12 RNAi trigger molecule comprises a sense strand having a 3′ extension of 1, 2, 3, 4, or 5 nucleotides in length. In some embodiments, one or more of the sense strand extension nucleotides comprises adenosine, uracil, or thymidine nucleotides, AT dinucleotide, or nucleotides which correspond to nucleotides in the F12 mRNA sequence. In other embodiments, the 3′ sense strand extension consists of Af, invdA, invdT, A(invdT), Af(invdT), U(invdT), Uf(invdT), AfAbuAu, dTdT, or dTsdT, wherein Af and Uf represent 2′-fluoro adenosine and uracil nucleotides respectively, invdA and invdT represent 3′-3′ linked (inverted) deoxyadenosine and deoxythimidine nucleotides respectively, Ab represents an abasic ribose, u represents a 2′-OMe modified uracil nucleotide, dT represents a deoxythimidine nucleotide, sdT represents a deoxythimidine nucleotide having a 5′ phosphorothioate, and U and A represent uracil and adenosine ribonucleotides.

In some embodiments, an F12 RNAi trigger molecule comprises a sense strand having a 5′ extension of 1, 2, 3, 4, 5, or 6 nucleotides in length. In some embodiments, one or more of the sense strand extension nucleotides comprise uracil or adenosine nucleotides or nucleotides which correspond to nucleotides in the F12 tnRNA sequence. In some embodiments, the sense strand 5′ extension can be, but is not limited to: uAuAus, uAuAu, UAUUAGfs, UfaUfaA, uauaA, AUAUU, AfuAfuU, auauU, uaUfau, uAuA(U_(UNA)), uauau, udAudAu, uuAga, uuAuu, uuGAu, uuaga, uAuga, aUaGas, uauaus, uAuaas, udAuau, adTaga, auaga, u(invdA)uau, gacau, ugaau, gcgau, uauga, uugga, auaga (each listed 5′ to 3′, notation is the same as for Tables 2 and 3). A sense strand may have a 3′ extension and/or a 5′ extension.

Unmodified F12 RNAi trigger sense strand and antisense strand sequences are provided in Table 1. Note that in each row, the antisense strand is not necessarily shown with the corresponding (complementary) sense strand. In forming F12 RNAi triggers, each of the nucleotides in each of the sequences listed in Table 1 may be a modified nucleotide.

TABLE 1 Unmodified F12 RNAi trigger antisense strand and sense strand sequences. SEQ ID SEQ ID No. Antisense Sequence (5′ → 3′) No. Sense Sequence (5′ → 3′) 1 TGGUGGUAGCACACCAGGGTT 225 CCCUGGUGUGCUACCACCAT 2 TGGGUGGUAGCACACCAGGTT 226 CCUGGUGUGCUACCACCCAT 3 TGGGGUGGUAGCACACCAGTT 227 CUGGUGUGCUACCACCCCAT 4 TCACUUUCUUGGGCUCCAATT 228 UUGGAGCCCAAGAAAGUGAT 5 TUCACUUUCUUGGGCUCCATT 229 UGGAGCCCAAGAAAGUGAAT 6 TUUCACUUUCUUGGGCUCCTT 230 GGAGCCCAAGAAAGUGAAAT 7 TUUUCACUUUCUUGGGCUCTT 231 GAGCCCAAGAAAGUGAAAAT 8 TCUUUCACUUUCUUGGGCUTT 232 AGCCCAAGAAAGUGAAAGAT 9 TUCUUUCACUUUCUUGGGCTT 233 GCCCAAGAAAGUGAAAGAAT 10 TGUCUUUCACUUUCUUGGGTT 234 CCCAAGAAAGUGAAAGACAT 11 TGGUCUUUCACUUUCUUGGTT 235 CCAAGAAAGUGAAAGACCAT 12 TUGGUCUUUCACUUUCUUGTT 236 CAAGAAAGUGAAAGACCAAT 13 TAGCUGAGGCUCAAAGCACTT 237 GUGCUUUGAGCCUCAGCUAT 14 TAAGCUGAGGCUCAAAGCATT 238 UGCUUUGAGCCUCAGCUUAT 15 TGAAGCUGAGGCUCAAAGCTT 239 GCUUUGAGCCUCAGCUUCAT 16 TGAGAAGCUGAGGCUCAAATT 240 UUUGAGCCUCAGCUUCUCAT 17 TGCAGGCCUGGCUGGCCAGTT 241 CUGGCCAGCCAGGCCUGCAT 18 TGCCCCCUCGAACUGGUGGTT 242 CCACCAGUUCGAGGGGGCAT 19 TUUGCGGUCACCACAGCCCTT 243 GGGCUGUGGUGACCGCAAAT 20 TGUUGCGGUCACCACAGCCTT 244 GGCUGUGGUGACCGCAACAT 21 TUGUUGCGGUCACCACAGCTT 245 GCUGUGGUGACCGCAACAAT 22 TUUGUUGCGGUCACCACAGTT 246 CUGUGGUGACCGCAACAAAT 23 TCUUGUUGCGGUCACCACATT 247 UGUGGUGACCGCAACAAGAT 24 TGCUUGUUGCGGUCACCACTT 248 GUGGUGACCGCAACAAGCAT 25 TGGCUUGUUGCGGUCACCATT 249 UGGUGACCGCAACAAGCCAT 26 TAAGCACUUUAUUGAGUUCTT 250 GAACUCAAUAAAGUGCUUAT 27 TAAAGCACUUUAUUGAGUUTT 251 AACUCAAUAAAGUGCUUUAT 28 TCAAAGCACUUUAUUGAGUTT 252 ACUCAAUAAAGUGCUUUGAT 29 TUCAAAGCACUUUAUUGAGTT 253 CUCAAUAAAGUGCUUUGAAT 30 TUUCAAAGCACUUUAUUGATT 254 UCAAUAAAGUGCUUUGAAAT 31 TUUUCAAAGCACUUUAUUGTT 255 CAAUAAAGUGCUUUGAAAAT 32 TUUUUCAAAGCACUUUAUUTT 256 AAUAAAGUGCUUUGAAAAAT 33 TCAUCCGUCCGUUGGUCCATT 257 UGGACCAACGGACGGAUGAT 34 TGCAUCCGUCCGUUGGUCCTT 258 GGACCAACGGACGGAUGCAT 35 TGGCAUCCGUCCGUUGGUCTT 259 GACCAACGGACGGAUGCCAT 36 TUGGCAUCCGUCCGUUGGUTT 260 ACCAACGGACGGAUGCCAAT 37 TAUGGCAUCCGUCCGUUGGTT 261 CCAACGGACGGAUGCCAUAT 38 TCAUGGCAUCCGUCCGUUGTT 262 CAACGGACGGAUGCCAUGAT 39 TUCAUGGCAUCCGUCCGUUTT 263 AACGGACGGAUGCCAUGAAT 40 TCUCAUGGCAUCCGUCCGUTT 264 ACGGACGGAUGCCAUGAGAT 41 TCAGAGCCCUCAUGGCAUCTT 265 GAUGCCAUGAGGGCUCUGAT 42 TGCAGAGCCCUCAUGGCAUTT 266 AUGCCAUGAGGGCUCUGCAT 43 TACCCCAGGAGCAGCAGAGTT 267 CUCUGCUGCUCCUGGGGUAT 44 TGGGAAGUGGCAGGGCUCCTT 268 GGAGCCCUGCCACUUCCCAT 45 TUGGUACAGCUGCCGGUGGTT 269 CCACCGGCAGCUGUACCAAT 46 TCUGGUCCUGAUCAAAGUUTT 270 AACUUUGAUCAGGACCAGAT 47 TGCUGGUCCUGAUCAAAGUTT 271 ACUUUGAUCAGGACCAGCAT 48 TUCGCUGGUCCUGAUCAAATT 272 UUUGAUCAGGACCAGCGAAT 49 TCCAUCGCUGGUCCUGAUCTT 273 GAUCAGGACCAGCGAUGGAT 50 TCCCAUCGCUGGUCCUGAUTT 274 AUCAGGACCAGCGAUGGGAT 51 TUCCCCAUCGCUGGUCCUGTT 275 CAGGACCAGCGAUGGGGAAT 52 TCUUUCUUGGGCUCCAAACTT 276 GUUUGGAGCCCAAGAAAGAT 53 TACUUUCUUGGGCUCCAAATT 277 UUUGGAGCCCAAGAAAGUAT 54 TCUGAGCCCGCGGCCAUCATT 278 UGAUGGCCGCGGGCUCAGAT 55 TUCCGAGGCCCACGGCUGATT 279 UCAGCCGUGGGCCUCGGAAT 56 TCUCCGAGGCCCACGGCUGTT 280 CAGCCGUGGGCCUCGGAGAT 57 TCCUCCGAGGCCCACGGCUTT 281 AGCCGUGGGCCUCGGAGGAT 58 TGGUGGCCUCCGAGGCCCATT 282 UGGGCCUCGGAGGCCACCAT 59 TAGGUGGCCUCCGAGGCCCTT 283 GGGCCUCGGAGGCCACCUAT 60 TUAGGUGGCCUCCGAGGCCTT 284 GGCCUCGGAGGCCACCUAAT 61 TGUAGGUGGCCUCCGAGGCTT 285 GCCUCGGAGGCCACCUACAT 62 TGUCCCCAGUUCCGCGCUUTT 286 AAGCGCGGAACUGGGGACAT 63 TUUCCGGCAGAAGGCGUGGTT 287 CCACGCCUUCUGCCGGAAAT 64 TGUUCCGGCAGAAGGCGUGTT 288 CACGCCUUCUGCCGGAACAT 65 TGGUUCCGGCAGAAGGCGUTT 289 ACGCCUUCUGCCGGAACCAT 66 TCCGGGUUCCGGCAGAAGGTT 290 CCUUCUGCCGGAACCCGGAT 67 TUCCGGGUUCCGGCAGAAGTT 291 CUUCUGCCGGAACCCGGAAT 68 TGUCCGGGUUCCGGCAGAATT 292 UUCUGCCGGAACCCGGACAT 69 TUGUCCGGGUUCCGGCAGATT 293 UCUGCCGGAACCCGGACAAT 70 TCGUUGUCCGGGUUCCGGCTT 294 GCCGGAACCCGGACAACGAT 71 TUCGUUGUCCGGGUUCCGGTT 295 CCGGAACCCGGACAACGAAT 72 TUUCCUGGUCAGGGAAGGCTT 296 GCCUUCCCUGACCAGGAAAT 73 TGUUCCUGGUCAGGGAAGGTT 297 CCUUCCCUGACCAGGAACAT 74 TCGUUCCUGGUCAGGGAAGTT 298 CUUCCCUGACCAGGAACGAT 75 TCCGUUCCUGGUCAGGGAATT 299 UUCCCUGACCAGGAACGGAT 76 TGCCGUUCCUGGUCAGGGATT 300 UCCCUGACCAGGAACGGCAT 77 TCAGUGGGCCGUUCCUGGUTT 301 ACCAGGAACGGCCCACUGAT 78 TAGCUCAGUGGGCCGUUCCTT 302 GGAACGGCCCACUGAGCUAT 79 TGAAGACAGACUCUUGCGGTT 303 CCGCAAGAGUCUGUCUUCAT 80 TUGCCGGCGCAGAAACUGUTT 304 ACAGUUUCUGCGCCGGCAAT 81 TGGCGAUGAGGCUGCCGGCTT 305 GCCGGCAGCCUCAUCGCCAT 82 TGGGCGAUGAGGCUGCCGGTT 306 CCGGCAGCCUCAUCGCCCAT 83 TGGGGCGAUGAGGCUGCCGTT 307 CGGCAGCCUCAUCGCCCCAT 84 TACCCAGCAGGGGGCGAUGTT 308 CAUCGCCCCCUGCUGGGUAT 85 TGCACCCAGCAGGGGGCGATT 309 UCGCCCCCUGCUGGGUGCAT 86 TAGCACCCAGCAGGGGGCGTT 310 CGCCCCCUGCUGGGUGCUAT 87 TUCAGCACCCAGCAGGGGGTT 311 CCCCCUGCUGGGUGCUGAAT 88 TCCGAGCACCACCGUCAGATT 312 UCUGACGGUGGUGCUCGGAT 89 TGGCCGAGCACCACCGUCATT 313 UGACGGUGGUGCUCGGCCAT 90 TUGGCCGAGCACCACCGUCTT 314 GACGGUGGUGCUCGGCCAAT 91 TUCCUGGCCGAGCACCACCTT 315 GGUGGUGCUCGGCCAGGAAT 92 TCAGCUGCCGUCCGCAUCCTT 316 GGAUGCGGACGGCAGCUGAT 93 TGGAGCGCGCAGCUGCCGUTT 317 ACGGCAGCUGCGCGCUCCAT 94 TACGUAAGGCGACAGGAGCTT 318 GCUCCUGUCGCCUUACGUAT 95 TCUGAACGUAAGGCGACAGTT 319 CUGUCGCCUUACGUUCAGAT 96 TCUGGCAUAUUCCUCCGCCTT 320 GGCGGAGGAAUAUGCCAGAT 97 TAGCUGGCAUAUUCCUCCGTT 321 CGGAGGAAUAUGCCAGCUAT 98 TGAAGCUGGCAUAUUCCUCTT 322 GAGGAAUAUGCCAGCUUCAT 99 TGGAAGCUGGCAUAUUCCUTT 323 AGGAAUAUGCCAGCUUCCAT 100 TCGGGCCUCCGGAAUCACCTT 324 GGUGAUUCCGGAGGCCCGAT 101 TGCCACUCUCUCACUGCGGTT 325 CCGCAGUGAGAGAGUGGCAT 102 TAGCCACUCUCUCACUGCGTT 326 CGCAGUGAGAGAGUGGCUAT 103 TAACAGAGCCGUCAUGGCGTT 327 CGCCAUGACGGCUCUGUUAT 104 TCAACAGAGCCGUCAUGGCTT 328 GCCAUGACGGCUCUGUUGAT 105 TACAACAGAGCCGUCAUGGTT 329 CCAUGACGGCUCUGUUGUAT 106 TAACAACAGAGCCGUCAUGTT 330 CAUGACGGCUCUGUUGUUAT 107 TGAACAACAGAGCCGUCAUTT 331 AUGACGGCUCUGUUGUUCAT 108 TGGAACAACAGAGCCGUCATT 332 UGACGGCUCUGUUGUUCCAT 109 TCGGUGGUACUGAAAGGGATT 333 UCCCUUUCAGUACCACCGAT 110 TUUGUGGAUGCAUUUGUGGTT 334 CCACAAAUGCAUCCACAAAT 111 TCAAGCAGUAUCCCCAUUGTT 335 CAAUGGGGAUACUGCUUGAT 112 TCUCCAAGCAGUAUCCCCATT 336 UGGGGAUACUGCUUGGAGAT 113 TGCUCCAAGCAGUAUCCCCTT 337 GGGGAUACUGCUUGGAGCAT 114 TGGGCUCCAAGCAGUAUCCTT 338 GGAUACUGCUUGGAGCCCAT 115 TGUGUUUGCUGCAAUGGUCTT 339 GACCAUUGCAGCAAACACAT 116 TUUCCGGUAGGUGGCCUCCTT 340 GGAGGCCACCUACCGGAAAT 117 TGUUCCGGUAGGUGGCCUCTT 341 GAGGCCACCUACCGGAACAT 118 TUGUUCCGGUAGGUGGCCUTT 342 AGGCCACCUACCGGAACAAT 119 TCUCAGUCAUGUUCCGGUATT 343 UACCGGAACAUGACUGAGAT 120 TGACGUGUGUCAUUAUCUGTT 344 CAGAUAAUGACACACGUCAT 121 TGGACGUGUGUCAUUAUCUTT 345 AGAUAAUGACACACGUCCAT 122 TUGGACGUGUGUCAUUAUCTT 346 GAUAAUGACACACGUCCAAT 123 TAUGGACGUGUGUCAUUAUTT 347 AUAAUGACACACGUCCAUAT 124 TACCAUGGACGUGUGUCAUTT 348 AUGACACACGUCCAUGGUAT 125 TAGUCCGCCCACCACGCGCTT 349 GCGCGUGGUGGGCGGACUAT 126 TUAGUCCGCCCACCACGCGTT 350 CGCGUGGUGGGCGGACUAAT 127 TCUAGUCCGCCCACCACGCTT 351 GCGUGGUGGGCGGACUAGAT 128 TACUAGUCCGCCCACCACGTT 352 CGUGGUGGGCGGACUAGUAT 129 TCAGAGCCACUAGUCCGCCTT 353 GGCGGACUAGUGGCUCUGAT 130 TGUUCCUCGGGCGCUGGCCTT 354 GGCCAGCGCCCGAGGAACAT 131 TAGUACCACUGUCAGUUCCTT 355 GGAACUGACAGUGGUACUAT 132 TUCUUGACCAAGUACCACUTT 356 AGUGGUACUUGGUCAAGAAT 133 TGAUCUUGACCAAGUACCATT 357 UGGUACUUGGUCAAGAUCAT 134 TCGAUCUUGACCAAGUACCTT 358 GGUACUUGGUCAAGAUCGAT 135 TGGCGAUCUUGACCAAGUATT 359 UACUUGGUCAAGAUCGCCAT 136 TUCGUGAAGGCGGUAGGAGTT 360 CUCCUACCGCCUUCACGAAT 137 TCCUCGUGAAGGCGGUAGGTT 361 CCUACCGCCUUCACGAGGAT 138 TCCCUCGUGAAGGCGGUAGTT 362 CUACCGCCUUCACGAGGGAT 139 TCGCAGAGCACUGUCUCAGTT 363 CUGAGACAGUGCUCUGCGAT 140 TCUUCAGCCCCCUCGAACUTT 364 AGUUCGAGGGGGCUGAAGAT 141 TUCUUCAGCCCCCUCGAACTT 365 GUUCGAGGGGGCUGAAGAAT 142 TAUUCUUCAGCCCCCUCGATT 366 UCGAGGGGGCUGAAGAAUAT 143 TUCUCCGUGCACGUUAGAGTT 367 CUCUAACGUGCACGGAGAAT 144 TCGUCUCCGUGCACGUUAGTT 368 CUAACGUGCACGGAGACGAT 145 TUGGCGUCUCCGUGCACGUTT 369 ACGUGCACGGAGACGCCAAT 146 ACUUUCACUUUCUUGGGCUTT 370 UAUAGCCCAAGAAAGUGAAAGAT 147 AGGUCUUUCACUUUCUUGGTT 371 AGCCCAAGAAAGUGAAAGUT 148 UGGUCUUUCACUUUCUUGGTT 372 UAUGCCCAAGAAAGUGAAAGAAT 149 UGGUCUUUCACUUUCUUGGGCUC 373 UAUCCCAAGAAAGUGAAAGACAT 150 TGGUCUUUCACUUUCUUGGGCUCUAU 374 UAUCCAAGAAAGUGAAAGACCAT 151 TGGUCUUUCACUUUCUUGGGCUCUTT 375 CCAAGAAAGUGAAAGACCUT 152 TGGUCUUUCACUUUCUUGGGCUCU 376 UAUCAAGAAAGUGAAAGACCAAT 153 TGGUCUUUCACUUUCUUGGGCUC 377 UAUUUUGAGCCUCAGCUUCUCAT 154 TCUUUCACUUUCUUGGGCUCCAA 378 GCCCAAGAAAGUGAAAGACCAUAU 155 TUCUUUCACUUUCUUGGGCUCCA 379 UAUAUGCCCAAGAAAGUGAAAGACCA 156 TGUCUUUCACUUUCUUGGGCUCC 380 UGCCCAAGAAAGUGAAAGACCA 157 TUGGUCUUUCACUUUCUUGGGCU 381 GCCCAAGAAAGUGAAAGACCA 158 TGAGAAGCUGAGGCUCAAAGCAC 382 GGAGCCCAAGAAAGUGAAAGA 159 TGAGAAGCUGAGGCUCAAAGCACUAU 383 GAGCCCAAGAAAGUGAAAGAA 160 TGGUCUUUCACUUUCUUGGGCAUAUA 384 AGCCCAAGAAAGUGAAAGACA 161 TGGUCUUUCACUUUCUUGGGCUCAUAUA 385 CCCAAGAAAGUGAAAGACCAA 162 TGAGAAGCUGAGGCUCAAAGCAUAUA 386 GCUUUGAGCCUCAGCUUCUCA 163 TGAGAAGCUGAGGCUCAAAGCACAUAUA 387 UAUAUGCUUUGAGCCUCAGCUUCUCA 164 TGGUCUUUCACUUUCUUGGGCUCUA 388 UAUAUGAGCCCAAGAAAGUGAAAGACCA 165 TCACUUUCUUGGGCUCCAAACAGUAU 389 UAUAUGUGCUUUGAGCCUCAGCUUCUCA 166 TUCACUUUCUUGGGCUCCAAACAUAU 390 UAUAUGUUUGGAGCCCAAGAAAGUGA 167 TUUCACUUUCUUGGGCUCCAAACUAU 391 UAUAUUUUGGAGCCCAAGAAAGUGAA 168 TUUUCACUUUCUUGGGCUCCAAAUAU 392 UAUAUUUGGAGCCCAAGAAAGUGAAA 169 TAGCUGAGGCUCAAAGCACUUCUUAU 393 UAUAUUGGAGCCCAAGAAAGUGAAAA 170 TGAAGCUGAGGCUCAAAGCACUUUAU 394 UAUAUAAGUGCUUUGAGCCUCAGCUA 171 TUUGUUGCGGUCACCACAGCCCGUAU 395 UAUAUGUGCUUUGAGCCUCAGCUUCA 172 TGCUUGUUGCGGUCACCACAGCCUAU 396 UAUAUGGCUGUGGUGACCGCAACAAA 173 TGGCUUGUUGCGGUCACCACAGCUAU 397 UAUAUCUGUGGUGACCGCAACAAGCA 174 TGGUCUUUCACUUUCUUGG 398 UAUAUUGUGGUGACCGCAACAAGCCA 175 TGGUCUUUCACUUUCUUG 399 UAUUAGCCCAAGAAAGUGAAAGACCA 176 TGGUCUUUCACUUUCUU 400 UAUAAGCCCAAGAAAGUGAAAGACCA 177 UGGUCUUUCACUUUCUUGGGCUCUAU 401 AUAUUGCCCAAGAAAGUGAAAGACCA 178 UGAAGCUGAGGCUCAAAGCACUUUAU 402 CCAAGAAAGUGAAAGACCAUAU 179 UCACUUUCUUGGGCUCCA 403 UGGAGCCCAAGAAAGUGA 180 UUCACUUUCUUGGGCUCC 404 GGAGCCCAAGAAAGUGAA 181 UUUCACUUUCUUGGGCUC 405 GAGCCCAAGAAAGUGAAA 182 UUUUCACUUUCUUGGGCU 406 AGCCCAAGAAAGUGAAAA 183 UCUUUCACUUUCUUGGGC 407 GCCCAAGAAAGUGAAAGA 184 UUCUUUCACUUUCUUGGG 408 CCCAAGAAAGUGAAAGAA 185 UGUCUUUCACUUUCUUGG 409 CCAAGAAAGUGAAAGACA 186 UGGUCUUUCACUUUCUUG 410 CAAGAAAGUGAAAGACCA 187 UUGGUCUUUCACUUUCUU 411 AAGAAAGUGAAAGACCAA 188 UAGCUGAGGCUCAAAGCA 412 UGCUUUGAGCCUCAGCUA 189 UGAAGCUGAGGCUCAAAG 413 CUUUGAGCCUCAGCUUCA 190 UGAGAAGCUGAGGCUCAA 414 UUGAGCCUCAGCUUCUCA 191 UUUGUUGCGGUCACCACA 415 UGUGGUGACCGCAACAAA 192 UCUUGUUGCGGUCACCAC 416 GUGGUGACCGCAACAAGA 193 UGCUUGUUGCGGUCACCA 417 UGGUGACCGCAACAAGCA 194 UGGCUUGUUGCGGUCACC 418 GGUGACCGCAACAAGCCA 195 UCACUUUCUUGGGCUCC 419 GGAGCCCAAGAAAGUGA 196 UUCACUUUCUUGGGCUC 420 GAGCCCAAGAAAGUGAA 197 UUUCACUUUCUUGGGCU 421 AGCCCAAGAAAGUGAAA 198 UUUUCACUUUCUUGGGC 422 GCCCAAGAAAGUGAAAA 199 UCUUUCACUUUCUUGGG 423 CCCAAGAAAGUGAAAGA 200 UUCUUUCACUUUCUUGG 424 CCAAGAAAGUGAAAGAA 201 UGUCUUUCACUUUCUUG 425 CAAGAAAGUGAAAGACA 202 UGGUCUUUCACUUUCUU 426 AAGAAAGUGAAAGACCA 203 UUGGUCUUUCACUUUCU 427 AGAAAGUGAAAGACCAA 204 UAGCUGAGGCUCAAAGC 428 GCUUUGAGCCUCAGCUA 205 UGAAGCUGAGGCUCAAA 429 UUUGAGCCUCAGCUUCA 206 UGAGAAGCUGAGGCUCA 430 UGAGCCUCAGCUUCUCA 207 UUUGUUGCGGUCACCAC 431 GUGGUGACCGCAACAAA 208 UCUUGUUGCGGUCACCA 432 UGGUGACCGCAACAAGA 209 UGCUUGUUGCGGUCACC 433 GGUGACCGCAACAAGCA 210 UGGCUUGUUGCGGUCAC 434 GUGACCGCAACAAGCCA 211 GGUCUUUCACUUUCUUGGGCUCUA 435 AUAUGCCCAAGAAAGUGAAAGACCA 212 GUCUUUCACUUUCUUGGGCUCUA 436 UAUGCCCAAGAAAGUGAAAGACCA 213 UCUUUCACUUUCUUGGGCUCUA 437 AUGCCCAAGAAAGUGAAAGACCA 214 GGUCUUUCACUUUCUUGGGCUCUAU 438 UAUAUGCCCAAGAAAGUGAAAGAUAU 215 GUCUUUCACUUUCUUGGGCUCUAU 439 UAUAUGCCCAAGAAAGUGAAAGACC 216 UGGUCUUUCACUUUCUUGGGCTCUAU 440 UAUGCCCAAGAAAGUGAAAGACCUAU 217 GGUCUUUCACUUUCUUGGGCUCU 441 UAUGCCCAAGAAAGUGAAAGACCAAU 218 TGGUCUUUCACUUUCUUGGGCU 442 UAUGCCCAAGAAAGUGAAAGACCAUU 219 GGUCUUUCACUUUCUUGGGCUC 443 UAUGCCCAAGAAAGUGAAAGACCAUA 220 UAUGGUCUUUCACUUUCUUGGGCUCU 444 UUAGAGCCCAAGAAAGUGAAAGACCA 221 TGGUCUUUCACUUUCUUGGGC 445 UUAUUGCCCAAGAAAGUGAAAGACCA 222 UGGUCUUUCACUUUCUUGGGCUUCAU 446 UUGAUGCCCAAGAAAGUGAAAGACCA 223 UUAUGGUCUUUCACUUUCUUGGGCUC 447 UAUGAGCCCAAGAAAGUGAAAGACCA 224 UGAUGGUCUUUCACUUUCUUGGGCUC 448 AUAGAGCCCAAGAAAGUGAAAGACCA 1307 UGGUCUUUCACUUUCUUGGGCUAUAU 449 AUGCCCAAGAAAGUGAAAGACCUAUU 1308 UCUUUCACUUUCUUGGG 450 AUGCCCAAGAAAGUGAAAGACCUGAU 1309 ACUUUCACUUUCUUGGG 1317 ATAGAGCCCAAGAAAGUGAAAGACCA 1310 UGGUCUUUCACUUUCUUGGGCAUUAU 1318 CCCAAGAAAGUGAAAGU 1311 UGGUCUUUCACUUUCUUGGGCUCAUA 1319 GAGCCCAAGAAAGUGAAAGACCUAUU 1312 AGGUCUUUCACUUUCUUGGGCUCUAU 1320 GAGCCCAAGAAAGUGAAAGACCUGAU 1313 GGUCUUUCACUUUCUUGGGCUCUAU 1321 UAUAUGCCCAAGAAAGUGAAAGACCU 1314 UCGUCUUUCACUUUCUUGGGCUCUAU 1315 UAGUCUUUCACUUUCUUGGGCUCUAU 1316 UUGUCUUUCACUUUCUUGGGCUCUAU 1407 GGGUGGUAGCACACCAGGG 1375 CCCUGGUGUGCUACCACCC 1408 GGGGUGGUAGCACACCAGG 1376 CCUGGUGUGCUACCACCCC 1409 GGGGGUGGUAGCACACCAG 1377 CUGGUGUGCUACCACCCCC 1410 UCACUUUCUUGGGCUCCAA 1378 UUGGAGCCCAAGAAAGUGA 1411 UUCACUUUCUUGGGCUCCA 1379 UGGAGCCCAAGAAAGUGAA 1412 UUUCACUUUCUUGGGCUCC 1380 GGAGCCCAAGAAAGUGAAA 1413 CUUUCACUUUCUUGGGCUC 1381 GAGCCCAAGAAAGUGAAAG 1414 UCUUUCACUUUCUUGGGCU 1382 AGCCCAAGAAAGUGAAAGA 1415 GUCUUUCACUUUCUUGGGC 1383 GCCCAAGAAAGUGAAAGAC 1416 GGUCUUUCACUUUCUUGGG 1384 CCCAAGAAAGUGAAAGACC 1417 UGGUCUUUCACUUUCUUGG 1385 CCAAGAAAGUGAAAGACCA 1418 GUGGUCUUUCACUUUCUUG 1386 CAAGAAAGUGAAAGACCAC 1419 AAGCUGAGGCUCAAAGCAC 1387 GUGCUUUGAGCCUCAGCUU 1420 GAAGCUGAGGCUCAAAGCA 1388 UGCUUUGAGCCUCAGCUUC 1421 AGAAGCUGAGGCUCAAAGC 1389 GCUUUGAGCCUCAGCUUCU 1422 GGAGAAGCUGAGGCUCAAA 1390 UUUGAGCCUCAGCUUCUCC 1423 GGCAGGCCUGGCUGGCCAG 1391 CUGGCCAGCCAGGCCUGCC 1424 CGCCCCCUCGAACUGGUGG 1392 CCACCAGUUCGAGGGGGCG 1425 GUUGCGGUCACCACAGCCC 1393 GGGCUGUGGUGACCGCAAC 1426 UGUUGCGGUCACCACAGCC 1394 GGCUGUGGUGACCGCAACA 1427 UUGUUGCGGUCACCACAGC 1395 GCUGUGGUGACCGCAACAA 1428 CUUGUUGCGGUCACCACAG 1396 CUGUGGUGACCGCAACAAG 1429 GCUUGUUGCGGUCACCACA 1397 UGUGGUGACCGCAACAAGC 1430 GGCUUGUUGCGGUCACCAC 1398 GUGGUGACCGCAACAAGCC 1431 UGGCUUGUUGCGGUCACCA 1399 UGGUGACCGCAACAAGCCA 1432 AAAGCACUUUAUUGAGUUC 1400 GAACUCAAUAAAGUGCUUU 1433 CAAAGCACUUUAUUGAGUU 1401 AACUCAAUAAAGUGCUUUG 1434 UCAAAGCACUUUAUUGAGU 1402 ACUCAAUAAAGUGCUUUGA 1435 UUCAAAGCACUUUAUUGAG 1403 CUCAAUAAAGUGCUUUGAA 1436 UUUCAAAGCACUUUAUUGA 1404 UCAAUAAAGUGCUUUGAAA 1437 UUUUCAAAGCACUUUAUUG 1405 CAAUAAAGUGCUUUGAAAA 1438 AUUUUCAAAGCACUUUAUU 1406 AAUAAAGUGCUUUGAAAAU 1463 TGGUGGUAGCACACCAGGGTT 1439 CCCUGGUGUGCUACCACCAT 1464 TGGGUGGUAGCACACCAGGTT 1440 CCUGGUGUGCUACCACCCAT 1465 TGGGGUGGUAGCACACCAGTT 1441 CUGGUGUGCUACCACCCCAT 1466 TCACUUUCUUGGGCUCCAATT 1442 UUGGAGCCCAAGAAAGUGAT 1467 TUCACUUUCUUGGGCUCCATT 1443 UGGAGCCCAAGAAAGUGAAT 1468 TUUCACUUUCUUGGGCUCCTT 1444 GGAGCCCAAGAAAGUGAAAT 1469 TUUUCACUUUCUUGGGCUCTT 1445 GAGCCCAAGAAAGUGAAAAT 1470 TAGCUGAGGCUCAAAGCACTT 1446 GCCCAAGAAAGUGAAAGAAT 1471 TAAGCUGAGGCUCAAAGCATT 1447 GUGCUUUGAGCCUCAGCUAT 1472 TGAAGCUGAGGCUCAAAGCTT 1448 UGCUUUGAGCCUCAGCUUAT 1473 TGCAGGCCUGGCUGGCCAGTT 1449 GCUUUGAGCCUCAGCUUCAT 1474 TGCCCCCUCGAACUGGUGGTT 1450 CUGGCCAGCCAGGCCUGCAT 1475 TUUGCGGUCACCACAGCCCTT 1451 CCACCAGUUCGAGGGGGCAT 1476 TGUUGCGGUCACCACAGCCTT 1452 GGGCUGUGGUGACCGCAAAT 1477 TUGUUGCGGUCACCACAGCTT 1453 GGCUGUGGUGACCGCAACAT 1478 TUUGUUGCGGUCACCACAGTT 1454 GCUGUGGUGACCGCAACAAT 1479 TCUUGUUGCGGUCACCACATT 1455 CUGUGGUGACCGCAACAAAT 1480 TGCUUGUUGCGGUCACCACTT 1456 UGUGGUGACCGCAACAAGAT 1481 TGGCUUGUUGCGGUCACCATT 1457 GUGGUGACCGCAACAAGCAT 1482 TAAGCACUUUAUUGAGUUCTT 1458 UGGUGACCGCAACAAGCCAT 1483 TAAAGCACUUUAUUGAGUUTT 1459 GAACUCAAUAAAGUGCUUAT 1484 TCAAAGCACUUUAUUGAGUTT 1460 CUCAAUAAAGUGCUUUGAAT 1485 TUCAAAGCACUUUAUUGAGTT 1461 UCAAUAAAGUGCUUUGAAAT 1486 TUUCAAAGCACUUUAUUGATT 1462 CAAUAAAGUGCUUUGAAAAT 1487 TUUUCAAAGCACUUUAUUGTT 1488 TUUUUCAAAGCACUUUAUUTT 1602 AUCGAAAGUGUUGACUCCA 1489 UGGAGUCAACACUUUCGAU 1603 AAUCGAAAGUGUUGACUCC 1490 GGAGUCAACACUUUCGAUU 1604 UGUACUUAUGCUCCUUGGG 1491 CCCAAGGAGCAUAAGUACA 1605 UUGUACUUAUGCUCCUUGG 1492 CCAAGGAGCAUAAGUACAA 1606 UUUGUACUUAUGCUCCUUG 1493 CAAGGAGCAUAAGUACAAA 1607 UCAGCUUUGUACUUAUGCU 1494 AGCAUAAGUACAAAGCUGA 1608 AACGACUGUGUGCUCUUCA 1495 UGAAGAGCACACAGUCGUU 1609 GAACGACUGUGUGCUCUUC 1496 GAAGAGCACACAGUCGUUC 1610 AGAACGACUGUGUGCUCUU 1497 AAGAGCACACAGUCGUUCU 1611 GACAGUGAGAACGACUGUG 1498 CACAGUCGUUCUCACUGUC 1612 GUGACAGUGAGAACGACUG 1499 CAGUCGUUCUCACUGUCAC 1613 GGUACAUUUGUGGUACAGC 1500 GCUGUACCACAAAUGUACC 1614 GGGUACAUUUGUGGUACAG 1501 CUGUACCACAAAUGUACCC 1615 UGGGUACAUUUGUGGUACA 1502 UGUACCACAAAUGUACCCA 1616 CUUGUGGGUACAUUUGUGG 1503 CCACAAAUGUACCCACAAG 1617 GACCCUUGCACUGGCAUCU 1504 AGAUGCCAGUGCAAGGGUC 1618 ACCUCUAGGCAGCGACCCC 1505 GGGGUCGCUGCCUAGAGGU 1619 CCGCGGCCAUCAUAGCAGC 1506 GCUGCUAUGAUGGCCGCGG 1620 CCCGCGGCCAUCAUAGCAG 1507 CUGCUAUGAUGGCCGCGGG 1621 GUAGCUGAGCCCGCGGCCA 1508 UGGCCGCGGGCUCAGCUAC 1622 GCGGUAGCUGAGCCCGCGG 1509 CCGCGGGCUCAGCUACCGC 1623 CGCACCCGAGAGCGUGGUC 1510 GACCACGCUCUCGGGUGCG 1624 GCGCACCCGAGAGCGUGGU 1511 ACCACGCUCUCGGGUGCGC 1625 GGCGCACCCGAGAGCGUGG 1512 CCACGCUCUCGGGUGCGCC 1626 AGUCCCCAGUUCCGCGCUU 1513 AAGCGCGGAACUGGGGACU 1627 AGGCGUGGCCGCCCAGUCC 1514 GGACUGGGCGGCCACGCCU 1628 UCGUUGUCCGGGUUCCGGC 1515 GCCGGAACCCGGACAACGA 1629 UGUCGUUGUCCGGGUUCCG 1516 CGGAACCCGGACAACGACA 1630 AUGUCGUUGUCCGGGUUCC 1517 GGAACCCGGACAACGACAU 1631 GAUGUCGUUGUCCGGGUUC 1518 GAACCCGGACAACGACAUC 1632 GGCGGAUGUCGUUGUCCGG 1519 CCGGACAACGACAUCCGCC 1633 CACGGGCGGAUGUCGUUGU 1520 ACAACGACAUCCGCCCGUG 1634 CCACGGGCGGAUGUCGUUG 1521 CAACGACAUCCGCCCGUGG 1635 ACCACGGGCGGAUGUCGUU 1522 AACGACAUCCGCCCGUGGU 1636 CACCACGGGCGGAUGUCGU 1523 ACGACAUCCGCCCGUGGUG 1637 GAAGCACCACGGGCGGAUG 1524 CAUCCGCCCGUGGUGCUUC 1638 CGAAGCACCACGGGCGGAU 1525 AUCCGCCCGUGGUGCUUCG 1639 CACGAAGCACCACGGGCGG 1526 CCGCCCGUGGUGCUUCGUG 1640 AGCACGAAGCACCACGGGC 1527 GCCCGUGGUGCUUCGUGCU 1641 GCAUGAGUGGGACAUGAAG 1528 CUUCAUGUCCCACUCAUGC 1642 CUUCGGCGGUGCCGGCUGC 1529 GCAGCCGGCACCGCCGAAG 1643 GACAGACUCUUGCGGAGCC 1530 GGCUCCGCAAGAGUCUGUC 1644 AGACAGACUCUUGCGGAGC 1531 GCUCCGCAAGAGUCUGUCU 1645 GGUCAUCGAAGACAGACUC 1532 GAGUCUGUCUUCGAUGACC 1646 GGGUCAUCGAAGACAGACU 1533 AGUCUGUCUUCGAUGACCC 1647 GACGCGGGUCAUCGAAGAC 1534 GUCUUCGAUGACCCGCGUC 1648 CGACGCGGGUCAUCGAAGA 1535 UCUUCGAUGACCCGCGUCG 1649 ACGACGCGGGUCAUCGAAG 1536 CUUCGAUGACCCGCGUCGU 1650 AACGACGCGGGUCAUCGAA 1537 UUCGAUGACCCGCGUCGUU 1651 CAACGACGCGGGUCAUCGA 1538 UCGAUGACCCGCGUCGUUG 1652 CCAACGACGCGGGUCAUCG 1539 CGAUGACCCGCGUCGUUGG 1653 GCCAACGACGCGGGUCAUC 1540 GAUGACCCGCGUCGUUGGC 1654 CCGCCAACGACGCGGGUCA 1541 UGACCCGCGUCGUUGGCGG 1655 CCCGCCAACGACGCGGGUC 1542 GACCCGCGUCGUUGGCGGG 1656 CCCGCGUAGCGCCACCAGC 1543 GCUGGUGGCGCUACGCGGG 1657 GCCCCGCGUAGCGCCACCA 1544 UGGUGGCGCUACGCGGGGC 1658 CGCCCCGCGUAGCGCCACC 1545 GGUGGCGCUACGCGGGGCG 1659 GCGCCCCGCGUAGCGCCAC 1546 GUGGCGCUACGCGGGGCGC 1660 GGGGUGCGCCCCGCGUAGC 1547 GCUACGCGGGGCGCACCCC 1661 GGCGAUGUAGGGGUGCGCC 1548 GGCGCACCCCUACAUCGCC 1662 GCGCGGCGAUGUAGGGGUG 1549 CACCCCUACAUCGCCGCGC 1663 CAGCGCGGCGAUGUAGGGG 1550 CCCCUACAUCGCCGCGCUG 1664 ACAGCGCGGCGAUGUAGGG 1551 CCCUACAUCGCCGCGCUGU 1665 UACAGCGCGGCGAUGUAGG 1552 CCUACAUCGCCGCGCUGUA 1666 GUACAGCGCGGCGAUGUAG 1553 CUACAUCGCCGCGCUGUAC 1667 AGUACAGCGCGGCGAUGUA 1554 UACAUCGCCGCGCUGUACU 1668 CCAGUACAGCGCGGCGAUG 1555 CAUCGCCGCGCUGUACUGG 1669 CCCCAGUACAGCGCGGCGA 1556 UCGCCGCGCUGUACUGGGG 1670 GAUGAGGCUGCCGGCGCAG 1557 CUGCGCCGGCAGCCUCAUC 1671 CCGUCAGAUCCUCGGGUGC 1558 GCACCCGAGGAUCUGACGG 1672 ACCGUCAGAUCCUCGGGUG 1559 CACCCGAGGAUCUGACGGU 1673 GCGAGAAGGCCUCGUGCAA 1560 UUGCACGAGGCCUUCUCGC 1674 GGCGAGAAGGCCUCGUGCA 1561 UGCACGAGGCCUUCUCGCC 1675 CAACAGAGCCAGGUCGUGC 1562 GCACGACCUGGCUCUGUUG 1676 CCUGAAGGCGCAACAGAGC 1563 GCUCUGUUGCGCCUUCAGG 1677 CAUCCUCCUGAAGGCGCAA 1564 UUGCGCCUUCAGGAGGAUG 1678 GAGCGCGCAGCUGCCGUCC 1565 GGACGGCAGCUGCGCGCUC 1679 GUAAGGCGACAGGAGCGCG 1566 CGCGCUCCUGUCGCCUUAC 1680 CGUAAGGCGACAGGAGCGC 1567 GCGCUCCUGUCGCCUUACG 1681 ACGUAAGGCGACAGGAGCG 1568 CGCUCCUGUCGCCUUACGU 1682 AACGUAAGGCGACAGGAGC 1569 GCUCCUGUCGCCUUACGUU 1683 GAACGUAAGGCGACAGGAG 1570 CUCCUGUCGCCUUACGUUC 1684 UGAACGUAAGGCGACAGGA 1571 UCCUGUCGCCUUACGUUCA 1685 GGCUGAACGUAAGGCGACA 1572 UGUCGCCUUACGUUCAGCC 1686 CGGCUGAACGUAAGGCGAC 1573 GUCGCCUUACGUUCAGCCG 1687 CCGGCUGAACGUAAGGCGA 1574 UCGCCUUACGUUCAGCCGG 1688 ACCGGCUGAACGUAAGGCG 1575 CGCCUUACGUUCAGCCGGU 1689 CACCGGCUGAACGUAAGGC 1576 GCCUUACGUUCAGCCGGUG 1690 CACACCGGCUGAACGUAAG 1577 CUUACGUUCAGCCGGUGUG 1691 AGGCACACCGGCUGAACGU 1578 ACGUUCAGCCGGUGUGCCU 1692 GCCGCUUGGCAGGCACACC 1579 GGUGUGCCUGCCAAGCGGC 1693 GCCCCCUCGAACUGGUGGC 1580 GCCACCAGUUCGAGGGGGC 1694 CCGCCCCCUCGAACUGGUG 1581 CACCAGUUCGAGGGGGCGG 1695 UAUUCCUCCGCCCCCUCGA 1582 UCGAGGGGGCGGAGGAAUA 1696 CUCGAGGAACCCUGCGCAG 1583 CUGCGCAGGGUUCCUCGAG 1697 CCUCGAGGAACCCUGCGCA 1584 UGCGCAGGGUUCCUCGAGG 1698 CCCUCGAGGAACCCUGCGC 1585 GCGCAGGGUUCCUCGAGGG 1699 CGGUGCCGCCCUCGAGGAA 1586 UUCCUCGAGGGCGGCACCG 1700 CAUCGGUGCCGCCCUCGAG 1587 CUCGAGGGCGGCACCGAUG 1701 GCAUCGGUGCCGCCCUCGA 1588 UCGAGGGCGGCACCGAUGC 1702 AGGGUGAGCCGGCGCUCUG 1589 CAGAGCGCCGGCUCACCCU 1703 AGCCCGAUCCCCAGCUGAU 1590 AUCAGCUGGGGAUCGGGCU 1704 CGGUCACCACAGCCCGAUC 1591 GAUCGGGCUGUGGUGACCG 1705 GACGCCUGGCUUGUUGCGG 1592 CCGCAACAAGCCAGGCGUC 1706 UAGACGCCUGGCUUGUUGC 1593 GCAACAAGCCAGGCGUCUA 1707 CACAUCGGUGUAGACGCCU 1594 AGGCGUCUACACCGAUGUG 1708 CCACAUCGGUGUAGACGCC 1595 GGCGUCUACACCGAUGUGG 1709 GCCACAUCGGUGUAGACGC 1596 GCGUCUACACCGAUGUGGC 1710 GGUGUGCUCCCGGAUCCAG 1597 CUGGAUCCGGGAGCACACC 1711 UGAGUCCCUGAGCAAUCAG 1598 CUGAUUGCUCAGGGACUCA 1712 AGAUGAGUCCCUGAGCAAU 1599 AUUGCUCAGGGACUCAUCU 1713 AGCACUUUAUUGAGUUCCU 1600 AGGAACUCAAUAAAGUGCU 1714 AAGCACUUUAUUGAGUUCC 1601 GGAACUCAAUAAAGUGCUU 1827 TUCGAAAGUGUUGACUCCATT 1715 UGGAGUCAACACUUUCGAAT 1828 TAUCGAAAGUGUUGACUCCTT 1716 GGAGUCAACACUUUCGAUAT 1829 TGUACUUAUGCUCCUUGGGTT 1717 CCCAAGGAGCAUAAGUACAT 1830 TUGUACUUAUGCUCCUUGGTT 1718 CCAAGGAGCAUAAGUACAAT 1831 TUUGUACUUAUGCUCCUUGTT 1719 CAAGGAGCAUAAGUACAAAT 1832 TCAGCUUUGUACUUAUGCUTT 1720 AGCAUAAGUACAAAGCUGAT 1833 TACGACUGUGUGCUCUUCATT 1721 UGAAGAGCACACAGUCGUAT 1834 TAACGACUGUGUGCUCUUCTT 1722 GAAGAGCACACAGUCGUUAT 1835 TGAACGACUGUGUGCUCUUTT 1723 AAGAGCACACAGUCGUUCAT 1836 TACAGUGAGAACGACUGUGTT 1724 CACAGUCGUUCUCACUGUAT 1837 TUGACAGUGAGAACGACUGTT 1725 CAGUCGUUCUCACUGUCAAT 1838 TGUACAUUUGUGGUACAGCTT 1726 GCUGUACCACAAAUGUACAT 1839 TGGUACAUUUGUGGUACAGTT 1727 CUGUACCACAAAUGUACCAT 1840 TGGGUACAUUUGUGGUACATT 1728 UGUACCACAAAUGUACCCAT 1841 TUUGUGGGUACAUUUGUGGTT 1729 CCACAAAUGUACCCACAAAT 1842 TACCCUUGCACUGGCAUCUTT 1730 AGAUGCCAGUGCAAGGGUAT 1843 TCCUCUAGGCAGCGACCCCTT 1731 GGGGUCGCUGCCUAGAGGAT 1844 TCGCGGCCAUCAUAGCAGCTT 1732 GCUGCUAUGAUGGCCGCGAT 1845 TCCGCGGCCAUCAUAGCAGTT 1733 CUGCUAUGAUGGCCGCGGAT 1846 TUAGCUGAGCCCGCGGCCATT 1734 UGGCCGCGGGCUCAGCUAAT 1847 TCGGUAGCUGAGCCCGCGGTT 1735 CCGCGGGCUCAGCUACCGAT 1848 TGCACCCGAGAGCGUGGUCTT 1736 GACCACGCUCUCGGGUGCAT 1849 TCGCACCCGAGAGCGUGGUTT 1737 ACCACGCUCUCGGGUGCGAT 1850 TGCGCACCCGAGAGCGUGGTT 1738 CCACGCUCUCGGGUGCGCAT 1851 TGUCCCCAGUUCCGCGCUUTT 1739 GGACUGGGCGGCCACGCCAT 1852 TGGCGUGGCCGCCCAGUCCTT 1740 GCCGGAACCCGGACAACGAT 1853 TCGUUGUCCGGGUUCCGGCTT 1741 CGGAACCCGGACAACGACAT 1854 TGUCGUUGUCCGGGUUCCGTT 1742 GGAACCCGGACAACGACAAT 1855 TUGUCGUUGUCCGGGUUCCTT 1743 GAACCCGGACAACGACAUAT 1856 TAUGUCGUUGUCCGGGUUCTT 1744 CCGGACAACGACAUCCGCAT 1857 TGCGGAUGUCGUUGUCCGGTT 1745 ACAACGACAUCCGCCCGUAT 1858 TACGGGCGGAUGUCGUUGUTT 1746 CAACGACAUCCGCCCGUGAT 1859 TCACGGGCGGAUGUCGUUGTT 1747 AACGACAUCCGCCCGUGGAT 1860 TCCACGGGCGGAUGUCGUUTT 1748 ACGACAUCCGCCCGUGGUAT 1861 TACCACGGGCGGAUGUCGUTT 1749 CAUCCGCCCGUGGUGCUUAT 1862 TAAGCACCACGGGCGGAUGTT 1750 AUCCGCCCGUGGUGCUUCAT 1863 TGAAGCACCACGGGCGGAUTT 1751 CCGCCCGUGGUGCUUCGUAT 1864 TACGAAGCACCACGGGCGGTT 1752 GCCCGUGGUGCUUCGUGCAT 1865 TGCACGAAGCACCACGGGCTT 1753 CUUCAUGUCCCACUCAUGAT 1866 TCAUGAGUGGGACAUGAAGTT 1754 GCAGCCGGCACCGCCGAAAT 1867 TUUCGGCGGUGCCGGCUGCTT 1755 GGCUCCGCAAGAGUCUGUAT 1868 TACAGACUCUUGCGGAGCCTT 1756 GCUCCGCAAGAGUCUGUCAT 1869 TGACAGACUCUUGCGGAGCTT 1757 GAGUCUGUCUUCGAUGACAT 1870 TGUCAUCGAAGACAGACUCTT 1758 AGUCUGUCUUCGAUGACCAT 1871 TGGUCAUCGAAGACAGACUTT 1759 GUCUUCGAUGACCCGCGUAT 1872 TACGCGGGUCAUCGAAGACTT 1760 UCUUCGAUGACCCGCGUCAT 1873 TGACGCGGGUCAUCGAAGATT 1761 CUUCGAUGACCCGCGUCGAT 1874 TCGACGCGGGUCAUCGAAGTT 1762 UUCGAUGACCCGCGUCGUAT 1875 TACGACGCGGGUCAUCGAATT 1763 UCGAUGACCCGCGUCGUUAT 1876 TAACGACGCGGGUCAUCGATT 1764 CGAUGACCCGCGUCGUUGAT 1877 TCAACGACGCGGGUCAUCGTT 1765 GAUGACCCGCGUCGUUGGAT 1878 TCCAACGACGCGGGUCAUCTT 1766 UGACCCGCGUCGUUGGCGAT 1879 TCGCCAACGACGCGGGUCATT 1767 GACCCGCGUCGUUGGCGGAT 1880 TCCGCCAACGACGCGGGUCTT 1768 GCUGGUGGCGCUACGCGGAT 1881 TCCGCGUAGCGCCACCAGCTT 1769 UGGUGGCGCUACGCGGGGAT 1882 TCCCCGCGUAGCGCCACCATT 1770 GGUGGCGCUACGCGGGGCAT 1883 TGCCCCGCGUAGCGCCACCTT 1771 GUGGCGCUACGCGGGGCGAT 1884 TCGCCCCGCGUAGCGCCACTT 1772 GCUACGCGGGGCGCACCCAT 1885 TGGGUGCGCCCCGCGUAGCTT 1773 GGCGCACCCCUACAUCGCAT 1886 TGCGAUGUAGGGGUGCGCCTT 1774 CACCCCUACAUCGCCGCGAT 1887 TCGCGGCGAUGUAGGGGUGTT 1775 CCCCUACAUCGCCGCGCUAT 1888 TAGCGCGGCGAUGUAGGGGTT 1776 CCCUACAUCGCCGCGCUGAT 1889 TCAGCGCGGCGAUGUAGGGTT 1777 CCUACAUCGCCGCGCUGUAT 1890 TACAGCGCGGCGAUGUAGGTT 1778 CUACAUCGCCGCGCUGUAAT 1891 TUACAGCGCGGCGAUGUAGTT 1779 UACAUCGCCGCGCUGUACAT 1892 TGUACAGCGCGGCGAUGUATT 1780 CAUCGCCGCGCUGUACUGAT 1893 TCAGUACAGCGCGGCGAUGTT 1781 UCGCCGCGCUGUACUGGGAT 1894 TCCCAGUACAGCGCGGCGATT 1782 CUGCGCCGGCAGCCUCAUAT 1895 TAUGAGGCUGCCGGCGCAGTT 1783 GCACCCGAGGAUCUGACGAT 1896 TCGUCAGAUCCUCGGGUGCTT 1784 CACCCGAGGAUCUGACGGAT 1897 TCCGUCAGAUCCUCGGGUGTT 1785 UUGCACGAGGCCUUCUCGAT 1898 TCGAGAAGGCCUCGUGCAATT 1786 UGCACGAGGCCUUCUCGCAT 1899 TGCGAGAAGGCCUCGUGCATT 1787 GCACGACCUGGCUCUGUUAT 1900 TAACAGAGCCAGGUCGUGCTT 1788 GCUCUGUUGCGCCUUCAGAT 1901 TCUGAAGGCGCAACAGAGCTT 1789 UUGCGCCUUCAGGAGGAUAT 1902 TAUCCUCCUGAAGGCGCAATT 1790 GGACGGCAGCUGCGCGCUAT 1903 TAGCGCGCAGCUGCCGUCCTT 1791 CGCGCUCCUGUCGCCUUAAT 1904 TUAAGGCGACAGGAGCGCGTT 1792 GCGCUCCUGUCGCCUUACAT 1905 TGUAAGGCGACAGGAGCGCTT 1793 CGCUCCUGUCGCCUUACGAT 1906 TCGUAAGGCGACAGGAGCGTT 1794 GCUCCUGUCGCCUUACGUAT 1907 TACGUAAGGCGACAGGAGCTT 1795 CUCCUGUCGCCUUACGUUAT 1908 TAACGUAAGGCGACAGGAGTT 1796 UCCUGUCGCCUUACGUUCAT 1909 TGAACGUAAGGCGACAGGATT 1797 UGUCGCCUUACGUUCAGCAT 1910 TGCUGAACGUAAGGCGACATT 1798 GUCGCCUUACGUUCAGCCAT 1911 TGGCUGAACGUAAGGCGACTT 1799 UCGCCUUACGUUCAGCCGAT 1912 TCGGCUGAACGUAAGGCGATT 1800 CGCCUUACGUUCAGCCGGAT 1913 TCCGGCUGAACGUAAGGCGTT 1801 GCCUUACGUUCAGCCGGUAT 1914 TACCGGCUGAACGUAAGGCTT 1802 CUUACGUUCAGCCGGUGUAT 1915 TACACCGGCUGAACGUAAGTT 1803 ACGUUCAGCCGGUGUGCCAT 1916 TGGCACACCGGCUGAACGUTT 1804 GGUGUGCCUGCCAAGCGGAT 1917 TCCGCUUGGCAGGCACACCTT 1805 GCCACCAGUUCGAGGGGGAT 1918 TCCCCCUCGAACUGGUGGCTT 1806 CACCAGUUCGAGGGGGCGAT 1919 TCGCCCCCUCGAACUGGUGTT 1807 UCGAGGGGGCGGAGGAAUAT 1920 TAUUCCUCCGCCCCCUCGATT 1808 CUGCGCAGGGUUCCUCGAAT 1921 TUCGAGGAACCCUGCGCAGTT 1809 UGCGCAGGGUUCCUCGAGAT 1922 TCUCGAGGAACCCUGCGCATT 1810 GCGCAGGGUUCCUCGAGGAT 1923 TCCUCGAGGAACCCUGCGCTT 1811 UUCCUCGAGGGCGGCACCAT 1924 TGGUGCCGCCCUCGAGGAATT 1812 CUCGAGGGCGGCACCGAUAT 1925 TAUCGGUGCCGCCCUCGAGTT 1813 UCGAGGGCGGCACCGAUGAT 1926 TCAUCGGUGCCGCCCUCGATT 1814 CAGAGCGCCGGCUCACCCAT 1927 TGGGUGAGCCGGCGCUCUGTT 1815 AUCAGCUGGGGAUCGGGCAT 1928 TGCCCGAUCCCCAGCUGAUTT 1816 GAUCGGGCUGUGGUGACCAT 1929 TGGUCACCACAGCCCGAUCTT 1817 CCGCAACAAGCCAGGCGUAT 1930 TACGCCUGGCUUGUUGCGGTT 1818 GCAACAAGCCAGGCGUCUAT 1931 TAGACGCCUGGCUUGUUGCTT 1819 AGGCGUCUACACCGAUGUAT 1932 TACAUCGGUGUAGACGCCUTT 1820 GGCGUCUACACCGAUGUGAT 1933 TCACAUCGGUGUAGACGCCTT 1821 GCGUCUACACCGAUGUGGAT 1934 TCCACAUCGGUGUAGACGCTT 1822 CUGGAUCCGGGAGCACACAT 1935 TGUGUGCUCCCGGAUCCAGTT 1823 CUGAUUGCUCAGGGACUCAT 1936 TGAGUCCCUGAGCAAUCAGTT 1824 AUUGCUCAGGGACUCAUCAT 1937 TGAUGAGUCCCUGAGCAAUTT 1825 AGGAACUCAAUAAAGUGCAT 1938 TGCACUUUAUUGAGUUCCUTT 1826 GGAACUCAAUAAAGUGCUAT 1939 TAGCACUUUAUUGAGUUCCTT 2172 GGUCUUUCACUUUCUUGGGCUC 2166 GCCCAAGAAAGUGAAAGACC 2173 GAGAAGCUGAGGCUCAAAGCAC 2167 GCUUUGAGCCUCAGCUUCUC 2174 GUCUUUCACUUUCUUGGGCUCC 2168 AGCCCAAGAAAGUGAAAGAC 2175 CUUUCACUUUCUUGGGCUCCAA 2169 GGAGCCCAAGAAAGUGAAAG 2176 UCUUUCACUUUCUUGGGCUCCA 2170 GAGCCCAAGAAAGUGAAAGA 2177 UGGUCUUUCACUUUCUUGGGCU 2171 CCCAAGAAAGUGAAAGACCA 2178 UGGUCUUUCACUUUCUUGGGCUCAGU 2183 GACAUGCCCAAGAAAGUGAAAGACCA 2179 UGGUCUUUCACUUUCUUGGGCUCCAA 2184 GCGAUGCCCAAGAAAGUGAAAGACCA 2180 UGGUCUUUCACUUUCUUGGGCUCCAG 2185 UGAAUGCCCAAGAAAGUGAAAGACCA 2181 UGGUCUUUCACUUUCUUGGGCUCGCG 2186 UUGGAGCCCAAGAAAGUGAAAGACCA 2182 UGGUCUUUCACUUUCUUGGGCUCUAT

The F12 RNAi triggers described herein are formed by annealing an antisense strand with a sense strand. In some embodiments, an F12 RNAi trigger antisense strand comprises a nucleotide sequence of any of the sequences in Tables 1 and 2. In some embodiments, an F12 RNAi trigger antisense strand comprises the sequence of nucleotides 1-17, 2-17, 1-18, 2-18, 1-19, 2-19, 1-20, 2-20, 1-21, 2-21, 1-22, 2-22, 1-23, 2-23, 1-24, 2-24, 1-25, 2-25, 1-26, or 2-26 of any of the sequences in Tables 1 and 2. In some embodiments, an F12 RNAi trigger sense strand comprises the nucleotide sequence of any of the sequences in Tables 1 and 3. In some embodiments, an F12 RNAi trigger sense strand comprises the sequence of nucleotides 1-17, 2-17, 1-18, 2-18, 1-19, 2-19, 1-20, 2-20, 1-21, 2-21, 1-22, 2-22, 1-23, 2-23, 1-24, 2-24, 1-25, 2-25, 1-26, or 2-26 of any of the sequences in Tables 1 and 3.

In some embodiments, the sense and antisense strands of the RNAi triggers described herein contain the same number of nucleotides. In some embodiments the sense and antisense strands of the RNAi triggers described herein contain different numbers of nucleotides. In some embodiments, the sense strand 5′ end and the antisense strand 3′ end of a herein described RNAi trigger form a blunt end. In some embodiments, the sense strand 3′ end and the antisense strand 5′ end of a herein described RNAi trigger form a blunt end. In some embodiments, both ends of a herein described RNAi trigger form a blunt end. In some embodiments, neither end of a herein described RNAi trigger is blunt-ended. As used herein a blunt end refers to an end of a double stranded trigger molecule in which the terminal nucleotides of the two annealed strands are complementary (form a complementary base-pair). In some embodiments, the sense strand 5′ end and the antisense strand 3′ end of a herein described RNAi trigger form a frayed end. In some embodiments, the sense strand 3′ end and the antisense strand 5′ end of a herein described RNAi trigger form a frayed end. In some embodiments, both ends of a herein described RNAi trigger form a frayed end. In some embodiments, neither end of a herein described RNAi trigger is a frayed end. As used herein a frayed end refers to an end of a double stranded trigger molecule in which the terminal nucleotides of the two annealed strands from a pair (i.e. do not form an overhang) but are not complementary (i.e. form a non-complementary pair). As used herein, an overhang is a stretch of one or more unpaired nucleotides at the end of one strand of a double stranded RNAi trigger molecule. The unpaired nucleotides may be on the sense strand or the antisense strand, creating either 3′ or 5′ overhangs. In some embodiments the RNAi trigger molecule contains: a blunt end and a frayed end, a blunt end and 5′ overhang end, a blunt end and a 3′ overhang end, a frayed end and a 5′ overhand end, a frayed end and a 3′ overhang end, two 5′ overhang ends, two 3′ overhang ends, a 5′ overhang end and a 3′ overhand end, two frayed ends, or two blunt ends.

In some embodiments, an F12 RNAi trigger contains one or more modified nucleotides. A nucleotide base (or nucleobase) is a heterocyclic pyrimidine or purine compound which is a constituent of all nucleic acids and includes adenine (A), guanine (G), cytosine (C), thymine (T), and uracil (U). As used herein, “G”, “g”, “C”, “c”, “A”, “a”, “U”, “u”, and “T”, each generally stand for a nucleobase, nucleoside, nucleotide or nucleotide mimic that contains guanine, cytosine, adenine, uracil and thymidine as a base, respectively. Also as used herein, the term “nucleotide” can include a modified nucleotide or nucleotide mimic, abasic site, or a surrogate replacement moiety. As used herein, a “modified nucleotide” is a nucleotide, deoxynucleotide, nucleotide mimic, abasic site, or a surrogate replacement moiety other than a ribonucleotide (2′-hydroxyl nucleotide). In some embodiments, a modified nucleotide comprises a 2′-modified nucleotide (i.e. a nucleotide with a group other than a hydroxyl group at the 2′ position of the five-membered sugar ring). Modified nucleotides include, but are not limited to: 2′-modified nucleotides, 2′-O-methyl nucleotides (represented herein as a lower case letter ‘n’ in a nucleotide sequence), 2′-deoxy-2′-fluoro nucleotides (represented herein as Nf, also represented herein as 2′-fluoro nucleotide), 2′-deoxy nucleotides (represented herein as dN), 2′-methoxyethyl (2′-O-2-methoxylethyl) nucleotides (represented herein as NM or 2′-MOE), 2′-amino nucleotides, 2′-alkyl nucleotides, 3′ to 3′ linkages (inverted) nucleotides (represented herein as invdN, invN, invn, invX), non-natural base comprising nucleotides, bridged nucleotides, peptide nucleic acids, 2′,3′-seco nucleotide mimics (unlocked nucleobase analogues, represented herein as N_(UNA or) NUNA), locked nucleotides (represented herein as N_(LNA) or NLNA), 3′-O-Methoxy (2′ internucleotide linked) nucleotide (represented herein as 3′-OMen), 2′-F-Arabino nucleotides (represented herein as NfANA or Nf_(ANA)), morpholino nucleotides, vinyl phosphonate deoxyribonucleotide (represented herein as vpdN), vinyl phosphonate nucleotides, and abasic nucleotides (represented herein as X or Ab). It is not necessary for all positions in a given compound to be uniformly modified. Conversely, more than one modification may be incorporated in a single F12 RNAi trigger or even in a single nucleotide thereof. The F12 RNAi trigger sense strands and antisense strands may be synthesized and/or modified by methods known in the art. Modification at one nucleotide is independent of modification of another nucleotide.

Modified nucleobases include synthetic and natural nucleobases, such as 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine, 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. In some embodiments 20% or fewer of the modified nucleotides are 2′-fluoro modified nucleotides.

In some embodiments, an F12 RNAi trigger sense strand contains a 2′-F nucleotide at position 11 from the 3′ end. In some embodiments, an F12 RNAi trigger sense strand contains a 2′-F nucleotide at position 12 from the 3′ end. In some embodiments, an F12 RNAi trigger sense strand contains a 2′-F nucleotide at position 13 from the 3′ end. In some embodiments, an F12 RNAi trigger sense strand contains at least two 2′-F nucleotides at positions 11, 12, and 13 from the 3′ end. In some embodiments, an F12 RNAi trigger sense strand contains 2′-F nucleotides at positions 11 and 12, positions 11 and 13, or positions 12 and 13 from the 3′ end. In some embodiments, an F12 RNAi trigger sense strand contains 2′-F nucleotides at positions 11, 12, and 13 from the 3′ end.

In some embodiments, an F12 RNAi trigger antisense strand contains a 2′-F nucleotide at position 2 from the 5′ end. In some embodiments, an F12 RNAi trigger antisense strand contains a 2′-F nucleotide at position 14 from the 5′ end. In some embodiments, an F12 RNAi trigger antisense strand contains 2′-F nucleotides at positions 2 and 14 from the 5′ end. In some embodiments, an F12 RNAi trigger contains at least two 2′-F nucleotides at positions 11, 12, and 13 from the 3′ end of the sense strand and at positions 2 and 14 from the 5′ end of the antisense strand.

In some embodiments, an F12 RNAi trigger antisense strand contains a 2′-F nucleotide at position 4 from the 5′ end. In some embodiments, an F12 RNAi trigger antisense strand contains a 2′-F nucleotide at position 6 from the 5′ end. In some embodiments, an F12 RNAi trigger antisense strand contains a 2′-F nucleotide at position 8 from the 5′ end. In some embodiments, an F12 RNAi trigger antisense strand contains a 2′-F nucleotide at position 10 from the 5′ end. In some embodiments, an F12 RNAi trigger antisense strand contains a 2′-F nucleotide at position 12 from the 5′ end. In some embodiments, an F12 RNAi trigger antisense strand contains at least two 2′-F nucleotides at positions 4, 6, 8, 10, and 12 from the 5′ end. In some embodiments, an F12 RNAi trigger antisense strand contains 2′-F nucleotides at positions 4 and 6, positions 4 and 8, positions 4 and 10, positions 4 and 12, positions 6 and 8, positions 6 and 10, positions 6 and 12, positions 8 and 10, positions 8 and 12, or positions 10 and 12 from the 5′ end. In some embodiments, an F12 RNAi trigger antisense strand contains at three 2′-F nucleotides at positions 4, 6, 8, 10, and 12 from the 5′ end. In some embodiments, an F12 RNAi trigger antisense strand contains at least four 2′-F nucleotides at positions 4, 6, 8, 10, and 12 from the 5′ end. In some embodiments, an F12 RNAi trigger antisense strand contains 2′-F nucleotides at positions 4, 6, 8, and 10, positions 4, 6, 8, and 12, positions 4, 6, 10, and 12, positions 4, 8, 10, and 12 or positions 6, 8, 10, and 12 from the 5′ end.

In some embodiments, an F12 RNAi trigger antisense strand contains a 2′-F nucleotide at position 2 and/or position 14 and one, two, or three 2′-F nucleotides at positions 11, 12, and 13 from the 5′ end. In some embodiments, an F12 RNAi trigger contains a 2′-F nucleotide at position 2 and/or position 14 and one, two, or three 2′-F nucleotides at positions 11, 12, and 13 from the 5′ end of the antisense strand, and at least two 2′-F nucleotides at positions 11, 12, and 13 from the 3′ end of the sense strand.

In some embodiments, one or more nucleotides of an F12 RNAi trigger are linked by non-phosphate-containing covalent internucleoside linkages. Modified internucleoside linkages or backbones include, for example, phosphorothioates, 5′-phosphorothioate group (represented herein as a lower case ‘s’ before a nucleotide, as in sN, sn, sNf, or sdN), chiral phosphorothioates, thiophosphate, phosphorodithioates, phosphotriesters, aminoalkyl-phosphotriesters, methyl and other alkyl phosphonates including 3′-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkyl-phosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3′-5′ linkages, 2′-5′ linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3′-5′ to 5′-3′ or 2′-5′ to 5′-2′. Various salts, mixed salts and free-acid forms are also included. In some embodiments, a 2′ modification may be combined with modified internucleoside linkages.

Modified internucleoside linkages or backbones can lack a phosphorus atom therein (e.g., oligonucleosides), which can be formed by short chain alkyl or cycloalkyl inter-sugar linkages, mixed heteroatom and alkyl or cycloalkyl inter-sugar linkages, or one or more short chain heteroatomic or heterocyclic inter-sugar linkages. Such modified linkages or backbones include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S, and CH₂ component parts.

In some embodiments, an F12 RNAi trigger can contain a modified backbone, i.e. the F12 RNAi trigger contains a non-standard linkage between two nucleotides. In some embodiments, the modified backbone one or more phosphorothioate linkages. For example, in some embodiments, a sense strand of an F12 RNAi trigger can contain 1, 2, 3, or 4 phosphorothioate linkages, an antisense strand of a F12 RNAi trigger can contain 1, 2, 3, or 4 phosphorothioate linkages, or both the sense strand and the antisense strand independently can contain 1, 2, 3, or 4 phosphorothioate linkages.

In some embodiments, an F12 RNAi trigger sense strand contains two phosphorothioate internucleotide linkages. In some embodiments, the two phosphorothioate internucleotide linkages are between the nucleotides at positions 1-3 from the 3′ end of the sense strand. In some embodiments, the two phosphorothioate internucleotide linkages are between the nucleotides at positions 1-3, 2-4, 3-5, 4-6, 4-5, or 6-8 from the 5′ end of the sense strand. In some embodiments, an F12 RNAi trigger antisense strand contains four phosphorothioate internucleotide linkages. In some embodiments, the four phosphorothioate internucleotide linkages are between the nucleotides at positions 1-3 from the 5′ end of the sense strand and between the nucleotides at positions 19-21, 20-22, 21-23, 22-24, 23-25, or 24-26 from the 5′ end. In some embodiments, an F12 RNAi trigger contains two phosphorothioate internucleotide linkages in the sense strand and four phosphorothioate internucleotide linkages in the antisense strand.

Examples of antisense strands containing modified nucleotides are provided in Table 2. Examples of sense strands containing modified nucleotides are provided in Table 3. In Tables 2 and 3, the following notations are used to indicate modified nucleotides, targeting groups and linking groups:

-   -   N=2′-OH (unmodified) ribonucleotide (capital letter without for         d indication)     -   n=2′-OMe modified nucleotide     -   Nf=2′-fluoro modified nucleotide     -   dN=2′-deoxy nucleotides     -   N_(UNA)=2′,3′-seco nucleotide mimics (unlocked nucleobase         analogs)     -   N_(LNA)=locked nucleotide     -   Nf_(ANA)=2′-F-Arabino nucleotide     -   NM=2′-methoxyethyl nucleotide     -   X=abasic ribose     -   R=ribitol     -   (invdN)=inverted deoxyribonucleotide (3′-3′ linked nucleotide)     -   (invX)=inverted abasic nucleotide     -   (invn)=inverted 2′-OMe nucleotide     -   s=phosphorothioate linked nucleotide     -   p=phosphate     -   vpdN=vinyl phosphonate deoxyribonucleotide     -   (3′OMen)=3′-OMe nucleotide

The following targeting groups and linking groups are listed in Tables 2 and 3 and their chemical structures are provided further below in Table 4: (NAG3), (C6-NAG3), (C6-PEG4-NAG3), (C6-C6-NAG3), (C6-C12-NAG3), (C11-NAG3), (C11-palm-NAG3), (C11-PEG3-NAG3), (NAG4), (NAG13), (NAG14), (NAG15), (NAG16), (NAG17), (NAG18), (NAG19), (NAG20), (NAG21), (NAG23), (Chol-TEG), (TEG-Chol), (Alk-C6), (Alk-BC9-C6), (Alk-C6-C6), (C6-C6-Alk), (Alk-C6-Ser), (Ser-C6-Alk), (Alk-NHCO-C6), (Alk-NHCO-SS-C6), (Alk-PEG4-C6), (Alk-PEG5-C6), (C6-PEG5-Alk), (Alk-PEG13-C6), (Alk-PEG5-Ser), (Alk-PEG13-Ser), (Alk-SS-C6), (C6-SS-Alk-Me), (Me-Alk-SS-C6), (C6-SMPT-Alk), (BCN), (DBCO-TEG), (C6-NH2), (NH2-C6), (NH2-C7), (NH2-Ser), (C3), (C12), (C6-SS-C6), (Cy5-C6), (Norbornene-C6), (Norbomene-Ser), (PAZ), (Ser-NH2), (Sp9), (Sp18), (Spermine), (Stearyl), (TetZ-C6) (NAG=N-Acetyl-galactosamine).

TABLE 2 Modified F12 RNAi trigger antisense strand sequences. SEQ ID Antisense Sequence Strand ID No. (5′ → 3′) AM00978-AS 451 dTGfgUfgGfuAfgCfaCfaCfcAfgGfgdTsdT AM00979-AS 452 dTGfgGfuGfgUfaGfcAfcAfcCfaGfgdTsdT AM00980-AS 453 dTGfgGfgUfgGfuAfgCfaCfaCfcAfgdTsdT AM00981-AS 454 dTCfaCfuUfuCfuUfgGfgCfuCfcAfadTsdT AM00982-AS 455 dTUfcAfcUfuUfcUfuGfgGfcUfcCfadTsdT AM00983-AS 456 dTUfuCfaCfuUfuCfuUfgGfgCfuCfcdTsdT AM00984-AS 457 dTUfuUfcAfcUfuUfcUfuGfgGfcUfcdTsdT AM00985-AS 458 dTCfuUfuCfaCfuUfuCfuUfgGfgCfudTsdT AM00986-AS 459 dTUfcUfuUfcAfcUfuUfcUfuGfgGfcdTsdT AM00987-AS 460 dTGfuCfuUfuCfaCfuUfuCfuUfgGfgdTsdT AM00988-AS 461 dTGfgUfcUfuUfcAfcUfuUfcUfuGfgdTsdT AM00989-AS 462 dTUfgGfuCfuUfuCfaCfuUfuCfuUfgdTsdT AM00990-AS 463 dTAfgCfuGfaGfgCfuCfaAfaGfcAfcdTsdT AM00991-AS 464 dTAfaGfcUfgAfgGfcUfcAfaAfgCfadTsdT AM00992-AS 465 dTGfaAfgCfuGfaGfgCfuCfaAfaGfcdTsdT AM00993-AS 466 dTGfaGfaAfgCfuGfaGfgCfuCfaAfadTsdT AM00994-AS 467 dTGfcAfgGfcCfuGfgCfuGfgCfcAfgdTsdT AM00995-AS 468 dTGfcCfcCfcUfcGfaAfcUfgGfuGfgdTsdT AM00996-AS 469 dTUfuGfcGfgUfcAfcCfaCfaGfcCfcdTsdT AM00997-AS 470 dTGfuUfgCfgGfuCfaCfcAfcAfgCfcdTsdT AM00998-AS 471 dTUfgUfuGfcGfgUfcAfcCfaCfaGfcdTsdT AM00999-AS 472 dTUfuGfuUfgCfgGfuCfaCfcAfcAfgdTsdT AM01000-AS 473 dTCfuUfgUfuGfcGfgUfcAfcCfaCfadTsdT AM01001-AS 474 dTGfcUfuGfuUfgCfgGfuCfaCfcAfcdTsdT AM01002-AS 475 dTGfgCfuUfgUfuGfcGfgUfcAfcCfadTsdT AM01003-AS 476 dTAfaGfcAfcUfuUfaUfuGfaGfuUfcdTsdT AM01004-AS 477 dTAfaAfgCfaCfuUfuAfuUfgAfgUfudTsdT AM01005-AS 478 dTCfaAfaGfcAfcUfuUfaUfuGfaGfudTsdT AM01006-AS 479 dTUfcAfaAfgCfaCfuUfuAfuUfgAfgdTsdT AM01007-AS 480 dTUfuCfaAfaGfcAfcUfuUfaUfuGfadTsdT AM01008-AS 481 dTUfuUfcAfaAfgCfaCfuUfuAfuUfgdTsdT AM01009-AS 482 dTUfuUfuCfaAfaGfcAfcUfuUfaUfudTsdT AM01377-AS 483 dTCfaUfcCfgUfcCfgUfuGfgUfcCfadTsdT AM01378-AS 484 dTGfcAfuCfcGfuCfcGfuUfgGfuCfcdTsdT AM01379-AS 485 dTGfgCfaUfcCfgUfcCfgUfuGfgUfcdTsdT AM01380-AS 486 dTUfgGfcAfuCfcGfuCfcGfuUfgGfudTsdT AM01381-AS 487 dTAfuGfgCfaUfcCfgUfcCfgUfuGfgdTsdT AM01382-AS 488 dTCfaUfgGfcAfuCfcGfuCfcGfuUfgdTsdT AM01383-AS 489 dTUfcAfuGfgCfaUfcCfgUfcCfgUfudTsdT AM01384-AS 490 dTCfuCfaUfgGfcAfuCfcGfuCfcGfudTsdT AM01385-AS 491 dTCfaGfaGfcCfcUfcAfuGfgCfaUfcdTsdT AM01386-AS 492 dTGfcAfgAfgCfcCfuCfaUfgGfcAfudTsdT AM01387-AS 493 dTAfcCfcCfaGfgAfgCfaGfcAfgAfgdTsdT AM01388-AS 494 dTGfgGfaAfgUfgGfcAfgGfgCfuCfcdTsdT AM01389-AS 495 dTUfgGfuAfcAfgCfuGfcCfgGfuGfgdTsdT AM01390-AS 496 dTCfuGfgUfcCfuGfaUfcAfaAfgUfudTsdT AM01391-AS 497 dTGfcUfgGfuCfcUfgAfuCfaAfaGfudTsdT AM01392-AS 498 dTUfcGfcUfgGfuCfcUfgAfuCfaAfadTsdT AM01393-AS 499 dTCfcAfuCfgCfuGfgUfcCfuGfaUfcdTsdT AM01394-AS 500 dTCfcCfaUfcGfcUfgGfuCfcUfgAfudTsdT AM01395-AS 501 dTUfcCfcCfaUfcGfcUfgGfuCfcUfgdTsdT AM01396-AS 502 dTCfuUfuCfuUfgGfgCfuCfcAfaAfcdTsdT AM01397-AS 503 dTAfcUfuUfcUfuGfgGfcUfcCfaAfadTsdT AM01399-AS 504 dTCfuGfaGfcCfcGfcGfgCfcAfuCfadTsdT AM01400-AS 505 dTUfcCfgAfgGfcCfcAfcGfgCfuGfadTsdT AM01401-AS 506 dTCfuCfcGfaGfgCfcCfaCfgGfcUfgdTsdT AM01402-AS 507 dTCfcUfcCfgAfgGfcCfcAfcGfgCfudTsdT AM01403-AS 508 dTGfgUfgGfcCfuCfcGfaGfgCfcCfadTsdT AM01404-AS 509 dTAfgGfuGfgCfcUfcCfgAfgGfcCfcdTsdT AM01405-AS 510 dTUfaGfgUfgGfcCfuCfcGfaGfgCfcdTsdT AM01406-AS 511 dTGfuAfgGfuGfgCfcUfcCfgAfgGfcdTsdT AM01407-AS 512 dTGfuCfcCfcAfgUfuCfcGfcGfcUfudTsdT AM01408-AS 513 dTUfuCfcGfgCfaGfaAfgGfcGfuGfgdTsdT AM01409-AS 514 dTGfuUfcCfgGfcAfgAfaGfgCfgUfgdTsdT AM01410-AS 515 dTGfgUfuCfcGfgCfaGfaAfgGfcGfudTsdT AM01411-AS 516 dTCfcGfgGfuUfcCfgGfcAfgAfaGfgdTsdT AM01412-AS 517 dTUfcCfgGfgUfuCfcGfgCfaGfaAfgdTsdT AM01413-AS 518 dTGfuCfcGfgGfuUfcCfgGfcAfgAfadTsdT AM01414-AS 519 dTUfgUfcCfgGfgUfuCfcGfgCfaGfadTsdT AM01415-AS 520 dTCfgUfuGfuCfcGfgGfuUfcCfgGfcdTsdT AM01416-AS 521 dTUfcGfuUfgUfcCfgGfgUfuCfcGfgdTsdT AM01417-AS 522 dTUfuCfcUfgGfuCfaGfgGfaAfgGfcdTsdT AM01418-AS 523 dTGfuUfcCfuGfgUfcAfgGfgAfaGfgdTsdT AM01419-AS 524 dTCfgUfuCfcUfgGfuCfaGfgGfaAfgdTsdT AM01420-AS 525 dTCfcGfuUfcCfuGfgUfcAfgGfgAfadTsdT AM01421-AS 526 dTGfcCfgUfuCfcUfgGfuCfaGfgGfadTsdT AM01422-AS 527 dTCfaGfuGfgGfcCfgUfuCfcUfgGfudTsdT AM01423-AS 528 dTAfgCfuCfaGfuGfgGfcCfgUfuCfcdTsdT AM01424-AS 529 dTGfaAfgAfcAfgAfcUfcUfuGfcGfgdTsdT AM01425-AS 530 dTUfgCfcGfgCfgCfaGfaAfaCfuGfudTsdT AM01426-AS 531 dTGfgCfgAfuGfaGfgCfuGfcCfgGfcdTsdT AM01427-AS 532 dTGfgGfcGfaUfgAfgGfcUfgCfcGfgdTsdT AM01428-AS 533 dTGfgGfgCfgAfuGfaGfgCfuGfcCfgdTsdT AM01429-AS 534 dTAfcCfcAfgCfaGfgGfgGfcGfaUfgdTsdT AM01430-AS 535 dTGfcAfcCfcAfgCfaGfgGfgGfcGfadTsdT AM01431-AS 536 dTAfgCfaCfcCfaGfcAfgGfgGfgCfgdTsdT AM01432-AS 537 dTUfcAfgCfaCfcCfaGfcAfgGfgGfgdTsdT AM01433-AS 538 dTCfcGfaGfcAfcCfaCfcGfuCfaGfadTsdT AM01434-AS 539 dTGfgCfcGfaGfcAfcCfaCfcGfuCfadTsdT AM01435-AS 540 dTUfgGfcCfgAfgCfaCfcAfcCfgUfcdTsdT AM01436-AS 541 dTUfcCfuGfgCfcGfaGfcAfcCfaCfcdTsdT AM01437-AS 542 dTCfaGfcUfgCfcGfuCfcGfcAfuCfcdTsdT AM01438-AS 543 dTGfgAfgCfgCfgCfaGfcUfgCfcGfudTsdT AM01439-AS 544 dTAfcGfuAfaGfgCfgAfcAfgGfaGfcdTsdT AM01440-AS 545 dTCfuGfaAfcGfuAfaGfgCfgAfcAfgdTsdT AM01441-AS 546 dTCfuGfgCfaUfaUfuCfcUfcCfgCfcdTsdT AM01442-AS 547 dTAfgCfuGfgCfaUfaUfuCfcUfcCfgdTsdT AM01443-AS 548 dTGfaAfgCfuGfgCfaUfaUfuCfcUfcdTsdT AM01444-AS 549 dTGfgAfaGfcUfgGfcAfuAfuUfcCfudTsdT AM01445-AS 550 dTCfgGfgCfcUfcCfgGfaAfuCfaCfcdTsdT AM01446-AS 551 dTGfcCfaCfuCfuCfuCfaCfuGfcGfgdTsdT AM01447-AS 552 dTAfgCfcAfcUfcUfcUfcAfcUfgCfgdTsdT AM01514-AS 553 dTAfaCfaGfaGfcCfgUfcAfuGfgCfgdTsdT AM01515-AS 554 dTCfaAfcAfgAfgCfcGfuCfaUfgGfcdTsdT AM01516-AS 555 dTAfcAfaCfaGfaGfcCfgUfcAfuGfgdTsdT AM01517-AS 556 dTAfaCfaAfcAfgAfgCfcGfuCfaUfgdTsdT AM01518-AS 557 dTGfaAfcAfaCfaGfaGfcCfgUfcAfudTsdT AM01519-AS 558 dTGfgAfaCfaAfcAfgAfgCfcGfuCfadTsdT AM01520-AS 559 dTCfgGfuGfgUfaCfuGfaAfaGfgGfadTsdT AM01521-AS 560 dTUfuGfuGfgAfuGfcAfuUfuGfuGfgdTsdT AM01522-AS 561 dTCfaAfgCfaGfuAfuCfcCfcAfuUfgdTsdT AM01523-AS 562 dTCfuCfcAfaGfcAfgUfaUfcCfcCfadTsdT AM01524-AS 563 dTGfcUfcCfaAfgCfaGfuAfuCfcCfcdTsdT AM01525-AS 564 dTGfgGfcUfcCfaAfgCfaGfuAfuCfcdTsdT AM01526-AS 565 dTGfuGfuUfuGfcUfgCfaAfuGfgUfcdTsdT AM01527-AS 566 dTUfuCfcGfgUfaGfgUfgGfcCfuCfcdTsdT AM01528-AS 567 dTGfuUfcCfgGfuAfgGfuGfgCfcUfcdTsdT AM01529-AS 568 dTUfgUfuCfcGfgUfaGfgUfgGfcCfudTsdT AM01530-AS 569 dTCfuCfaGfuCfaUfgUfuCfcGfgUfadTsdT AM01531-AS 570 dTGfaCfgUfgUfgUfcAfuUfaUfcUfgdTsdT AM01532-AS 571 dTGfgAfcGfuGfuGfuCfaUfuAfuCfudTsdT AM01533-AS 572 dTUfgGfaCfgUfgUfgUfcAfuUfaUfcdTsdT AM01534-AS 573 dTAfuGfgAfcGfuGfuGfuCfaUfuAfudTsdT AM01535-AS 574 dTAfcCfaUfgGfaCfgUfgUfgUfcAfudTsdT AM01536-AS 575 dTAfgUfcCfgCfcCfaCfcAfcGfcGfcdTsdT AM01537-AS 576 dTUfaGfuCfcGfcCfcAfcCfaCfgCfgdTsdT AM01538-AS 577 dTCfuAfgUfcCfgCfcCfaCfcAfcGfcdTsdT AM01539-AS 578 dTAfcUfaGfuCfcGfcCfcAfcCfaCfgdTsdT AM01540-AS 579 dTCfaGfaGfcCfaCfuAfgUfcCfgCfcdTsdT AM01541-AS 580 dTGfuUfcCfuCfgGfgCfgCfuGfgCfcdTsdT AM01542-AS 581 dTAfgUfaCfcAfcUfgUfcAfgUfuCfcdTsdT AM01543-AS 582 dTUfcUfuGfaCfcAfaGfuAfcCfaCfudTsdT AM01544-AS 583 dTGfaUfcUfuGfaCfcAfaGfuAfcCfadTsdT AM01545-AS 584 dTCfgAfuCfuUfgAfcCfaAfgUfaCfcdTsdT AM01546-AS 585 dTCfgAfuCfuUfgAfcCfaAfgUfaCfcdTsdT AM01547-AS 586 dTUfcGfuGfaAfgGfcGfgUfaGfgAfgdTsdT AM01548-AS 587 dTCfcUfcGfuGfaAfgGfcGfgUfaGfgdTsdT AM01549-AS 588 dTCfcCfuCfgUfgAfaGfgCfgGfuAfgdTsdT AM01550-AS 589 dTCfgCfaGfaGfcAfcUfgUfcUfcAfgdTsdT AM01551-AS 590 dTCfuUfcAfgCfcCfcCfuCfgAfaCfudTsdT AM01552-AS 591 dTUfcUfuCfaGfcCfcCfcUfcGfaAfcdTsdT AM01553-AS 592 dTAfuUfcUfuCfaGfcCfcCfcUfcGfadTsdT AM01554-AS 593 dTUfcUfcCfgUfgCfaCfgUfuAfgAfgdTsdT AM01555-AS 594 dTCfgUfcUfcCfgUfgCfaCfgUfuAfgdTsdT AM01556-AS 595 dTUfgGfcGfuCfuCfcGfuGfcAfcGfudTsdT AM01621-AS 596 dACfuUfuCfaCfuUfuCfuUfgGfgCfudTsdT AM01622-AS 597 dTCfuUfuC_(UNA)aCfuUfuCfuUfgGfgCfudTsdT AM01623-AS 598 dTCfuUfuCfA_(UNA)CfuUfuCfuUfgGfgCfudTsdT AM01624-AS 599 dTUfcUfuU_(UNA)cAfcUfuUfcUfuGfgGfcdTsdT AM01625-AS 600 dTUfcUfuUfC_(UNA)AfcUfuUfcUfuGfgGfcdTsdT AM01626-AS 601 dTGfuCfuU_(UNA)uCfaCfuUfuCfuUfgGfgdTsdT AM01627-AS 602 dTGfuCfuUfU_(UNA)CfaCfuUfuCfuUfgGfgdTsdT AM01628-AS 603 dAGfgUfcUfuUfcAfcUfuUfcUfuGfgdTsdT AM01629-AS 604 dTGfgUfcU_(UNA)uUfcAfcUfuUfcUfuGfgdTsdT AM01630-AS 605 dTGfgUfcUfU_(UNA)UfcAfcUfuUfcUfuGfgdTsdT AM01631-AS 606 dTUfgGfuC_(UNA)uUfuCfaCfuUfuCfuUfgdTsdT AM01632-AS 607 dTUfgGfuCfU_(UNA)UfuCfaCfuUfuCfuUfgdTsdT AM01633-AS 608 dTGfaGfaA_(UNA)gCfuGfaGfgCfuCfaAfadTsdT AM01634-AS 609 dTGfaGfaAfG_(UNA)CfuGfaGfgCfuCfaAfadTsdT AM01903-AS 610 vpdTGfuCfuU_(UNA)uCfaCfuUfuCfuUfgGfgdTsdT AM01904-AS 611 vpdTGfuCfuU_(UNA)uCfaCfuUfuCfuUfgGfgsdTsdT AM01906-AS 612 vpdTGfgUfcU_(UNA)uUfcAfcUfuUfcUfuGfgdTsdT AM01907-AS 613 vpdTGfgUfcU_(UNA)uUfcAfcUfuUfcUfuGfgsdTsdT AM01909-AS 614 vpdTGfaGfaA_(UNA)gCfuGfaGfgCfuCfaAfadTsdT AM01910-AS 615 vpdTGfaGfaA_(UNA)gCfuGfaGfgCfuCfaAfasdTsdT AM01915-AS 616 vpdTGfgUfcUfU_(UNA)UfcAfcUfuUfcUfuGfgdTsdT AM01916-AS 617 vpdTGfgUfcUfU_(UNA)UfcAfcUfuUfcUfuGfgsdTsdT AM01917-AS 618 dTsGfsgUfcUfU_(UNA)UfcAfcUfuUfcUfuGfgsdTsdT AM01918-AS 619 dTsGfsuCfuU_(UNA)uCfaCfuUfuCfuUfgGfgsdTsdT AM01919-AS 620 dTsGfsgUfcU_(UNA)uUfcAfcUfuUfcUfuGfgsdTsdT AM01920-AS 621 dTsGfsaGfaA_(UNA)gCfuGfaGfgCfuCfaAfasdTsdT AM01921-AS 622 dTsGfsuCfuU_(UNA)uCfaCfuuuCfuUfgGfgsdTsdT AM01923-AS 623 dTsGfsgUfcU_(UNA)uUfcAfcuuUfcUfuGfgsdTsdT AM01925-AS 624 dTsGfsaGfaA_(UNA)gCfuGfaggCfuCfaAfasdTsdT AM01927-AS 625 dTsGfsgUfcUfU_(UNA)UfcAfcuuUfcUfuGfgsdTsdT AM01928-AS 626 usGfsgUfcUfU_(UNA)UfcAfcuuUfcUfuGfgsdTsdT AM01929-AS 627 usGfsgUfcU_(UNA)uUfcAfcuuUfcUfuGfgsdTsdT AM01930-AS 628 usGfsgUfcUuNAuUfcAfcuuUfcUfuGfgGfcsusc AM01931-AS 629 usGfsgUfcUfU_(UNA)UfcAfcuuUfcUfuGfgGfcsusc AM01996-AS 630 dTGfgUfcU_(UNA)uUfcAfcuuUfcUfuGfgdTsdT AM01997-AS 631 dTGfgUfcUfU_(UNA)UfcAfcuuUfcUfuGfgdTsdT AM02060-AS 632 dTGfuCfuU_(UNA)uCfaCfuuuCfuUfgGfgdTsdT AM02062-AS 633 dTGfaGfaA_(UNA)gCfuGfaggCfuCfaAfadTsdT AM02112-AS 634 pdTGfgUfcUfuUfcAfcUfuUfcUfuGfgdTsdT AM02113-AS 635 pdTGfgUfcU_(UNA)uUfcAfcUfuUfcUfuGfgdTsdT AM02164-AS 636 dTsGfsgUfcU_(UNA)uUfcAfcuuUfcUfuGfgGfcuscsuAu AM02165-AS 637 dTsGfsgUfcUfuUfcAfcuuUfcUfuGfgGfcuscsuAu AM02166-AS 638 dTsGfsgUfcU_(UNA)uUfcAfcuuUfcUfuGfgGfcucusdTsdT AM02167-AS 639 dTsGfsgUfcUfuUfcAfcuuUfcUfuGfgGfcucusdTsdT AM02171-AS 640 dTsGfsgUfcUfuUfcAfcuuUfcUfuGfgGfcuscsu AM02172-AS 641 dTsGfsgUfcUfuUfcAfcuuUfcUfuGfgGfcsusc AM02197-AS 642 dTsCfsuUfuCfaCfuUfucuUfgGfgCfuCfcsasa AM02198-AS 643 dTsUfscUfuUfcAfcUfuucUfuGfgGfcUfcscsa AM02199-AS 644 dTsGfsuCfuUfuCfaCfuuuCfuUfgGfgCfuscsc AM02200-AS 645 dTsUfsgGfuCfuUfuCfacuUfuCfuUfgGfgscsu AM02201-AS 646 dTsGfsaGfaAfgCfuGfaggCfuCfaAfaGfcsasc AM02208-AS 647 dTsGfsgUfcUfuUfcAfcuuUfcUfuGfgGfcsuscuAu AM02331-AS 648 dTsGfsgUfcU_(UNA)uUfcAfcUfuUfcUfuGfgGfcuscsuAu AM02332-AS 649 dTsGfsgUfcUfU_(UNA)UfcAfcUfuUfcUfuGfgGfcuscsuAu AM02333-AS 650 dTsGfsgUfcUfuU_(UNA)cAfcUfuUfcUfuGfgGfcuscsuAu AM02334-AS 651 dTsGfsgUfcUfuUfC_(UNA)AfcUfuUfcUfuGfgGfcuscsuAu AM02335-AS 652 dTsGfsgUfcUfuUfcA_(UNA)cUfuUfcUfuGfgGfcuscsuAu AM02336-AS 653 dTsGfsgUfcUfuUfcAfC_(UNA)UfuUfcUfuGfgGfcuscsuAu AM02337-AS 654 dTsGfsgUfcUfuUfcAfcU_(UNA)uUfcUfuGfgGfcuscsuAu AM02338-AS 655 dTsGfsgUfcUfuUfcAfcUfU_(UNA)UfcUfuGfgGfcuscsuAu AM02339-AS 656 dTsGfsgUfcUfuUfcAfcUfuU_(UNA)cUfuGfgGfcuscsuAu AM02340-AS 657 dTsGfsgUfcUfuUfcAfcUfuUfC_(UNA)UfuGfgGfcuscsuAu AM02348-AS 658 dTsGfsgUfcUfuUfcAfcUfuUfcUfuGfgGfcuscsuAu AM02349-AS 659 dTsGfsgUfcUfuUfcAfcuUfUfcUfuGfgGfcuscsuAu AM02350-AS 660 dTsGfsgUfcUfuUfcAfcuUfucUfuGfgGfcuscsuAu AM02354-AS 661 dTsGfsgUfcUfuUfcAfcUfUfuCfuUfgGfgCfusCfsuAu AM02395-AS 662 dTsGfsaGfaAfgCfuGfaGfgCfuCfaAfaGfcascsuAu AM02396-AS 663 dTsGfsaGfaAfgCfuGfagGfCfuCfaAfaGfcascsuAu AM02397-AS 664 dTsGfsaGfaAfgCfuGfagGfcuCfaAfaGfcascsuAu AM02398-AS 665 dTsGfsaGfaAfgCfuGfaGfGfcUfcAfaAfgCfasCfsuAu AM02432-AS 666 dTsGfsgUfcUfuUfcAfcUfuUfcUfuGfgGfcasusAua AM02433-AS 667 dTsGfsgUfcUfuUfcAfcUfuUfcUfuGfgGfcauAfsusa AM02434-AS 668 dTsGfsgUfcUfuUfcAfcUfuUfcUfuGfgGfcUfcasusAua AM02437-AS 669 dTsGfsaGfaAfgCfuGfaGfgCfuCfaAfaGfcasusAua AM02438-AS 670 dTsGfsaGfaAfgCfuGfaGfgCfuCfaAfaGfcauAfsusa AM02439-AS 671 dTsGfsaGfaAfgCfuGfaGfgCfuCfaAfaGfcAfcasusAua AM02460-AS 672 pdTsGfsgUfcUfuUfcAfcuuUfcUfuGfgGfcuscsuAu AM02461-AS 673 pdTsGfsgUfcUfuUfcAfcuuUfcUfuGfgGfcuscsuA AM02462-AS 674 dTsGfsgUfcUfuUfcAfcuuUfcUfuGfgGfcuscsuA AM02464-AS 675 dTsCfsaCfuUfuCfuUfgGfgCfuCfcAfaAfcAfsgsuAu AM02466-AS 676 dTsUfscAfcUfuUfcUfuGfgGfcUfcCfaAfaCfsasuAu AM02468-AS 677 dTsUfsuCfaCfuUfuCfuUfgGfgCfuCfcAfaAfscsuAu AM02470-AS 678 dTsUfsuUfcAfcUfuUfcUfuGfgGfcUfcCfaAfsasuAu AM02472-AS 679 dTsAfsgCfuGfaGfgCfuCfaAfaGfcAfcUfuCfsusuAu AM02474-AS 680 dTsGfsaAfgCfuGfaGfgCfuCfaAfaGfcAfcUfsusuAu AM02476-AS 681 dTsUfsuGfuUfgCfgGfuCfaCfcAfcAfgCfcCfsgsuAu AM02478-AS 682 dTsGfscUfuGfuUfgCfgGfuCfaCfcAfcAfgCfscsuAu AM02480-AS 683 dTsGfsgCfuUfgUfuGfcGfgUfcAfcCfaCfaGfscsuAu AM02487-AS 684 dTsGfgUfcUfuUfcAfcuUfUfcUfuGfgGfcucsuAu AM02488-AS 685 dTsGfgUfcUfuUfcAfcuUfUfcUfuGfgGfcucuAu AM02492-AS 686 dTsGfgUfcUfuUfcAfcuuUfcUfuGfgGfcucsuAu AM02493-AS 687 dTsGfgUfcUfuUfcAfcuuUfcUfuGfgGfcucuAu AM02502-AS 688 dTsGfgUfcUfuUfcAfcUfUfucUfuGfgGfcucsuAu AM02503-AS 689 dTsGfgUfcUfuUfcAfcUfUfucUfuGfgGfcucuAu AM02504-AS 690 dTsGfgUfcUfuUfcAfcUfuuCfUfuGfgGfcucsuAu AM02505-AS 691 dTsGfgUfcUfuUfcAfcUfuuCfUfuGfgGfcucuAu AM02506-AS 692 dTsGfgUfcUfuUfcAfcUfuUfCfuuGfgGfcucsuAu AM02507-AS 693 dTsGfgUfcUfuUfcAfcUfuUfCfuuGfgGfcucuAu AM02543-AS 694 dTsGfgUfcUfuUfcAfcUfU_(UNA)UfcUfuGfgGfcucsuAu AM02544-AS 695 dTsGfgUfcUfuUfcA_(UNA)cUfuUfcUfuGfgGfcucsuAu AM02579-AS 696 dTsgsuCfuUfuCfaCfuuuCfuUfgggCfuscsc AM02582-AS 697 dTsUfsgguCfuUfuCfacuUfuCfuUfgggscsu AM02585-AS 698 dTsgsaGfaAfgCfuGfaggCfuCfaAfagcsasc AM02631-AS 699 dTsGfgUfcUfuUfcAfcuUfUfcUfuGfgGfcusCUAU AM02632-AS 700 dTsGfgUfcUfuUfcAfcuUfUfcUfuGfgGfcusCuAfu AM02633-AS 701 dTsGfgUfcUfuUfcAfcuUfUfcUfuGfgGfcusCuau AM02640-AS 702 dTsGfgUfcU_(UNA)uUfcAfcuUfUfcUfuGfgGfcucsuAu AM02641-AS 703 dTGfgUfcU_(UNA)uUfcAfcUfuUfcUfuGfgdTsdT(PAZ) AM02642-AS 704 dTGfgUfcU_(UNA)uUfcAfcUfuUfcUfuGfg(PAZ) AM02643-AS 705 dTGfgUfcU_(UNA)uUfcAfcUfuUfcUfuGfX(PAZ) AM02644-AS 706 dTGfgUfcU_(UNA)uUfcAfcUfuUfcUfuXX(PAZ) AM02645-AS 707 dTGfgUfcUfuUfcAfcUfuUfcUfuGfgdTsdT(PAZ) AM02646-AS 708 dTGfgUfcUfuUfcAfcUfuUfcUfuGfg(PAZ) AM02647-AS 709 dTGfgUfcUfuUfcAfcUfuUfcUfuGfX(PAZ) AM02648-AS 710 dTGfgUfcUfuUfcAfcUfuUfcUfuXX(PAZ) AM02650-AS 711 dTsgsgUfcUfuUfcAfcuuUfcUfugggcsusc AM02656-AS 712 usGfsgUfcUfuUfcAfcuuUfcUfuGfgGfcsuscuAu AM02657-AS 713 usGfsaAfgCfuGfaGfgCfuCfaAfaGfcAfcUfsusuAu AM02658-AS 714 dTsgsaAfgCfuGfaGfgCfuCfaAfaGfcAfcUfsusuAu AM02659-AS 715 dTsGfsaAfgCfugaGfgCfuCfaAfaGfcAfcUfsusuAu AM02660-AS 716 dTsGfsaAfgCfuGfaggCfuCfaAfaGfcAfcUfsusuAu AM02661-AS 717 dTsGfsaAfgCfuGfaGfgCfuCfaAfagcAfcUfsusuAu AM02662-AS 718 dTsgsaAfgCfugaggCfuCfaAfagcAfcUfsusuAu AM02691-AS 719 usCfsaCfuUfuCfuUfgGfgCfuCfcAfXs(PAZ) AM02692-AS 720 usUfscAfcUfuUfcUfuGfgGfcUfcCfXs(PAZ) AM02693-AS 721 usUfsuCfaCfuUfuCfuUfgGfgCfuCfXs(PAZ) AM02694-AS 722 usUfsuUfcAfcUfuUfcUfuGfgGfcUfXs(PAZ) AM02695-AS 723 usCfsuUfuCfaCfuUfuCfuUfgGfgCfXs(PAZ) AM02696-AS 724 usUfscUfuUfcAfcUfuUfcUfuGfgGfXs(PAZ) AM02697-AS 725 usGfsuCfuUfuCfaCfuUfuCfuUfgGfXs(PAZ) AM02698-AS 726 usGfsgUfcUfuUfcAfcUfuUfcUfuGfXs(PAZ) AM02699-AS 727 usUfsgGfuCfuUfuCfaCfuUfuCfuUfXs(PAZ) AM02700-AS 728 usAfsgCfuGfaGfgCfuCfaAfaGfcAfXs(PAZ) AM02701-AS 729 usGfsaAfgCfuGfaGfgCfuCfaAfaGfXs(PAZ) AM02702-AS 730 usGfsaGfaAfgCfuGfaGfgCfuCfaAfXs(PAZ) AM02703-AS 731 usUfsuGfuUfgCfgGfuCfaCfcAfcAfXs(PAZ) AM02704-AS 732 usCfsuUfgUfuGfcGfgUfcAfcCfaCfXs(PAZ) AM02705-AS 733 usGfscUfuGfuUfgCfgGfuCfaCfcAfXs(PAZ) AM02706-AS 734 usGfsgCfuUfgUfuGfcGfgUfcAfcCfXs(PAZ) AM02707-AS 735 usCfsaCfuUfuCfuUfgGfgCfuCfcXXs(PAZ) AM02708-AS 736 usUfscAfcUfuUfcUfuGfgGfcUfcXXs(PAZ) AM02709-AS 737 usUfsuCfaCfuUfuCfuUfgGfgCfuXXs(PAZ) AM02710-AS 738 usUfsuUfcAfcUfuUfcUfuGfgGfcXXs(PAZ) AM02711-AS 739 usCfsuUfuCfaCfuUfuCfuUfgGfgXXs(PAZ) AM02712-AS 740 usUfscUfuUfcAfcUfuUfcUfuGfgXXs(PAZ) AM02713-AS 741 usGfsuCfuUfuCfaCfuUfuCfuUfgXXs(PAZ) AM02714-AS 742 usGfsgUfcUfuUfcAfcUfuUfcUfuXXs(PAZ) AM02715-AS 743 usUfsgGfuCfuUfuCfaCfuUfuCfuXXs(PAZ) AM02716-AS 744 usAfsgCfuGfaGfgCfuCfaAfaGfcXXs(PAZ) AM02717-AS 745 usGfsaAfgCfuGfaGfgCfuCfaAfaXXs(PAZ) AM02718-AS 746 usGfsaGfaAfgCfuGfaGfgCfuCfaXXs(PAZ) AM02719-AS 747 usUfsuGfuUfgCfgGfuCfaCfcAfcXXs(PAZ) AM02720-AS 748 usCfsuUfgUfuGfcGfgUfcAfcCfaXXs(PAZ) AM02721-AS 749 usGfscUfuGfuUfgCfgGfuCfaCfcXXs(PAZ) AM02722-AS 750 usGfsgCfuUfgUfuGfcGfgUfcAfcXXs(PAZ) AM02846-AS 751 pdTsGfgUfcUfuUfcAfcuUfUfcUfuGfgGfcucsuAu AM02847-AS 752 pdTsGfgUfcUfuUfcAfcUfuUfCfuuGfgGfcucuAu AM02871-AS 753 usGfgUfcUfuUfcAfcUfuUfCfuuGfgGfcucuAu AM02874-AS 754 dTsGfgUfcUfuUfcAfcUfuUfCfuuGfgGfcucuA AM02875-AS 755 GfgUfcUfuUfcAfcUfuUfCfuuGfgGfcucuA AM02876-AS 756 gUfcUfuUfcAfcUfuUfCfuuGfgGfcucuA AM02877-AS 757 UfcUfuUfcAfcUfuUfCfuuGfgGfcucuA AM02878-AS 758 pdTsGfgUfcUfuUfcAfcUfuUfCfuuGfgGfcucuA AM02879-AS 759 pGfgUfcUfuUfcAfcUfuUfCfuuGfgGfcucuA AM02880-AS 760 pgUfcUfuUfcAfcUfuUfCfuuGfgGfcucuA AM02881-AS 761 pUfcUfuUfcAfcUfuUfCfuuGfgGfcucuA AM02882-AS 762 GfgUfcUfuUfcAfcUfuUfCfuuGfgGfcucuAu AM02883-AS 763 pGfgUfcUfuUfcAfcUfuUfCfuuGfgGfcucuAu AM02884-AS 764 dTsGfgUfcUfuUfcAfcUfuUfCfuuGfgGfcucu AM02885-AS 765 pdTsGfgUfcUfuUfcAfcUfuUfCfuuGfgGfcucu AM02953-AS 766 usgsgUfcUfuUfcAfcuuUfcUfugggcsuscuAu AM02962-AS 767 usGfsgUfcUfuUfcAfcuuUfcUfugggcsuscuAu AM02963-AS 768 usGfsgUfcUfuucAfcuuUfcuugggcsuscuAu AM02964-AS 769 usGfsgUfcuuUfcAfcuuUfcuugggcsuscuAu AM02965-AS 770 usGfsgucUfuUfcAfcuuUfcuugggcsuscuAu AM02966-AS 771 usGfsgUfcuuucAfcuuUfcUfugggcsuscuAu AM02967-AS 772 usGfsgucUfuucAfcuuUfcUfugggcsuscuAu AM02968-AS 773 usGfsgucuuUfcAfcuuUfcUfugggcsuscuAu AM02969-AS 774 usGfsgUfCfUfuucAfcuuUfcuugggcsuscuAu AM02970-AS 775 usGfsgUfCfuuUfcAfcuuUfcuugggcsuscuAu AM02971-AS 776 usGfsguCfUfuUfcAfcuuUfcuugggcsuscuAu AM02996-AS 777 gsgUfcUfuUfcAfcuuUfcUfugggcsuscuAu AM02997-AS 778 gUfcUfuUfcAfcuuUfcUfugggcsuscuAu AM03024-AS 779 dTGfgUfcUfuUfcAfcUfuUfCfuuGfgGfcucuAu AM03026-AS 780 gUfcUfuUfcAfcUfuUfCfuuGfgGfcucuAu AM03075-AS 781 usCfsaCfuUfuCfuUfgGfgCfuCfcXX AM03076-AS 782 usCfsuUfuCfaCfuUfuCfuUfgGfgXX AM03077-AS 783 usGfsgUfcUfuUfcAfcUfuUfcUfuXX AM03078-AS 784 usUfsgGfuCfuUfuCfaCfuUfuCfuXX AM03109-AS 785 usGfsgUfcUfuUfcAfcuuUfcUfuGfgGfcsTMsCMuAu AM03110-AS 786 usGfsgUfcUfuUfcAfcuuUfcUfuGfgGfcTMCMuAu AM03111-AS 787 usGfsgUfcUfuUfcAfcuuUfcUfuGfgGfcucuAu AM03154-AS 788 usGfsgucuuucacuuUfcuugggcsuscuAu AM03155-AS 789 usGfsgucuuucAfcuuUfcuugggcsuscuAu AM03156-AS 790 usGfsgucuuUfcacuuUfcuugggcsuscuAu AM03157-AS 791 usGfsgucuuUfcAfcuuUfcuugggcsuscuAu AM03201-AS 792 dTsGfgUfcUfuUfcAfcUfuUfCfuuGfgGfcuc AM03202-AS 793 pdTsGfgUfcUfuUfcAfcUfuUfCfuuGfgGfcuc AM03203-AS 794 GfgUfcUfuUfcAfcUfuUfCfuuGfgGfcucu AM03204-AS 795 pGfgUfcUfuUfcAfcUfuUfCfuuGfgGfcucu AM03205-AS 796 dTsGfgUfcUfuUfcAfcUfuUfCfuuGfgGfcu AM03206-AS 797 pdTsGfgUfcUfuUfcAfcUfuUfCfuuGfgGfcu AM03207-AS 798 GfgUfcUfuUfcAfcUfuUfCfuuGfgGfcuc AM03208-AS 799 pGfgUfcUfuUfcAfcUfuUfCfuuGfgGfcuc AM03211-AS 800 usGfsguCfUfuUfcAfcuuUfcuugggcsuscuau AM03212-AS 801 usGfsguCfUfuUfcAfcuuUfcuugggcsuscudAu AM03215-AS 802 uAusGfsguCfUfuUfcAfcuuUfcuugggcsuscu AM03342-AS 803 usCfsuUfuCfaCfuUfuCfuUfgGfgXsXs(PAZ) AM03343-AS 804 usCfsuUfuCfaCfuUfuCfuUfgGfgXsX(PAZ) AM03344-AS 805 usCfsuUfuCfaCfuUfuCfuUfgGfgXsX AM03345-AS 806 usCfsuUfuCfaCfuUfuCfuUfgGfgXs(PAZ) AM03346-AS 807 usCfsuUfuCfaCfuUfuCfuUfgGfgs(PAZ) AM03347-AS 808 usCfsuUfuCfaCfuUfuCfuUfgGfgRRs(PAZ) AM03348-AS 809 usCfsuUfuCfaCfuUfuCfuUfgGfg(C3)(C3)s(PAZ) AM03349-AS 810 usCfsuUfuCfaCfuUfuCfuUfgGfg(Sp9)s(PAZ) AM03350-AS 811 usCfsuUfuCfaCfuUfuCfuUfgGfg(Sp18)s(PAZ) AM03351-AS 812 usCfsuUfuCfaCfuUfuCfuUfgGfg(C12)s(PAZ) AM03352-AS 813 usCfsuUfuCfaCfuUfuCfuUfgGfg(C3)s(PAZ) AM03353-AS 814 usCfsuUfuCfaCfuUfuCfuUfgGfgXX(PAZ) AM03359-AS 815 usCfsuuuCfaCfuuuCfuUfgggXXs(PAZ) AM03365-AS 816 usGfsgUfcUfuUfcacuuUfcuuXXs(PAZ) AM03366-AS 817 usGfsgucuuucAfcUfuUfcUfuXXs(PAZ) AM03367-AS 818 dTsGfgUfcUfuUfcAfcUfuUfCfuuGfgGfc AM03368-AS 819 pdTsGfgUfcUfuUfcAfcUfuUfCfuuGfgGfc AM03410-AS 820 uAusGfsgucuuUfcAfcuuUfcuugggcsuscu AM03415-AS 821 usGfsgucuuUfcAfcuuUfcuugggscsucuAu AM03416-AS 822 usGfsgucuuUfcAfcuuUfcuuggsgscucuAu AM03417-AS 823 usGfsgucuuUfcAfcuuUfcuugggcuscuAu AM03418-AS 824 usGfgucuuUfcAfcuuUfcuugggcsuscuAu AM03419-AS 825 usGfgucuuUfcAfcuuUfcuugggcuscuAu AM03483-AS 826 vpdTGfsgucuuUfcAfcuuUfcuugggcsuscuAu AM03484-AS 827 vpdTsGfsgucuuUfcAfcuuUfcuugggcsuscuAu AM03485-AS 828 dTsGfsgucuuUfcAfcuuUfcuugggcsuscuAu AM03580-AS 829 usGfsgucuuUfcAfcuuUfcuugggcsusucAu AM03581-AS 830 usGfsgucuuUfcAfcuuUfcuugggcsuscuau AM03584-AS 831 dTsGfgUfcUfuUfcAfcUfuUfCfuuGfgGfcauaua AM03585-AS 832 dTsGfgUfcUfuUfcAfcUfuUfCfuuGfgGfcucuau AM03589-AS 833 uuAusGfsgucuuUfcAfcuuUfcuugggcsusc AM03590-AS 834 uGAusGfsgucuuUfcAfcuuUfcuugggcsusc AM03643-AS 835 (NH2-C6)usGfsgucuuUfcAfcuuUfcuugggcsuscuAu AM03644-AS 836 (Cy5-C6)usGfsgucuuUfcAfcuuUfcuugggcsuscuAu AM03662-AS 1322 usGfsGfucuuUfcAfcuuUfcuugggcsuscuAu AM03663-AS 1323 usGfsGfucuuUfCfaCfuuUfcuugggcsuscuAu AM03664-AS 1324 usGfsgucuuUfCfaCfuuUfcuugggcsuscuAu AM03665-AS 1325 usGfsguCfuuUfCfaCfuuUfcuugggcsuscuAu AM03666-AS 1326 usGfsguCfuuuCfaCfuuUfcuugggcsuscuAu AM03667-AS 1327 usGfsGfucuuuCfaCfuuUfcuugggcsuscuAu AM03668-AS 1328 usGfsgucuuUfcAfcuuUfcuugggcsus(invdA)uAu AM03732-AS 1329 usCfsuUfuCfaCfuUfuCfuUfgGMGMXXs(PAZ) AM03733-AS 1330 usCfsuUfuCfaCfuUfuCfuUfgsGfsgXXs(PAZ) AM03734-AS 1331 usCfsuUfuCfaCfuUfuCfuUfgsGfsgXX(PAZ) AM03735-AS 1332 asCfsuUfuCfaCfuUfuCfuUfgGfgXXs(PAZ) AM03736-AS 1333 usCfsuuuCfaCfuuuCfuUfgGMGMXXs(PAZ) AM03737-AS 1334 asCfsuuuCfaCfuuuCfuUfgggXXs(PAZ) AM03785-AS 1335 usGfsgucuuUfcAfcuuUfcuugggcsuscudAu AM03786-AS 1336 usGfsgucuuUfcAfcuuUfcuugggcsasuuau AM03787-AS 1337 usGfsgucuuUfcAfcuuUfcuugggcsuscaua AM03788-AS 1338 usGfsgucuuUfcAfcuuUfcuugggcsuscu(invdA)u AM03789-AS 1339 asGfsgucuuUfcAfcuuUfcuugggcsuscuau AM03790-AS 1340 (invdA)sGfsgucuuUfcAfcuuUfcuugggcsuscuau AM03791-AS 1341 XsGfsgucuuUfcAfcuuUfcuugggcsuscuau AM03792-AS 1342 (invX)sGfsgucuuUfcAfcuuUfcuugggcsuscuau AM03793-AS 1343 (invu)sGfsgucuuUfcAfcuuUfcuugggcsuscuau AM03794-AS 1344 (3′OMeu)sGfsgucuuUfcAfcuuUfcuugggcsuscuau AM03795-AS 1345 usCfsgucuuUfcAfcuuUfcuugggcsuscuau AM03796-AS 1346 usAfsgucuuUfcAfcuuUfcuugggcsuscuau AM03797-AS 1347 usUfsgucuuUfcAfcuuUfcuugggcsuscuau AM03798-AS 1348 usdGsgucuuUfcAfcuuUfcuugggcsuscuau AM03799-AS 2187 (SO3)usGfsgucuuUfcAfcuuUfcuugggcsuscuAu AM03803-AS 2188 usGfsgucuuUfcAfcuuUfcuugggcsusccag AM03804-AS 2189 usGfsgucuuUfcAfcuuUfcuugggcsuscagu AM03805-AS 2190 usGfsgucuuUfcAfcuuUfcuugggcsuscgcg AM03808-AS 2191 usGfsgucuuUfcAfcuuUfcuugggcsusccaa AM03809-AS 2192 usCfsuUfuCfaCfuUfuCfuUfgGfG_(LNA)XXs(PAZ) AM03810-AS 2193 usCfsuUfuCfaCfuUfuCfuUfgG_(LNA)gXXs(PAZ) AM03811-AS 2194 usCfsuUfuCfaCfuUfuCfuUfgG_(LNA)G_(LNA)XXs(PAZ) AM03819-AS 2195 usGfANAsgucuuUfcAfcuuUfcuugggcsuscuau AM03820-AS 2196 usGfsgucuuUfANAcAfcuuUfcuugggcsuscuau AM03821-AS 2197 usGfsgucuuUfcAfANAcuuUfcuugggcsuscuau AM03822-AS 2198 usGfsgucuuUfcAfcuuUfANAcuugggcsuscuau AM03832-AS 2199 usCfsuUfuCfaCfuUfuCfuUfgGfgsXsXs(PAZ) AM03833-AS 2200 usCfsuUfuCfaCfuUfuCfuUfgGfgs(C12)s(PAZ) AM03851-AS 2201 usGfsgucuuUfcAfcuuUfcuugggcucusasu AM03852-AS 2202 usGfsgucuuUfcAfcuuUfcuugggcucu(invdA)u AM03853-AS 2203 usGfsgucuuUfcAfcuuUfcuugggcucuAMTM AM03854-AS 2204 usGfsgucuuUfcAfcuuUfcuugggcucusAMsTM AM03855-AS 2205 TMsGfsgucuuUfcAfcuuUfcuugggcsuscuAu 2053 dTUfcGfaAfaGfuGfuUfgAfcUfcCfadTsdT 2054 dTAfuCfgAfaAfgUfgUfuGfaCfuCfcdTsdT 2055 dTGfuAfcUfuAfuGfcUfcCfuUfgGfgdTsdT 2056 dTUfgUfaCfuUfaUfgCfuCfcUfuGfgdTsdT 2057 dTUfuGfuAfcUfuAfuGfcUfcCfuUfgdTsdT 2058 dTCfaGfcUfuUfgUfaCfuUfaUfgCfudTsdT 2059 dTAfcGfaCfuGfuGfuGfcUfcUfuCfadTsdT 2060 dTAfaCfgAfcUfgUfgUfgCfuCfuUfcdTsdT 2061 dTGfaAfcGfaCfuGfuGfuGfcUfcUfudTsdT 2062 dTAfcAfgUfgAfgAfaCfgAfcUfgUfgdTsdT 2063 dTUfgAfcAfgUfgAfgAfaCfgAfcUfgdTsdT 2064 dTGfuAfcAfuUfuGfuGfgUfaCfaGfcdTsdT 2065 dTGfgUfaCfaUfuUfgUfgGfuAfcAfgdTsdT 2066 dTGfgGfuAfcAfuUfuGfuGfgUfaCfadTsdT 2067 dTUfuGfuGfgGfuAfcAfuUfuGfuGfgdTsdT 2068 dTAfcCfcUfuGfcAfcUfgGfcAfuCfudTsdT 2069 dTCfcUfcUfaGfgCfaGfcGfaCfcCfcdTsdT 2070 dTCfgCfgGfcCfaUfcAfuAfgCfaGfcdTsdT 2071 dTCfcGfcGfgCfcAfuCfaUfaGfcAfgdTsdT 2072 dTUfaGfcUfgAfgCfcCfgCfgGfcCfadTsdT 2073 dTCfgGfuAfgCfuGfaGfcCfcGfcGfgdTsdT 2074 dTGfcAfcCfcGfaGfaGfcGfuGfgUfcdTsdT 2075 dTCfgCfaCfcCfgAfgAfgCfgUfgGfudTsdT 2076 dTGfcGfcAfcCfcGfaGfaGfcGfuGfgdTsdT 2077 dTGfuCfcCfcAfgUfuCfcGfcGfcUfudTsdT 2078 dTGfgCfgUfgGfcCfgCfcCfaGfuCfcdTsdT 2079 dTCfgUfuGfuCfcGfgGfuUfcCfgGfcdTsdT 2080 dTGfuCfgUfuGfuCfcGfgGfuUfcCfgdTsdT 2081 dTUfgUfcGfuUfgUfcCfgGfgUfuCfcdTsdT 2082 dTAfuGfuCfgUfuGfuCfcGfgGfuUfcdTsdT 2083 dTGfcGfgAfuGfuCfgUfuGfuCfcGfgdTsdT 2084 dTAfcGfgGfcGfgAfuGfuCfgUfuGfudTsdT 2085 dTCfaCfgGfgCfgGfaUfgUfcGfuUfgdTsdT 2086 dTCfcAfcGfgGfcGfgAfuGfuCfgUfudTsdT 2087 dTAfcCfaCfgGfgCfgGfaUfgUfcGfudTsdT 2088 dTAfaGfcAfcCfaCfgGfgCfgGfaUfgdTsdT 2089 dTGfaAfgCfaCfcAfcGfgGfcGfgAfudTsdT 2090 dTAfcGfaAfgCfaCfcAfcGfgGfcGfgdTsdT 2091 dTGfcAfcGfaAfgCfaCfcAfcGfgGfcdTsdT 2092 dTCfaUfgAfgUfgGfgAfcAfuGfaAfgdTsdT 2093 dTUfuCfgGfcGfgUfgCfcGfgCfuGfcdTsdT 2094 dTAfcAfgAfcUfcUfuGfcGfgAfgCfcdTsdT 2095 dTGfaCfaGfaCfuCfuUfgCfgGfaGfcdTsdT 2096 dTGfuCfaUfcGfaAfgAfcAfgAfcUfcdTsdT 2097 dTGfgUfcAfuCfgAfaGfaCfaGfaCfudTsdT 2098 dTAfcGfcGfgGfuCfaUfcGfaAfgAfcdTsdT 2099 dTGfaCfgCfgGfgUfcAfuCfgAfaGfadTsdT 2100 dTCfgAfcGfcGfgGfuCfaUfcGfaAfgdTsdT 2101 dTAfcGfaCfgCfgGfgUfcAfuCfgAfadTsdT 2102 dTAfaCfgAfcGfcGfgGfuCfaUfcGfadTsdT 2103 dTCfaAfcGfaCfgCfgGfgUfcAfuCfgdTsdT 2104 dTCfcAfaCfgAfcGfcGfgGfuCfaUfcdTsdT 2105 dTCfgCfcAfaCfgAfcGfcGfgGfuCfadTsdT 2106 dTCfcGfcCfaAfcGfaCfgCfgGfgUfcdTsdT 2107 dTCfcGfcGfuAfgCfgCfcAfcCfaGfcdTsdT 2108 dTCfcCfcGfcGfuAfgCfgCfcAfcCfadTsdT 2109 dTGfcCfcCfgCfgUfaGfcGfcCfaCfcdTsdT 2110 dTCfgCfcCfcGfcGfuAfgCfgCfcAfcdTsdT 2111 dTGfgGfuGfcGfcCfcCfgCfgUfaGfcdTsdT 2112 dTGfcGfaUfgUfaGfgGfgUfgCfgCfcdTsdT 2113 dTCfgCfgGfcGfaUfgUfaGfgGfgUfgdTsdT 2114 dTAfgCfgCfgGfcGfaUfgUfaGfgGfgdTsdT 2115 dTCfaGfcGfcGfgCfgAfuGfuAfgGfgdTsdT 2116 dTAfcAfgCfgCfgGfcGfaUfgUfaGfgdTsdT 2117 dTUfaCfaGfcGfcGfgCfgAfuGfuAfgdTsdT 2118 dTGfuAfcAfgCfgCfgGfcGfaUfgUfadTsdT 2119 dTCfaGfuAfcAfgCfgCfgGfcGfaUfgdTsdT 2120 dTCfcCfaGfuAfcAfgCfgCfgGfcGfadTsdT 2121 dTAfuGfaGfgCfuGfcCfgGfcGfcAfgdTsdT 2122 dTCfgUfcAfgAfuCfcUfcGfgGfuGfcdTsdT 2123 dTCfcGfuCfaGfaUfcCfuCfgGfgUfgdTsdT 2124 dTCfgAfgAfaGfgCfcUfcGfuGfcAfadTsdT 2125 dTGfcGfaGfaAfgGfcCfuCfgUfgCfadTsdT 2126 dTAfaCfaGfaGfcCfaGfgUfcGfuGfcdTsdT 2127 dTCfuGfaAfgGfcGfcAfaCfaGfaGfcdTsdT 2128 dTAfuCfcUfcCfuGfaAfgGfcGfcAfadTsdT 2129 dTAfgCfgCfgCfaGfcUfgCfcGfuCfcdTsdT 2130 dTUfaAfgGfcGfaCfaGfgAfgCfgCfgdTsdT 2131 dTGfuAfaGfgCfgAfcAfgGfaGfcGfcdTsdT 2132 dTCfgUfaAfgGfcGfaCfaGfgAfgCfgdTsdT 2133 dTAfcGfuAfaGfgCfgAfcAfgGfaGfcdTsdT 2134 dTAfaCfgUfaAfgGfcGfaCfaGfgAfgdTsdT 2135 dTGfaAfcGfuAfaGfgCfgAfcAfgGfadTsdT 2136 dTGfcUfgAfaCfgUfaAfgGfcGfaCfadTsdT 2137 dTGfgCfuGfaAfcGfuAfaGfgCfgAfcdTsdT 2138 dTCfgGfcUfgAfaCfgUfaAfgGfcGfadTsdT 2139 dTCfcGfgCfuGfaAfcGfuAfaGfgCfgdTsdT 2140 dTAfcCfgGfcUfgAfaCfgUfaAfgGfcdTsdT 2141 dTAfcAfcCfgGfcUfgAfaCfgUfaAfgdTsdT 2142 dTGfgCfaCfaCfcGfgCfuGfaAfcGfudTsdT 2143 dTCfcGfcUfuGfgCfaGfgCfaCfaCfcdTsdT 2144 dTCfcCfcCfuCfgAfaCfuGfgUfgGfcdTsdT 2145 dTCfgCfcCfcCfuCfgAfaCfuGfgUfgdTsdT 2146 dTAfuUfcCfuCfcGfcCfcCfcUfcGfadTsdT 2147 dTUfcGfaGfgAfaCfcCfuGfcGfcAfgdTsdT 2148 dTCfuCfgAfgGfaAfcCfcUfgCfgCfadTsdT 2149 dTCfcUfcGfaGfgAfaCfcCfuGfcGfcdTsdT 2150 dTGfgUfgCfcGfcCfcUfcGfaGfgAfadTsdT 2151 dTAfuCfgGfuGfcCfgCfcCfuCfgAfgdTsdT 2152 dTCfaUfcGfgUfgCfcGfcCfcUfcGfadTsdT 2153 dTGfgGfuGfaGfcCfgGfcGfcUfcUfgdTsdT 2154 dTGfcCfcGfaUfcCfcCfaGfcUfgAfudTsdT 2155 dTGfgUfcAfcCfaCfaGfcCfcGfaUfcdTsdT 2156 dTAfcGfcCfuGfgCfuUfgUfuGfcGfgdTsdT 2157 dTAfgAfcGfcCfuGfgCfuUfgUfuGfcdTsdT 2158 dTAfcAfuCfgGfuGfuAfgAfcGfcCfudTsdT 2159 dTCfaCfaUfcGfgUfgUfaGfaCfgCfcdTsdT 2160 dTCfcAfcAfuCfgGfuGfuAfgAfcGfcdTsdT 2161 dTGfuGfuGfcUfcCfcGfgAfuCfcAfgdTsdT 2162 dTGfaGfuCfcCfuGfaGfcAfaUfcAfgdTsdT 2163 dTGfaUfgAfgUfcCfcUfgAfgCfaAfudTsdT 2164 dTGfcAfcUfuUfaUfuGfaGfuUfcCfudTsdT 2165 dTAfgCfaCfuUfuAfuUfgAfgUfuCfcdTsdT

TABLE 3 Modified F12 RNAi trigger sense strand sequences. SEQ ID Sense Sequence Strand ID No. (5′ → 3′) AM00913-SS 837 CfcCfuGfgUfgUfgCfuAfcCfaCfcAf(invdT) AM00914-SS 838 CfcUfgGfuGfuGfcUfaCfcAfcCfcAf(invdT) AM00915-SS 839 CfuGfgUfgUfgCfuAfcCfaCfcCfcAf(invdT) AM00916-SS 840 UfuGfgAfgCfcCfaAfgAfaAfgUfgAf(invdT) AM00917-SS 841 UfgGfaGfcCfcAfaGfaAfaGfuGfaAf(invdT) AM00918-SS 842 GfgAfgCfcCfaAfgAfaAfgUfgAfaAf(invdT) AM00919-SS 843 GfaGfcCfcAfaGfaAfaGfuGfaAfaAf(invdT) AM00920-SS 844 AfgCfcCfaAfgAfaAfgUfgAfaAfgAf(invdT) AM00921-SS 845 GfcCfcAfaGfaAfaGfuGfaAfaGfaAf(invdT) AM00922-SS 846 CfcCfaAfgAfaAfgUfgAfaAfgAfcAf(invdT) AM00923-SS 847 CfcAfaGfaAfaGfuGfaAfaGfaCfcAf(invdT) AM00924-SS 848 CfaAfgAfaAfgUfgAfaAfgAfcCfaAf(invdT) AM00925-SS 849 GfuGfcUfuUfgAfgCfcUfcAfgCfuAf(invdT) AM00926-SS 850 UfgCfuUfuGfaGfcCfuCfaGfcUfuAf(invdT) AM00927-SS 851 GfcUfuUfgAfgCfcUfcAfgCfuUfcAf(invdT) AM00928-SS 852 UfuUfgAfgCfcUfcAfgCfuUfcUfcAf(invdT) AM00929-SS 853 CfuGfgCfcAfgCfcAfgGfcCfuGfcAf(invdT) AM00930-SS 854 CfcAfcCfaGfuUfcGfaGfgGfgGfcAf(invdT) AM00931-SS 855 GfgGfcUfgUfgGfuGfaCfcGfcAfaAf(invdT) AM00932-SS 856 GfgCfuGfuGfgUfgAfcCfgCfaAfcAf(invdT) AM00933-SS 857 GfcUfgUfgGfuGfaCfcGfcAfaCfaAf(invdT) AM00934-SS 858 CfuGfuGfgUfgAfcCfgCfaAfcAfaAf(invdT) AM00935-SS 859 UfgUfgGfuGfaCfcGfcAfaCfaAfgAf(invdT) AM00936-SS 860 GfuGfgUfgAfcCfgCfaAfcAfaGfcAf(invdT) AM00937-SS 861 UfgGfuGfaCfcGfcAfaCfaAfgCfcAf(invdT) AM00938-SS 862 GfaAfcUfcAfaUfaAfaGfuGfcUfuAf(invdT) AM00939-SS 863 AfaCfuCfaAfuAfaAfgUfgCfuUfuAf(invdT) AM00940-SS 864 AfcUfcAfaUfaAfaGfuGfcUfuUfgAf(invdT) AM00941-SS 865 CfuCfaAfuAfaAfgUfgCfuUfuGfaAf(invdT) AM00942-SS 866 UfcAfaUfaAfaGfuGfcUfuUfgAfaAf(invdT) AM00943-SS 867 CfaAfuAfaAfgUfgCfuUfuGfaAfaAf(invdT) AM00944-SS 868 AfaUfaAfaGfuGfcUfuUfgAfaAfaAf(invdT) AM01307-SS 869 UfgGfaCfcAfaCfgGfaCfgGfaUfgAf(invdT) AM01308-SS 870 GfgAfcCfaAfcGfgAfcGfgAfuGfcAf(invdT) AM01309-SS 871 GfaCfcAfaCfgGfaCfgGfaUfgCfcAf(invdT) AM01310-SS 872 AfcCfaAfcGfgAfcGfgAfuGfcCfaAf(invdT) AM01311-SS 873 CfcAfaCfgGfaCfgGfaUfgCfcAfuAf(invdT) AM01312-SS 874 CfaAfcGfgAfcGfgAfuGfcCfaUfgAf(invdT) AM01313-SS 875 AfaCfgGfaCfgGfaUfgCfcAfuGfaAf(invdT) AM01314-SS 876 AfcGfgAfcGfgAfuGfcCfaUfgAfgAf(invdT) AM01315-SS 877 GfaUfgCfcAfuGfaGfgGfcUfcUfgAf(invdT) AM01316-SS 878 AfuGfcCfaUfgAfgGfgCfuCfuGfcAf(invdT) AM01317-SS 879 CfuCfuGfcUfgCfuCfcUfgGfgGfuAf(invdT) AM01318-SS 880 GfgAfgCfcCfuGfcCfaCfuUfcCfcAf(invdT) AM01319-SS 881 CfcAfcCfgGfcAfgCfuGfuAfcCfaAf(invdT) AM01320-SS 882 AfaCfuUfuGfaUfcAfgGfaCfcAfgAf(invdT) AM01321-SS 883 AfcUfuUfgAfuCfaGfgAfcCfaGfcAf(invdT) AM01322-SS 884 UfuUfgAfuCfaGfgAfcCfaGfcGfaAf(invdT) AM01323-SS 885 GfaUfcAfgGfaCfcAfgCfgAfuGfgAf(invdT) AM01324-SS 886 AfuCfaGfgAfcCfaGfcGfaUfgGfgAf(invdT) AM01325-SS 887 CfaGfgAfcCfaGfcGfaUfgGfgGfaAf(invdT) AM01326-SS 888 GfuUfuGfgAfgCfcCfaAfgAfaAfgAf(invdT) AM01327-SS 889 UfuUfgGfaGfcCfcAfaGfaAfaGfuAf(invdT) AM01328-SS 890 UfgAfuGfgCfcGfcGfgGfcUfcAfgAf(invdT) AM01329-SS 891 UfcAfgCfcGfuGfgGfcCfuCfgGfaAf(invdT) AM01330-SS 892 CfaGfcCfgUfgGfgCfcUfcGfgAfgAf(invdT) AM01331-SS 893 AfgCfcGfuGfgGfcCfuCfgGfaGfgAf(invdT) AM01332-SS 894 UfgGfgCfcUfcGfgAfgGfcCfaCfcAf(invdT) AM01333-SS 895 GfgGfcCfuCfgGfaGfgCfcAfcCfuAf(invdT) AM01334-SS 896 GfgCfcUfcGfgAfgGfcCfaCfcUfaAf(invdT) AM01335-SS 897 GfcCfuCfgGfaGfgCfcAfcCfuAfcAf(invdT) AM01336-SS 898 AfaGfcGfcGfgAfaCfuGfgGfgAfcAf(invdT) AM01337-SS 899 CfcAfcGfcCfuUfcUfgCfcGfgAfaAf(invdT) AM01338-SS 900 CfaCfgCfcUfuCfuGfcCfgGfaAfcAf(invdT) AM01339-SS 901 AfcGfcCfuUfcUfgCfcGfgAfaCfcAf(invdT) AM01340-SS 902 CfcUfuCfuGfcCfgGfaAfcCfcGfgAf(invdT) AM01341-SS 903 CfuUfcUfgCfcGfgAfaCfcCfgGfaAf(invdT) AM01342-SS 904 UfuCfuGfcCfgGfaAfcCfcGfgAfcAf(invdT) AM01343-SS 905 UfcUfgCfcGfgAfaCfcCfgGfaCfaAf(invdT) AM01344-SS 906 GfcCfgGfaAfcCfcGfgAfcAfaCfgAf(invdT) AM01345-SS 907 CfcGfgAfaCfcCfgGfaCfaAfcGfaAf(invdT) AM01346-SS 908 GfcCfuUfcCfcUfgAfcCfaGfgAfaAf(invdT) AM01347-SS 909 CfcUfuCfcCfuGfaCfcAfgGfaAfcAf(invdT) AM01348-SS 910 CfuUfcCfcUfgAfcCfaGfgAfaCfgAf(invdT) AM01349-SS 911 UfuCfcCfuGfaCfcAfgGfaAfcGfgAf(invdT) AM01350-SS 912 UfcCfcUfgAfcCfaGfgAfaCfgGfcAf(invdT) AM01351-SS 913 AfcCfaGfgAfaCfgGfcCfcAfcUfgAf(invdT) AM01352-SS 914 GfgAfaCfgGfcCfcAfcUfgAfgCfuAf(invdT) AM01353-SS 915 CfcGfcAfaGfaGfuCfuGfuCfuUfcAf(invdT) AM01354-SS 916 AfcAfgUfuUfcUfgCfgCfcGfgCfaAf(invdT) AM01355-SS 917 GfcCfgGfcAfgCfcUfcAfuCfgCfcAf(invdT) AM01356-SS 918 CfcGfgCfaGfcCfuCfaUfcGfcCfcAf(invdT) AM01357-SS 919 CfgGfcAfgCfcUfcAfuCfgCfcCfcAf(invdT) AM01358-SS 920 CfaUfcGfcCfcCfcUfgCfuGfgGfuAf(invdT) AM01359-SS 921 UfcGfcCfcCfcUfgCfuGfgGfuGfcAf(invdT) AM01360-SS 922 CfgCfcCfcCfuGfcUfgGfgUfgCfuAf(invdT) AM01361-SS 923 CfcCfcCfuGfcUfgGfgUfgCfuGfaAf(invdT) AM01362-SS 924 UfcUfgAfcGfgUfgGfuGfcUfcGfgAf(invdT) AM01363-SS 925 UfgAfcGfgUfgGfuGfcUfcGfgCfcAf(invdT) AM01364-SS 926 GfaCfgGfuGfgUfgCfuCfgGfcCfaAf(invdT) AM01365-SS 927 GfgUfgGfuGfcUfcGfgCfcAfgGfaAf(invdT) AM01366-SS 928 GfgAfuGfcGfgAfcGfgCfaGfcUfgAf(invdT) AM01367-SS 929 AfcGfgCfaGfcUfgCfgCfgCfuCfcAf(invdT) AM01368-SS 930 GfcUfcCfuGfuCfgCfcUfuAfcGfuAf(invdT) AM01369-SS 931 CfuGfuCfgCfcUfuAfcGfuUfcAfgAf(invdT) AM01370-SS 932 GfgCfgGfaGfgAfaUfaUfgCfcAfgAf(invdT) AM01371-SS 933 CfgGfaGfgAfaUfaUfgCfcAfgCfuAf(invdT) AM01372-SS 934 GfaGfgAfaUfaUfgCfcAfgCfuUfcAf(invdT) AM01373-SS 935 AfgGfaAfuAfuGfcCfaGfcUfuCfcAf(invdT) AM01374-SS 936 GfgUfgAfuUfcCfgGfaGfgCfcCfgAf(invdT) AM01375-SS 937 CfcGfcAfgUfgAfgAfgAfgUfgGfcAf(invdT) AM01376-SS 938 CfgCfaGfuGfaGfaGfaGfuGfgCfuAf(invdT) AM01471-SS 939 CfgCfcAfuGfaCfgGfcUfcUfgUfuAf(invdT) AM01472-SS 940 GfcCfaUfgAfcGfgCfuCfuGfuUfgAf(invdT) AM01473-SS 941 CfcAfuGfaCfgGfcUfcUfgUfuGfuAf(invdT) AM01474-SS 942 CfaUfgAfcGfgCfuCfuGfuUfgUfuAf(invdT) AM01475-SS 943 AfuGfaCfgGfcUfcUfgUfuGfuUfcAf(invdT) AM01476-SS 944 UfgAfcGfgCfuCfuGfuUfgUfuCfcAf(invdT) AM01477-SS 945 UfcCfcUfuUfcAfgUfaCfcAfcCfgAf(invdT) AM01478-SS 946 CfcAfcAfaAfuGfcAfuCfcAfcAfaAf(invdT) AM01479-SS 947 CfaAfuGfgGfgAfuAfcUfgCfuUfgAf(invdT) AM01480-SS 948 UfgGfgGfaUfaCfuGfcUfuGfgAfgAf(invdT) AM01481-SS 949 GfgGfgAfuAfcUfgCfuUfgGfaGfcAf(invdT) AM01482-SS 950 GfgAfuAfcUfgCfuUfgGfaGfcCfcAf(invdT) AM01483-SS 951 GfaCfcAfuUfgCfaGfcAfaAfcAfcAf(invdT) AM01484-SS 952 GfgAfgGfcCfaCfcUfaCfcGfgAfaAf(invdT) AM01485-SS 953 GfaGfgCfcAfcCfuAfcCfgGfaAfcAf(invdT) AM01486-SS 954 AfgGfcCfaCfcUfaCfcGfgAfaCfaAf(invdT) AM01487-SS 955 UfaCfcGfgAfaCfaUfgAfcUfgAfgAf(invdT) AM01488-SS 956 CfaGfaUfaAfuGfaCfaCfaCfgUfcAf(invdT) AM01489-SS 957 AfgAfuAfaUfgAfcAfcAfcGfuCfcAf(invdT) AM01490-SS 958 GfaUfaAfuGfaCfaCfaCfgUfcCfaAf(invdT) AM01491-SS 959 AfuAfaUfgAfcAfcAfcGfuCfcAfuAf(invdT) AM01492-SS 960 AfuGfaCfaCfaCfgUfcCfaUfgGfuAf(invdT) AM01493-SS 961 GfcGfcGfuGfgUfgGfgCfgGfaCfuAf(invdT) AM01494-SS 962 CfgCfgUfgGfuGfgGfcGfgAfcUfaAf(invdT) AM01495-SS 963 GfcGfuGfgUfgGfgCfgGfaCfuAfgAf(invdT) AM01496-SS 964 CfgUfgGfuGfgGfcGfgAfcUfaGfuAf(invdT) AM01497-SS 965 GfgCfgGfaCfuAfgUfgGfcUfcUfgAf(invdT) AM01498-SS 966 GfgCfcAfgCfgCfcCfgAfgGfaAfcAf(invdT) AM01499-SS 967 GfgAfaCfuGfaCfaGfuGfgUfaCfuAf(invdT) AM01500-SS 968 AfgUfgGfuAfcUfuGfgUfcAfaGfaAf(invdT) AM01501-SS 969 UfgGfuAfcUfuGfgUfcAfaGfaUfcAf(invdT) AM01502-SS 970 GfgUfaCfuUfgGfuCfaAfgAfuCfgAf(invdT) AM01503-SS 971 UfaCfuUfgGfuCfaAfgAfuCfgCfcAf(invdT) AM01504-SS 972 CfuCfcUfaCfcGfcCfuUfcAfcGfaAf(invdT) AM01505-SS 973 CfcUfaCfcGfcCfuUfcAfcGfaGfgAf(invdT) AM01506-SS 974 CfuAfcCfgCfcUfuCfaCfgAfgGfgAf(invdT) AM01507-SS 975 CfuGfaGfaCfaGfuGfcUfcUfgCfgAf(invdT) AM01508-SS 976 AfgUfuCfgAfgGfgGfgCfuGfaAfgAf(invdT) AM01509-SS 977 GfuUfcGfaGfgGfgGfcUfgAfaGfaAf(invdT) AM01510-SS 978 UfcGfaGfgGfgGfcUfgAfaGfaAfuAf(invdT) AM01511-SS 979 CfuCfuAfaCfgUfgCfaCfgGfaGfaAf(invdT) AM01512-SS 980 CfuAfaCfgUfgCfaCfgGfaGfaCfgAf(invdT) AM01513-SS 981 AfcGfuGfcAfcGfgAfgAfcGfcCfaAf(invdT) AM01613-SS 982 (Chol-TEG)uAuAfgCfcCfaAfgAfaAfgUfgAfaAfgAf(invdT) AM01614-SS 983 AfgCfcCfaAfgAfaAfgUfgAfaAfgUf(invdT) AM01615-SS 984 (Chol-TEG)uAuGfcCfcAfaGfaAfaGfuGfaAfaGfaAf(invdT) AM01616-SS 985 (Chol-TEG)uAuCfcCfaAfgAfaAfgUfgAfaAfgAfcAf(invdT) AM01617-SS 986 (Chol-TEG)uAuCfcAfaGfaAfaGfuGfaAfaGfaCfcAf(invdT) AM01618-SS 987 CfcAfaGfaAfaGfuGfaAfaGfaCfcUf(invdT) AM01619-SS 988 (Chol-TEG)uAuCfaAfgAfaAfgUfgAfaAfgAfcCfaAf(invdT) AM01620-SS 989 (Chol-TEG)uAuUfuUfgAfgCfcUfcAfgCfuUfcUfcAf(invdT) AM01905-SS 990 (Chol-TEG)uAuCfcCfaAfgAfaAfgUfgAfaAfgAfscsAf(invdT) AM01908-SS 991 (Chol-TEG)uAuCfcAfaGfaAfaGfuGfaAfaGfaCfscsAf(invdT) AM01911-SS 992 (Chol-TEG)uAuUfuUfgAfgCfcUfcAfgCfuUfcUfscsAf(invdT) AM01922-SS 993 (Chol-TEG)uAuCfcCfaAfgAfAfAfgUfgAfaAfgAfscsAf(invdT) AM01924-SS 994 (Chol-TEG)uAuCfcAfaGfaAfAfGfuGfaAfaGfaCfscsAf(invdT) AM01926-SS 995 (Chol-TEG)uAuUfuUfgAfgCfCfUfcAfgCfuUfcUfscsAf(invdT) AM01932-SS 996 GfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAfXuAu(TEG-Chol) AM01995-SS 997 (Chol-TEG)uAuCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(invdT) AM02061-SS 998 (Chol-TEG)uAuCfcCfaAfgAfAfAfgUfgAfaAfgAfcAf(invdT) AM02063-SS 999 (Chol-TEG)uAuUfuUfgAfgCfCfUfcAfgCfuUfcUfcAf(invdT) AM02084-SS 1000 (Alk-SS-C6)CfcAfaGfaAfaGfuGfaAfaGfaCfcAf(invdT) AM02085-SS 1001 (NH2-C6)CfcAfaGfaAfaGfuGfaAfaGfaCfcAf(invdT) AM02168-SS 1002 uAuAusGfscCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C6-SS-C6)(TEG- Chol) AM02169-SS 1003 (Chol-TEG)uAuAusGfscCfcAfaGfaAfAfGfuGfaAfaGfaCfscsAf AM02173-SS 1004 usGfscCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C6-SS-C6)(TEG-Chol) AM02174-SS 1005 GfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C6-SS-C6)(TEG-Chol) AM02196-SS 1006 (Chol-TEG)uAuAusGfscCfcAfaGfaAfAfGfuGfaAfaGfaCfc(invdA) AM02202-SS 1007 GfsgsAfgCfcCfaAfGfAfaAfgUfgAfaAfgAf(C6-NH2) AM02203-SS 1008 GfsasGfcCfcAfaGfAfAfaGfuGfaAfaGfaAf(C6-NH2) AM02204-SS 1009 AfsgsCfcCfaAfgAfAfAfgUfgAfaAfgAfcAf(C6-NH2) AM02205-SS 1010 GfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C6-NH2) AM02206-SS 1011 CfscsCfaAfgAfaAfGfUfgAfaAfgAfcCfaAf(C6-NH2) AM02207-SS 1012 GfscsUfuUfgAfgCfCfUfcAfgCfuUfcUfcAf(C6-NH2) AM02209-SS 1013 uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C6-NH2) AM02269-SS 1014 GfsgsAfgCfcCfaAfGfAfaAfgUfgAfaAfgAf(C6-SS-Alk-Me) AM02270-SS 1015 GfsasGfcCfcAfaGfAfAfaGfuGfaAfaGfaAf(C6-SS-Alk-Me) AM02271-SS 1016 AfsgsCfcCfaAfgAfAfAfgUfgAfaAfgAfcAf(C6-SS-Alk-Me) AM02272-SS 1017 GfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C6-SS-Alk-Me) AM02273-SS 1018 CfscsCfaAfgAfaAfGfUfgAfaAfgAfcCfaAf(C6-SS-Alk-Me) AM02274-SS 1019 GfscsUfuUfgAfgCfCfUfcAfgCfuUfcUfcAf(C6-SS-Alk-Me) AM02275-SS 1020 uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C6-SS-Alk-Me) AM02328-SS 1021 uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(NAG3) AM02329-SS 1022 uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C11-NAG3) AM02330-SS 1023 (Chol-TEG)uAuAusGfscCfcAfaGfaAfaGfuGfaAfaGfaCfscsAf AM02351-SS 1024 (Chol-TEG)uAuAusGfscCfcAfaGfaaAfGfuGfaAfaGfaCfscsAf AM02352-SS 1025 (Chol-TEG)uAuAusGfscCfcAfaGfAfaAfGfuGfaAfaGfaCfscsAf AM02353-SS 1026 (Chol-TEG)uAuAusgsCfcCfaAfgAfaAfGfuGfaAfaGfaCfscsAf AM02355-SS 1027 (Chol-TEG)uAuAusGfscCfcAfaGfaAfaGfuGfA_(UNA)AfaGfaCfscsAf AM02356-SS 1028 (Chol-TEG)uAuAusGfscCfcAfaGfaAfaGfuG_(UNA)aAfaGfaCfscsAf AM02357-SS 1029 (Chol-TEG)uAuAusGfscCfcAfaGfaAfaGfU_(UNA)GfaAfaGfaCfscsAf AM02358-SS 1030 (Chol-TEG)uAuAusGfscCfcAfaGfaAfaG_(UNA)uGfaAfaGfaCfscsAf AM02359-SS 1031 (Chol-TEG)uAuAusGfscCfcAfaGfaAfA_(UNA)GfuGfaAfaGfaCfscsAf AM02360-SS 1032 (Chol-TEG)uAuAusGfscCfcAfaGfaA_(UNA)aGfuGfaAfaGfaCfscsAf AM02361-SS 1033 (Chol-TEG)uAuAusGfscCfcAfaGfA_(UNA)AfaGfuGfaAfaGfaCfscsAf AM02362-SS 1034 (Chol-TEG)uAuAusGfscCfcAfaG_(UNA)aAfaGfuGfaAfaGfaCfscsAf AM02399-SS 1035 (Chol-TEG)uAuAusGfscUfuUfgAfgCfcUfcAfgCfuUfcUfscsAf AM02400-SS 1036 (Chol-TEG)uAuAusGfscUfuUfgAfgcCfUfcAfgCfuUfcUfscsAf AM02401-SS 1037 (Chol-TEG)uAuAusGfscUfuUfgAfGfcCfUfcAfgCfuUfcUfscsAf AM02402-SS 1038 (Chol-TEG)uAuAusgsCfuUfuGfaGfCfcUfcAfgCfuUfcUfscsAf AM02403-SS 1039 (NAG4)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfc(invdA) AM02431-SS 1040 (Chol-TEG)uAuAusGfscCfcAfaGfaAfaGfuGfaAfaGfaCfc(invdA) AM02435-SS 1041 (Chol-TEG)uAusasuGfaGfcCfcAfaGfaAfaGfuGfaAfaGfaCfc(invdA) AM02436-SS 1042 (Chol-TEG)uAuAusGfscUfuUfgAfgCfcUfcAfgCfuUfcUfc(invdA) AM02440-SS 1043 (Chol-TEG)uAusasuGfuGfcUfuUfgAfgCfcUfcAfgCfuUfcUfc(invdA) AM02457-SS 1044 GfscsUfuUfgAfgCfCfUfcAfgCfuUfcUfcAf(C6-SMPT-Alk) AM02458-SS 1045 uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C6-SMPT-Alk) AM02459-SS 1046 uAuAusGfscCfcAfaGfaAfAfGfuGfaAfaGfaCfc(invdA) AM02463-SS 1047 uAuAusGfsuUfuGfgAfgCfcCfaAfgAfaAfgUfgAf(C6-NH2) AM02465-SS 1048 uAuAusUfsuUfgGfaGfcCfcAfaGfaAfaGfuGfaAf(C6-NH2) AM02467-SS 1049 uAuAusUfsuGfgAfgCfcCfaAfgAfaAfgUfgAfaAf(C6-NH2) AM02469-SS 1050 uAuAusUfsgGfaGfcCfcAfaGfaAfaGfuGfaAfaAf(C6-NH2) AM02471-SS 1051 uAuAusAfsaGfuGfcUfuUfgAfgCfcUfcAfgCfuAf(C6-NH2) AM02473-SS 1052 uAuAusGfsuGfcUfuUfgAfgCfcUfcAfgCfuUfcAf(C6-NH2) AM02475-SS 1053 uAuAusGfsgCfuGfuGfgUfgAfcCfgCfaAfcAfaAf(C6-NH2) AM02477-SS 1054 uAuAusCfsuGfuGfgUfgAfcCfgCfaAfcAfaGfcAf(C6-NH2) AM02479-SS 1055 uAuAusUfsgUfgGfuGfaCfcGfcAfaCfaAfgCfcAf(C6-NH2) AM02490-SS 1056 (Chol-TEG)uAuAusGfcCfcAfaGfaaAfGfuGfaAfaGfaCfc(invdA) AM02491-SS 1057 (Chol-TEG)uAuAuGfcCfcAfaGfaaAfGfuGfaAfaGfaCfc(invdA) AM02494-SS 1058 (Chol-TEG)uAuAusGfcCfcAfaGfaAfAfGfuGfaAfaGfaCfc(invdA) AM02495-SS 1059 (Chol-TEG)uAuAuGfcCfcAfaGfaAfAfGfuGfaAfaGfaCfc(invdA) AM02496-SS 1060 (Chol-TEG)uAuAusGfcCfcAfaGfAfaaGfuGfaAfaGfaCfc(invdA) AM02497-SS 1061 (Chol-TEG)uAuAuGfcCfcAfaGfAfaaGfuGfaAfaGfaCfc(invdA) AM02498-SS 1062 (Chol-TEG)uAuAusGfcCfcAfagAfAfaGfuGfaAfaGfaCfc(invdA) AM02499-SS 1063 (Chol-TEG)uAuAuGfcCfcAfagAfAfaGfuGfaAfaGfaCfc(invdA) AM02500-SS 1064 (Chol-TEG)uAuAusGfcCfcAfAfgaAfaGfuGfaAfaGfaCfc(invdA) AM02501-SS 1065 (Chol-TEG)uAuAuGfcCfcAfAfgaAfaGfuGfaAfaGfaCfc(invdA) AM02513-SS 1066 uAuAusGfsuUfuGfgAfgCfcCfaAfgAfaAfgUfgAf(C6-SS-Alk-Me) AM02514-SS 1067 uAuAusUfsuUfgGfaGfcCfcAfaGfaAfaGfuGfaAf(C6-SS-Alk-Me) AM02515-SS 1068 uAuAusUfsuGfgAfgCfcCfaAfgAfaAfgUfgAfaAf(C6-SS-Alk-Me) AM02516-SS 1069 uAuAusUfsgGfaGfcCfcAfaGfaAfaGfuGfaAfaAf(C6-SS-Alk-Me) AM02517-SS 1070 uAuAusAfsaGfuGfcUfuUfgAfgCfcUfcAfgCfuAf(C6-SS-Alk-Me) AM02518-SS 1071 uAuAusGfsuGfcUfuUfgAfgCfcUfcAfgCfuUfcAf(C6-SS-Alk-Me) AM02519-SS 1072 uAuAusGfsgCfuGfuGfgUfgAfcCfgCfaAfcAfaAf(C6-SS-Alk-Me) AM02520-SS 1073 uAuAusCfsuGfuGfgUfgAfcCfgCfaAfcAfaGfcAf(C6-SS-Alk-Me) AM02521-SS 1074 uAuAusUfsgUfgGfuGfaCfcGfcAfaCfaAfgCfcAf(C6-SS-Alk-Me) AM02530-SS 1075 (NH2-C6)GfcCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C11-PEG3-NAG3) AM02545-SS 1076 (Chol-TEG)uAuAuGfscCfcAfaGfaAfaGfuGfaAfaGfaCfc(invdA) AM02550-SS 1077 (Me-Alk-SS-C6)GfcCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C11-PEG3- NAG3) AM02553-SS 1078 (Chol-TEG)uAuAusGfcCfcAfaGfaAfA_(UNA)GfuGfaAfaGfaCfc(invdA) AM02554-SS 1079 (Chol-TEG)uAuAusGfcCfcAfaGfaA_(UNA)aGfuGfaAfaGfaCfc(invdA) AM02555-SS 1080 (Chol-TEG)uAuAusGfcCfcAfaGfA_(UNA)AfaGfuGfaAfaGfaCfc(invdA) AM02556-SS 1081 (Chol-TEG)uAuAusGfcCfcAfaG_(UNA)aAfaGfuGfaAfaGfaCfc(invdA) AM02580-SS 1082 AfsgsCfcCfaAfgAfaAfgUfgAfaAfgAfcAf(C6-NH2) AM02581-SS 1083 AfsgsCfcCfaAfgAfaAfgUfgAfaAfgAfcAf(C6-SS-Alk-Me) AM02583-SS 1084 CfscsCfaAfgAfaagUfgAfaAfgAfcCfaAf(C6-NH2) AM02584-SS 1085 CfscsCfaAfgAfaagUfgAfaAfgAfcCfaAf(C6-SS-Alk-Me) AM02634-SS 1086 (Chol-TEG)UAUUAGfscCfcAfaGfaaAfGfuGfaAfaGfaCfc(invdA) AM02635-SS 1087 (Chol-TEG)UfaUfaAGfscCfcAfaGfaaAfGfuGfaAfaGfaCfc(invdA) AM02636-SS 1088 (Chol-TEG)uauaAGfscCfcAfaGfaaAfGfuGfaAfaGfaCfc(invdA) AM02637-SS 1089 (Chol-TEG)AUAUUGfscCfcAfaGfaaAfGfuGfaAfaGfaCfc(invdA) AM02638-SS 1090 (Chol-TEG)AfuAfuUGfscCfcAfaGfaaAfGfuGfaAfaGfaCfc(invdA) AM02639-SS 1091 (Chol-TEG)auauUGfscCfcAfaGfaaAfGfuGfaAfaGfaCfc(invdA) AM02649-SS 1092 CfcAfaGfaAfaGfuGfaAfaGfaCfcAfuAu(TEG-Chol) AM02651-SS 1093 gscsCfcAfagaAfAfGfugaAfagaCfcAf(C6-NH2) AM02652-SS 1094 gscsCfcAfagaAfAfGfugaAfagaCfcAf(C6-SS-Alk-Me) AM02653-SS 1095 uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C11-PEG3-NAG3) AM02654-SS 1096 (DBCO-TEG)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C11- PEG3-NAG3) AM02655-SS 1097 uAuAusGfsuGfcUfuUfgAfgCfcUfcAfgCfuUfcAf(C11-PEG3-NAG3) AM02663-SS 1098 uAuAusgsuGfcUfuUfgAfgCfcUfcAfgCfuUfcAf(C11-PEG3-NAG3) AM02664-SS 1099 uAuAusGfsugcUfuUfgAfgCfcUfcAfgCfuUfcAf(C11-PEG3-NAG3) AM02665-SS 1100 uAuAusgsugcUfuUfgAfgCfcUfcAfgCfuUfcAf(C11-PEG3-NAG3) AM02666-SS 1101 (DBCO-TEG)uAuAusgsugcUfuUfgAfgCfcUfcAfgCfuUfcAf(C11-PEG3- NAG3) AM02723-SS 1102 usGfsgAfgCfcCfaAfgAfaAfgUfg(invdA) AM02724-SS 1103 gsGfsaGfcCfcAfaGfaAfaGfuGfa(invdA) AM02725-SS 1104 gsAfsgCfcCfaAfgAfaAfgUfgAfa(invdA) AM02726-SS 1105 asGfscCfcAfaGfaAfaGfuGfaAfa(invdA) AM02727-SS 1106 gsCfscCfaAfgAfaAfgUfgAfaAfg(invdA) AM02728-SS 1107 csCfscAfaGfaAfaGfuGfaAfaGfa(invdA) AM02729-SS 1108 csCfsaAfgAfaAfgUfgAfaAfgAfc(invdA) AM02730-SS 1109 csAfsaGfaAfaGfuGfaAfaGfaCfc(invdA) AM02731-SS 1110 asAfsgAfaAfgUfgAfaAfgAfcCfa(invdA) AM02732-SS 1111 usGfscUfuUfgAfgCfcUfcAfgCfu(invdA) AM02733-SS 1112 csUfsuUfgAfgCfcUfcAfgCfuUfc(invdA) AM02734-SS 1113 usUfsgAfgCfcUfcAfgCfuUfcUfc(invdA) AM02735-SS 1114 usGfsuGfgUfgAfcCfgCfaAfcAfa(invdA) AM02736-SS 1115 gsUfsgGfuGfaCfcGfcAfaCfaAfg(invdA) AM02737-SS 1116 usGfsgUfgAfcCfgCfaAfcAfaGfc(invdA) AM02738-SS 1117 gsGfsuGfaCfcGfcAfaCfaAfgCfc(invdA) AM02739-SS 1118 GfsgsAfgCfcCfaAfgAfaAfgUfg(invdA) AM02740-SS 1119 GfsasGfcCfcAfaGfaAfaGfuGfa(invdA) AM02741-SS 1120 AfsgsCfcCfaAfgAfaAfgUfgAfa(invdA) AM02742-SS 1121 GfscsCfcAfaGfaAfaGfuGfaAfa(invdA) AM02743-SS 1122 CfscsCfaAfgAfaAfgUfgAfaAfg(invdA) AM02744-SS 1123 CfscsAfaGfaAfaGfuGfaAfaGfa(invdA) AM02745-SS 1124 CfsasAfgAfaAfgUfgAfaAfgAfc(invdA) AM02746-SS 1125 AfsasGfaAfaGfuGfaAfaGfaCfc(invdA) AM02747-SS 1126 AfsgsAfaAfgUfgAfaAfgAfcCfa(invdA) AM02748-SS 1127 GfscsUfuUfgAfgCfcUfcAfgCfu(invdA) AM02749-SS 1128 UfsusUfgAfgCfcUfcAfgCfuUfc(invdA) AM02750-SS 1129 UfsgsAfgCfcUfcAfgCfuUfcUfc(invdA) AM02751-SS 1130 GfsusGfgUfgAfcCfgCfaAfcAfa(invdA) AM02752-SS 1131 UfsgsGfuGfaCfcGfcAfaCfaAfg(invdA) AM02753-SS 1132 GfsgsUfgAfcCfgCfaAfcAfaGfc(invdA) AM02754-SS 1133 GfsusGfaCfcGfcAfaCfaAfgCfc(invdA) AM02842-SS 1134 (NH2-C6)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C11- PEG3-NAG3) AM02843-SS 1135 (NH2-C6)uAuAusgsugcUfuUfgAfgCfcUfcAfgCfuUfcAf(C11-PEG3- NAG3) AM02844-SS 1136 (Alk-C6)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C11- PEG3-NAG3) AM02845-SS 1137 (Alk-C6)uAuAusgsugcUfuUfgAfgCfcUfcAfgCfuUfcAf(C11-PEG3- NAG3) AM02867-SS 1138 (Spermine)uAuAusGfsuGfcUfuUfgAfgCfcUfcAfgCfuUfcAf(C11- PEG3-NAG3) AM02868-SS 1139 (Spermine)(Spermine)uAuAusGfsuGfcUfuUfgAfgCfcUfcAfgCfuUfc Af(C11-PEG3-NAG3) AM02869-SS 1140 (Spermine)(Spermine)(Spermine)uAuAusGfsuGfcUfuUfgAfgCfcUf cAfgCfuUfcAf(C11-PEG3-NAG3) AM02872-SS 1141 uAuAusGfcCfcAfAfgaAfaGfuGfaAfaGfaCfc(invdA) AM02954-SS 1142 uAuAugscsCfcAfagaAfAfGfugaAfagaCfcAf(C6-NH2) AM02955-SS 1143 uAuAugscsCfcAfagaAfAfGfugaAfagaCfcAf(C6-SS-Alk-Me) AM02956-SS 1144 uAuAugscsCfcAfagaAfAfGfugaAfagaCfcAf(C11-PEG3-NAG3) AM02960-SS 1145 uAuAugscsccaagaaAfGfugaaagacca(C11-PEG3-NAG3) AM02961-SS 1146 uAuAugscsccaagaAfaGfugaaagacca(C11-PEG3-NAG3) AM02974-SS 1147 (Stearyl)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C11- PEG3-NAG3) AM03028-SS 1148 (Chol-TEG)AuAusGfcCfcAfAfgaAfaGfuGfaAfaGfaCfc(invdA) AM03029-SS 1149 (Chol-TEG)uAusGfcCfcAfAfgaAfaGfuGfaAfaGfaCfc(invdA) AM03031-SS 1150 (BCN)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C11-PEG3- NAG3) AM03032-SS 1151 uaUfauGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C11-PEG3-NAG3) AM03033-SS 1152 (Me-Alk-SS- C6)uaUfauGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C11-PEG3- NAG3) AM03034-SS 1153 (NH2-C6)uaUfauGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C11- PEG3-NAG3) AM03035-SS 1154 AuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C11-PEG3-NAG3) AM03044-SS 1155 (Norbornene- C6)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C11-PEG3- NAG3) AM03045-SS 1156 (Alk-BC9-C6)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C11- PEG3-NAG3) AM03046-SS 1157 uAuAugscsCfcAfagaAfAfGfugaAfagaCfcAf(C6-NAG3) AM03052-SS 1158 (NH2-Ser)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfc(invdA) AM03053-SS 1159 (NH2-Ser)(NH2-Ser)(NH2- Ser)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfc(invdA) AM03054-SS 1160 (Norbornene- Ser)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfc(invdA) AM03055-SS 1161 (Norbornene-Ser)(Norbornene-Ser)(Norbornene- Ser)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfc(invdA) AM03056-SS 1162 (NH2-C6)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfc(invdA) AM03057-SS 1163 (Norbornene- C6)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfc(invdA) AM03071-SS 1164 GfsgsAfgCfcCfaAfgAfaAfgUfgAf(C11-PEG3-NAG3) AM03072-SS 1165 CfscsCfaAfgAfaAfgUfgAfaAfgAf(C11-PEG3-NAG3) AM03073-SS 1166 AfsasGfaAfaGfuGfaAfaGfaCfcAf(C11-PEG3-NAG3) AM03074-SS 1167 AfsgsAfaAfgUfgAfaAfgAfcCfaAf(C11-PEG3-NAG3) AM03083-SS 1168 (Spermine)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C11- PEG3-NAG3) AM03084-SS 1169 (Spermine)(Spermine)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCf cAf(C11-PEG3-NAG3) AM03085-SS 1170 (Spermine)(Spermine)(Spermine)uAuAuGfscsCfcAfaGfaAfAfGfuG faAfaGfaCfcAf(C11-PEG3-NAG3) AM03086-SS 1171 (NH2-C6)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C6-NH2) AM03112-SS 1172 uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfCMAM(C11-PEG3-NAG3) AM03113-SS 1173 uAuAU_(UNA)GfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C11-PEG3-NAG3) AM03114-SS 1174 (Spermine)GfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C11-PEG3- NAG3) AM03115-SS 1175 (Spermine)(Spermine)(Spermine)GfscsCfcAfaGfaAfAfGfuGfaAfa GfaCfcAf(C11-PEG3-NAG3) AM03117-SS 1176 (Alk-C6-C6)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C11- PEG3-NAG3) AM03118-SS 1177 (Alk-PEG4- C6)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C11-PEG3- NAG3) AM03132-SS 1178 uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C6-NAG3) AM03133-SS 1179 uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C6-PEG4-NAG3) AM03135-SS 1180 (C6-PEG4- NAG3)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfc(invdA) AM03136-SS 1181 uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfauAu(C6-NH2) AM03137-SS 1182 uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfauAu(C6-PEG4-NAG3) AM03138-SS 1183 (TetZ-C6)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C11- PEG3-NAG3) AM03139-SS 1184 (Alk-PEG5- C6)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C11-PEG3- NAG3) AM03140-SS 1185 (Alk-NHCO- C6)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C11-PEG3- NAG3) AM03141-SS 1186 (Alk-NHCO-SS- C6)uaUfauGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C11-PEG3- NAG3) AM03142-SS 1187 uAuAusGfscCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C11-PEG3-NAG3) AM03143-SS 1188 uAuAuGfsusGfcUfuUfgAfgCfcUfcAfgCfuUfcAf(C11-PEG3-NAG3) AM03145-SS 1189 (NH2-C6)(NH2- Ser)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfc(invdA) AM03146-SS 1190 (NH2-C6)(NH2-Ser)(NH2- Ser)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfc(invdA) AM03147-SS 1191 (NH2-C6)(NH2-Ser)(NH2-Ser)(NH2- Ser)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfc(invdA) AM03152-SS 1192 uAuAugscsccaagaaaGfuGfaaagacca(C11-PEG3-NAG3) AM03153-SS 1193 uAuAugscsccaagaaaGfugaaagacca(C11-PEG3-NAG3) AM03177-SS 1194 uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C6-C12-NAG3) AM03178-SS 1195 uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C11-palm-NAG3) AM03179-SS 1196 uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C6-SS-C6)(C11- palm-NAG3) AM03180-SS 1197 uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfauAu(C11-palm-NAG3) AM03181-SS 1198 (Alk-C6-C6)(Alk-C6- Ser)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfc(invdA) AM03182-SS 1199 (Alk-C6-C6)(Alk-C6-Ser)(Alk-C6- Ser)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfc(invdA) AM03183-SS 1200 (Alk-C6-C6)(Alk-C6-Ser)(Alk-C6-Ser)(Alk-C6- Ser)uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfc(invdA) AM03209-SS 1201 uaUfaugscsccaagaAfaGfugaaagacca(C11-PEG3-NAG3) AM03210-SS 1202 uauaugscsccaagaAfaGfugaaagacca(C11-PEG3-NAG3) AM03213-SS 1203 udAudAugscsccaagaAfaGfugaaagacca(C11-PEG3-NAG3) AM03214-SS 1204 uAugscsccaagaAfaGfugaaagaccuAu(C11-PEG3-NAG3) AM03217-SS 1205 uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C6-C6-NAG3) AM03218-SS 1206 uAuAuGfscsCfcAfaGfaAfAfGfuGfaAfaGfaCfcAf(C6-SS-C6)(C11- PEG3-NAG3) AM03327-SS 1207 uAuAugscsccaagaaAfGfugaaagacCMAM(C11-PEG3-NAG3) AM03328-SS 1208 uAuAugscsccaagaaAfGfugaaagacca(C6-NH2) AM03329-SS 1209 uAuAugscsccaagaaAfGfugaaagacca(C6-NAG3) AM03338-SS 1210 uAuAugscsccaagaaAfGfugaaagacca(NH2-C7) AM03339-SS 1211 uAuAugscsccaagaaAfGfugaaagacca(NAG13) AM03354-SS 1212 cscscaAfgAfaagugaaaga(C11-PEG3-NAG3) AM03355-SS 1213 cscscaaGfAfaagugaaaga(C11-PEG3-NAG3) AM03356-SS 1214 CfscsCfaAfgAfaAfgUfgAfaAfGMAM(C11-PEG3-NAG3) AM03357-SS 1215 CMsCMsCfaAfgAfaAfgUfgAfaAfGMAM(C11-PEG3-NAG3) AM03358-SS 1216 CMsCMsCfaAfgAfaAfgUfgAfaAfgAf(C11-PEG3-NAG3) AM03360-SS 1217 asasgaAfaGfugaaagacca(C11-PEG3-NAG3) AM03361-SS 1218 asasgaaAfGfugaaagacca(C11-PEG3-NAG3) AM03362-SS 1219 AfsasGfaAfaGfuGfaAfaGfaCfCMAM(C11-PEG3-NAG3) AM03363-SS 1220 AMsAMsGfaAfaGfuGfaAfaGfaCfCMAM(C11-PEG3-NAG3) AM03364-SS 1221 AMsAMsGfaAfaGfuGfaAfaGfaCfcAf(C11-PEG3-NAG3) AM03369-SS 1222 (NH2-Ser)uAuAugscsccaagaAfaGfugaaagacc(invdA) AM03370-SS 1223 (NH2-C6)(NH2-Ser)uAuAugscsccaagaAfaGfugaaagacc(invdA) AM03371-SS 1224 (NH2-C6)(NH2-Ser)(NH2-Ser)(NH2- Ser)uAuAugscsccaagaAfaGfugaaagacc(invdA) AM03372-SS 1225 (Alk-C6-Ser)uAuAugscsccaagaAfaGfugaaagacc(invdA) AM03373-SS 1226 (Alk-C6-C6)(Alk-C6- Ser)uAuAugscsccaagaAfaGfugaaagacc(invdA) AM03374-SS 1227 (Alk-C6-C6)(Alk-C6-Ser)3(Alk-C6-Ser)(Alk-C6- Ser)uAuAugscsccaagaAfaGfugaaagacc(invdA) AM03398-SS 1228 (Chol-TEG)uAuAugscsccaagaAfaGfugaaagacc(invdA) AM03399-SS 1229 (Chol-TEG)uAuAugscsccaagaAfaGfugaaagacca AM03400-SS 1230 (NH2-Ser)uauaugscsccaagaAfaGfugaaagacc(invdA) AM03401-SS 1231 (Alk-C6-Ser)uauaugscsccaagaAfaGfugaaagacc(invdA) AM03402-SS 1232 uAuAugscsccaagaAfaGfugaaagacca(NAG13) AM03403-SS 1233 uAuAugscsccaagaAfAfGfugaaagacca(NAG13) AM03404-SS 1234 uAuAugscsccaagaAfAfgugaaagacca(NAG13) AM03405-SS 1235 uAuAugscsccaagaaaGfUfgaaagacca(NAG13) AM03406-SS 1236 uAuAugscsccaagaAfaGfugaaagacCMAM(NAG13) AM03407-SS 1237 uAugscsccaagaAfaGfugaaagaccaAu(NAG13) AM03408-SS 1238 uAugscsccaagaAfaGfugaaagaccuAu(NAG13) AM03409-SS 1239 uaugscsccaagaAfaGfugaaagaccuAu(NAG13) AM03411-SS 1240 uAuAusgscccaagaAfaGfugaaagacca(NAG13) AM03412-SS 1241 uAuAsusgcccaagaAfaGfugaaagacca(NAG13) AM03413-SS 1242 uAuAugscccaagaAfaGfugaaagacca(NAG13) AM03414-SS 1243 uAuAugcsccaagaAfaGfugaaagacca(NAG13) AM03420-SS 1244 (NH2-C6)(NH2-Ser)uAugscsccaagaAfaGfugaaagaccuAu(Ser- NH2)(C6-NH2) AM03421-SS 1245 (Alk-C6-C6)(Alk-C6- Ser)uAugscsccaagaAfaGfugaaagaccuAu(Ser-C6-Alk)(C6-C6-Alk) AM03422-SS 1246 (NH2-C6)uAugscsccaagaAfaGfugaaagaccuAu(C6-NH2) AM03423-SS 1247 (Alk-C6-C6)uAugscsccaagaAfaGfugaaagaccuAu(C6-C6-Alk) AM03428-SS 1248 uAugscsccaagaAfaGfugaaagaccsusAu(NAG13) AM03429-SS 1249 uAugscsccaagaAfaGfugaaagacc(invdA)Au(NAG13) AM03430-SS 1250 uAugscsccaagaAfaGfugaaagacCMAMAu(NAG13) AM03431-SS 1251 (NH2-C6)uAuAugscsccaagaAfaGfugaaagacc(invdA) AM03432-SS 1252 (Alk-C6-C6)uAuAugscsccaagaAfaGfugaaagacc(invdA) AM03433-SS 1253 (NH2-C6)uauaugscsccaagaAfaGfugaaagacc(invdA) AM03434-SS 1254 (Alk-C6-C6)uauaugscsccaagaAfaGfugaaagacc(invdA) AM03435-SS 1255 (Alk-PEG5-Ser)uAuAugscsccaagaAfaGfugaaagacc(invdA) AM03436-SS 1256 (Alk-PEG5-C6)(Alk-PEG5- Ser)uAuAugscsccaagaAfaGfugaaagacc(invdA) AM03437-SS 1257 (Alk-PEG5-Ser)uauaugscsccaagaAfaGfugaaagacc(invdA) AM03438-SS 1258 (Alk-PEG5-C6)uAuAugscsccaagaAfaGfugaaagacc(invdA) AM03439-SS 1259 (Alk-PEG5-C6)uauaugscsccaagaAfaGfugaaagacc(invdA) AM03440-SS 1260 (Alk-PEG5-C6)uAugscsccaagaAfaGfugaaagaccuAu(C6-PEG5-Alk) AM03456-SS 1261 uAuAugscsccaagaAfaGfugaaagaccA_(LNA)(NAG13) AM03463-SS 1262 uAuAuG_(LNA)scsccaagaAfaGfugaaagaccA_(LNA)(NAG13) AM03464-SS 1263 uAuAuG_(LNA)scsccaagaAfaGfugaaagacca(NAG13) AM03476-SS 1264 uAugscsccaagaAfaGfugaaagaccuau(NAG13) AM03477-SS 1265 uAugscsccaagaAfaGfugaaagaccudAu(NAG13) AM03478-SS 1266 uAugscsccaagaAfaGfugaaagaccaau(NAG13) AM03479-SS 1267 uAugscsccaagaAfaGfugaaagaccauu(NAG13) AM03480-SS 1268 uAugscsccaagaAfaGfugaaagaccaua(NAG13) AM03481-SS 1269 uAugscsccaagaAfaGfugaaagaccaUu(NAG13) AM03482-SS 1270 uAugscsccaagaAfaGfugaaagaccaUa(NAG13) AM03520-SS 1271 uAuAuG_(LNA)csccaagaAfaGfugaaagacca(NAG13) AM03521-SS 1272 uAuAuG_(LNA)csccaagaAfaGfugaaagaccA_(LNA)(NAG13) AM03540-SS 1273 (Alk-PEG13-C6)uAuAugscsccaagaAfaGfugaaagacc(invdA) AM03541-SS 1274 (Alk-PEG13-C6)(Alk-PEG13- Ser)uAuAugscsccaagaAfaGfugaaagacc(invdA) AM03570-SS 1275 (NH2-C6)uuAgagscsccaagaAfaGfugaaagacc(invdA) AM03571-SS 1276 (Alk-C6-C6)uuAgagscsccaagaAfaGfugaaagacc(invdA) AM03572-SS 1277 (NH2-C6)uuAuugscsccaagaAfaGfugaaagacc(invdA) AM03573-SS 1278 (Alk-C6-C6)uuAuugscsccaagaAfaGfugaaagacc(invdA) AM03574-SS 1279 (NH2-C6)uuGAugscsccaagaAfaGfugaaagacc(invdA) AM03575-SS 1280 (Alk-C6-C6)uuGAugscsccaagaAfaGfugaaagacc(invdA) AM03576-SS 1281 (NH2-C6)uuagagscsccaagaAfaGfugaaagacc(invdA) AM03577-SS 1282 (Alk-C6-C6)uuagagscsccaagaAfaGfugaaagacc(invdA) AM03578-SS 1283 (NH2-C6)uAugagscsccaagaAfaGfugaaagacc(invdA) AM03579-SS 1284 (Alk-C6-C6)uAugagscsccaagaAfaGfugaaagacc(invdA) AM03582-SS 1285 uAuAugscsccaagaAfaGfugaaagacca(C6-NH2) AM03583-SS 1286 uAugscsccaagaAfaGfugaaagaccuAu(C6-NH2) AM03586-SS 1287 (Chol-TEG)aUaGasGfcCfcAfAfgaAfaGfuGfaAfaGfaCfc(invdA) AM03587-SS 1288 (Chol-TEG)uauausGfcCfcAfAfgaAfaGfuGfaAfaGfaCfc(invdA) AM03588-SS 1289 uAuAugscsccaagaAfaGfugaaagacca(NAG14) AM03591-SS 1290 AugscsccaagaAfaGfugaaagaccuAuu(NAG13) AM03592-SS 1291 AugscsccaagaAfaGfugaaagaccuGAu(NAG13) AM03628-SS 1292 uAuAugscsccaagaAfaGfugaaagacca(NAG15) AM03629-SS 1293 uAuAugscsccaagaAfaGfugaaagacca(NAG16) AM03630-SS 1294 uAuAugscsccaagaAfaGfugaaagacca(NAG17) AM03631-SS 1295 (NAG18)uAuAugscsccaagaAfaGfugaaagacc(invdA) AM03632-SS 1296 (NAG18)uauaugscsccaagaAfaGfugaaagacc(invdA) AM03633-SS 1297 uAuAugscsccaagaAfaGfugaaagacca(NAG18) AM03634-SS 1298 uAugscsccaagaAfaGfugaaagaccuAu(NAG18) AM03635-SS 1299 (NAG19)uAuAugscsccaagaAfaGfugaaagacc(invdA) AM03636-SS 1300 (NAG19)uauaugscsccaagaAfaGfugaaagacc(invdA) AM03637-SS 1301 uAuAugscsccaagaAfaGfugaaagacca(NAG19) AM03638-SS 1302 uAugscsccaagaAfaGfugaaagaccuAu(NAG19) AM03639-SS 1303 (NAG20)uAuAugscsccaagaAfaGfugaaagacc(invdA) AM03640-SS 1304 (NAG20)uauaugscsccaagaAfaGfugaaagacc(invdA) AM03641-SS 1305 uAuAugscsccaagaAfaGfugaaagacca(NAG20) AM03642-SS 1306 uAugscsccaagaAfaGfugaaagaccuAu(NAG20) AM03653-SS 1359 uauaugscsccaagaAfaGfugaaagacca(NAG13) AM03654-SS 1360 udAudAugscsccaagaAfaGfugaaagacca(NAG13) AM03669-SS 1361 uAuAugscsccaagaAfaGfugaaagacc(invdA)(NAG13) AM03684-SS 1362 uAuAugscsccaagaAfaGfugaaagacca AM03703-SS 1363 (NAG21)uAuAugscsccaagaAfaGfugaaagacc(invdA) AM03704-SS 1364 (NAG21)uauaugscsccaagaAfaGfugaaagacc(invdA) AM03705-SS 1357 gagscsccaagaAfaGfugaaagaccuAuu(NAG13) AM03706-SS 1358 gagscsccaagaAfaGfugaaagaccuGAu(NAG13) AM03726-SS 1351 cscscaAfgAfaagugaaaga(NAG13) AM03727-SS 1352 XscsccaAfgAfaagugaaaga(NAG13) AM03728-SS 1353 XsXscccaAfgAfaagugaaaga(NAG13) AM03729-SS 1354 CMsCMscaAfgAfaagugaaaGMAM(NAG13) AM03730-SS 1355 cscscaAfgAfaagugaaaGMAM(NAG13) AM03731-SS 1356 cscscaAfgAfaagugaaagu(NAG13) AM03738-SS 1365 (NAG23)uAuAugscsccaagaAfaGfugaaagacc(invdA) AM03739-SS 1366 (NAG23)uauaugscsccaagaAfaGfugaaagacc(invdA) AM03775-SS 1367 udAuaugscsccaagaAfaGfugaaagacca(NAG13) AM03776-SS 1374 udAugagscsccaagaAfaGfugaaagacca(NAG13) AM03777-SS 1349 adTagagscsccaagaAfaGfugaaagacca(NAG13) AM03778-SS 1350 auagagscsccaagaAfaGfugaaagacca(NAG13) AM03779-SS 1368 uauaugscsccaagaAfaGfugaaagacc(invdA)(NAG13) AM03780-SS 1369 u(invdA)uaugscsccaagaAfaGfugaaagacca(NAG13) AM03781-SS 1373 udAuaugscsccaagaAfaGfugaaagaccu(NAG13) AM03782-SS 1370 udAuaugscsccaagaAfaGfugaaagacc(invdA)(NAG13) AM03783-SS 1371 udAuaugscsccaagaAfaGfugaaagacc(inva)(NAG13) AM03784-SS 1372 udAuaugscsccaagaAfaGfugaaagacc(3′OMea)(NAG13) AM03800-SS 2206 gacaugscsccaagaAfaGfugaaagacca(NAG13) AM03801-SS 2207 ugaaugscsccaagaAfaGfugaaagacca(NAG13) AM03802-SS 2208 gcgaugscsccaagaAfaGfugaaagacca(NAG13) AM03806-SS 2209 uaugagscsccaagaAfaGfugaaagacca(NAG13) AM03807-SS 2210 uuggagscsccaagaAfaGfugaaagacca(NAG13) AM03812-SS 2211 cscscaAfgAfaagugaaagA_(LNA)(NAG13) AM03813-SS 2212 cscscaAfgAfaagugaaaG_(LNA)a(NAG13) AM03814-SS 2213 csmC_(LNA)scaAfgAfaagugaaaga(NAG13) AM03815-SS 2214 mC_(LNA)scscaAfgAfaagugaaaga(NAG13) AM03816-SS 2215 cscscaAfgAfaagugaaaG_(LNA)A_(LNA)(NAG13) AM03817-SS 2216 mC_(LNA)smC_(LNA)scaAfgAfaagugaaaga(NAG13) AM03818-SS 2217 mC_(LNA)scscaAfgAfaagugaaagA_(LNA)(NAG13) AM03834-SS 2218 CfscsCfaAfgAfaAfgUfgAfaAfGMAM(NAG13) AM03836-SS 2219 (NAG18)uaugagscsccaagaAfaGfugaaagacc(invdA) AM03838-SS 2220 (NAG18)auagagscsccaagaAfaGfugaaagacc(invdA) AM03840-SS 2221 (NAG18)gacaugscsccaagaAfaGfugaaagacc(invdA) AM03842-SS 2222 (NAG18)ugaaugscsccaagaAfaGfugaaagacc(invdA) AM03844-SS 2223 (NAG18)gcgaugscsccaagaAfaGfugaaagacc(invdA) AM03846-SS 2224 (NAG18)uauaugcccaagaAfaGfugaaagacc(invdA) AM03848-SS 2225 (NAG18)uauaugcccaagaAfaGfugaaagacCM(invdA) AM03850-SS 2226 (NAG18)uauaugcccaagaAfaGfugaaagaCMCM(invdA) AM03886-SS 2227 (Alk-PEG4-C6)uauaugscsccaagaAfaGfugaaagacca(NAG13) 1940 UfgGfaGfuCfaAfcAfcUfuUfcGfaAfdT 1941 GfgAfgUfcAfaCfaCfuUfuCfgAfuAfdT 1942 CfcCfaAfgGfaGfcAfuAfaGfuAfcAfdT 1943 CfcAfaGfgAfgCfaUfaAfgUfaCfaAfdT 1944 CfaAfgGfaGfcAfuAfaGfuAfcAfaAfdT 1945 AfgCfaUfaAfgUfaCfaAfaGfcUfgAfdT 1946 UfgAfaGfaGfcAfcAfcAfgUfcGfuAfdT 1947 GfaAfgAfgCfaCfaCfaGfuCfgUfuAfdT 1948 AfaGfaGfcAfcAfcAfgUfcGfuUfcAfdT 1949 CfaCfaGfuCfgUfuCfuCfaCfuGfuAfdT 1950 CfaGfuCfgUfuCfuCfaCfuGfuCfaAfdT 1951 GfcUfgUfaCfcAfcAfaAfuGfuAfcAfdT 1952 CfuGfuAfcCfaCfaAfaUfgUfaCfcAfdT 1953 UfgUfaCfcAfcAfaAfuGfuAfcCfcAfdT 1954 CfcAfcAfaAfuGfuAfcCfcAfcAfaAfdT 1955 AfgAfuGfcCfaGfuGfcAfaGfgGfuAfdT 1956 GfgGfgUfcGfcUfgCfcUfaGfaGfgAfdT 1957 GfcUfgCfuAfuGfaUfgGfcCfgCfgAfdT 1958 CfuGfcUfaUfgAfuGfgCfcGfcGfgAfdT 1959 UfgGfcCfgCfgGfgCfuCfaGfcUfaAfdT 1960 CfcGfcGfgGfcUfcAfgCfuAfcCfgAfdT 1961 GfaCfcAfcGfcUfcUfcGfgGfuGfcAfdT 1962 AfcCfaCfgCfuCfuCfgGfgUfgCfgAfdT 1963 CfcAfcGfcUfcUfcGfgGfuGfcGfcAfdT 1964 AfaGfcGfcGfgAfaCfuGfgGfgAfcAfdT 1965 GfgAfcUfgGfgCfgGfcCfaCfgCfcAfdT 1966 GfcCfgGfaAfcCfcGfgAfcAfaCfgAfdT 1967 CfgGfaAfcCfcGfgAfcAfaCfgAfcAfdT 1968 GfgAfaCfcCfgGfaCfaAfcGfaCfaAfdT 1969 GfaAfcCfcGfgAfcAfaCfgAfcAfuAfdT 1970 CfcGfgAfcAfaCfgAfcAfuCfcGfcAfdT 1971 AfcAfaCfgAfcAfuCfcGfcCfcGfuAfdT 1972 CfaAfcGfaCfaUfcCfgCfcCfgUfgAfdT 1973 AfaCfgAfcAfuCfcGfcCfcGfuGfgAfdT 1974 AfcGfaCfaUfcCfgCfcCfgUfgGfuAfdT 1975 CfaUfcCfgCfcCfgUfgGfuGfcUfuAfdT 1976 AfuCfcGfcCfcGfuGfgUfgCfuUfcAfdT 1977 CfcGfcCfcGfuGfgUfgCfuUfcGfuAfdT 1978 GfcCfcGfuGfgUfgCfuUfcGfuGfcAfdT 1979 CfuUfcAfuGfuCfcCfaCfuCfaUfgAfdT 1980 GfcAfgCfcGfgCfaCfcGfcCfgAfaAfdT 1981 GfgCfuCfcGfcAfaGfaGfuCfuGfuAfdT 1982 GfcUfcCfgCfaAfgAfgUfcUfgUfcAfdT 1983 GfaGfuCfuGfuCfuUfcGfaUfgAfcAfdT 1984 AfgUfcUfgUfcUfuCfgAfuGfaCfcAfdT 1985 GfuCfuUfcGfaUfgAfcCfcGfcGfuAfdT 1986 UfcUfuCfgAfuGfaCfcCfgCfgUfcAfdT 1987 CfuUfcGfaUfgAfcCfcGfcGfuCfgAfdT 1988 UfuCfgAfuGfaCfcCfgCfgUfcGfuAfdT 1989 UfcGfaUfgAfcCfcGfcGfuCfgUfuAfdT 1990 CfgAfuGfaCfcCfgCfgUfcGfuUfgAfdT 1991 GfaUfgAfcCfcGfcGfuCfgUfuGfgAfdT 1992 UfgAfcCfcGfcGfuCfgUfuGfgCfgAfdT 1993 GfaCfcCfgCfgUfcGfuUfgGfcGfgAfdT 1994 GfcUfgGfuGfgCfgCfuAfcGfcGfgAfdT 1995 UfgGfuGfgCfgCfuAfcGfcGfgGfgAfdT 1996 GfgUfgGfcGfcUfaCfgCfgGfgGfcAfdT 1997 GfuGfgCfgCfuAfcGfcGfgGfgCfgAfdT 1998 GfcUfaCfgCfgGfgGfcGfcAfcCfcAfdT 1999 GfgCfgCfaCfcCfcUfaCfaUfcGfcAfdT 2000 CfaCfcCfcUfaCfaUfcGfcCfgCfgAfdT 2001 CfcCfcUfaCfaUfcGfcCfgCfgCfuAfdT 2002 CfcCfuAfcAfuCfgCfcGfcGfcUfgAfdT 2003 CfcUfaCfaUfcGfcCfgCfgCfuGfuAfdT 2004 CfuAfcAfuCfgCfcGfcGfcUfgUfaAfdT 2005 UfaCfaUfcGfcCfgCfgCfuGfuAfcAfdT 2006 CfaUfcGfcCfgCfgCfuGfuAfcUfgAfdT 2007 UfcGfcCfgCfgCfuGfuAfcUfgGfgAfdT 2008 CfuGfcGfcCfgGfcAfgCfcUfcAfuAfdT 2009 GfcAfcCfcGfaGfgAfuCfuGfaCfgAfdT 2010 CfaCfcCfgAfgGfaUfcUfgAfcGfgAfdT 2011 UfuGfcAfcGfaGfgCfcUfuCfuCfgAfdT 2012 UfgCfaCfgAfgGfcCfuUfcUfcGfcAfdT 2013 GfcAfcGfaCfcUfgGfcUfcUfgUfuAfdT 2014 GfcUfcUfgUfuGfcGfcCfuUfcAfgAfdT 2015 UfuGfcGfcCfuUfcAfgGfaGfgAfuAfdT 2016 GfgAfcGfgCfaGfcUfgCfgCfgCfuAfdT 2017 CfgCfgCfuCfcUfgUfcGfcCfuUfaAfdT 2018 GfcGfcUfcCfuGfuCfgCfcUfuAfcAfdT 2019 CfgCfuCfcUfgUfcGfcCfuUfaCfgAfdT 2020 GfcUfcCfuGfuCfgCfcUfuAfcGfuAfdT 2021 CfuCfcUfgUfcGfcCfuUfaCfgUfuAfdT 2022 UfcCfuGfuCfgCfcUfuAfcGfuUfcAfdT 2023 UfgUfcGfcCfuUfaCfgUfuCfaGfcAfdT 2024 GfuCfgCfcUfuAfcGfuUfcAfgCfcAfdT 2025 UfcGfcCfuUfaCfgUfuCfaGfcCfgAfdT 2026 CfgCfcUfuAfcGfuUfcAfgCfcGfgAfdT 2027 GfcCfuUfaCfgUfuCfaGfcCfgGfuAfdT 2028 CfuUfaCfgUfuCfaGfcCfgGfuGfuAfdT 2029 AfcGfuUfcAfgCfcGfgUfgUfgCfcAfdT 2030 GfgUfgUfgCfcUfgCfcAfaGfcGfgAfdT 2031 GfcCfaCfcAfgUfuCfgAfgGfgGfgAfdT 2032 CfaCfcAfgUfuCfgAfgGfgGfgCfgAfdT 2033 UfcGfaGfgGfgGfcGfgAfgGfaAfuAfdT 2034 CfuGfcGfcAfgGfgUfuCfcUfcGfaAfdT 2035 UfgCfgCfaGfgGfuUfcCfuCfgAfgAfdT 2036 GfcGfcAfgGfgUfuCfcUfcGfaGfgAfdT 2037 UfuCfcUfcGfaGfgGfcGfgCfaCfcAfdT 2038 CfuCfgAfgGfgCfgGfcAfcCfgAfuAfdT 2039 UfcGfaGfgGfcGfgCfaCfcGfaUfgAfdT 2040 CfaGfaGfcGfcCfgGfcUfcAfcCfcAfdT 2041 AfuCfaGfcUfgGfgGfaUfcGfgGfcAfdT 2042 GfaUfcGfgGfcUfgUfgGfuGfaCfcAfdT 2043 CfcGfcAfaCfaAfgCfcAfgGfcGfuAfdT 2044 GfcAfaCfaAfgCfcAfgGfcGfuCfuAfdT 2045 AfgGfcGfuCfuAfcAfcCfgAfuGfuAfdT 2046 GfgCfgUfcUfaCfaCfcGfaUfgUfgAfdT 2047 GfcGfuCfuAfcAfcCfgAfuGfuGfgAfdT 2048 CfuGfgAfuCfcGfgGfaGfcAfcAfcAfdT 2049 CfuGfaUfuGfcUfcAfgGfgAfcUfcAfdT 2050 AfuUfgCfuCfaGfgGfaCfuCfaUfcAfdT 2051 AfgGfaAfcUfcAfaUfaAfaGfuGfcAfdT 2052 GfgAfaCfuCfaAfuAfaAfgUfgCfuAfdT

A sense strand containing a sequence listed in Table 1 or 3 can be hybridized to any antisense strand containing a sequence listed in Table 1 or 2 provided the two sequences have a region of at least 90% complementarity over a contiguous 16, 17, 18, 19, 20, or 21 nucleotide sequence; representative sequences are exemplified by the Duplex ID Nos. shown in Table 24. In some embodiments an F12 RNAi trigger consists of any of the Duplex ID Nos. presented herein. In some embodiments an F12 RNAi trigger comprises of any of the Duplex ID Nos. presented herein. In some embodiments, an F12 RNAi trigger comprises the sense strand and antisense strand nucleotide sequences of any of the Duplex ID Nos. presented herein. In some embodiments, an F12 RNAi trigger comprises the sense strand and antisense strand nucleotide sequences of any of the Duplex ID Nos. presented herein and a targeting group and/or linking group wherein the targeting group and/or linking group is covalently linked to the sense strand or the antisense strand. In some embodiments, an F12 RNAi trigger comprises the sense strand and antisense strand modified nucleotide sequences of any of the Duplex ID Nos. presented herein. In some embodiments, an F12 RNAi trigger comprises the sense strand and antisense strand modified nucleotide sequences of any of the Duplex ID Nos. presented herein and a targeting group and/or linking group wherein the targeting group and/or linking group is covalently linked to the sense strand or the antisense strand. In some embodiments, a F12 RNAi trigger comprises Duplex ID Nos. AD00900, AD01001, AD01520, AD02639, AD02640, AD02023, AD02642, AD02708, AD02807, AD02822, AD02867, or AD02868. In some embodiments, a F12 RNAi trigger comprises SEQ ID No. 11, SEQ ID No. 150, or SEQ ID No. 177. In some embodiments, a F12 RNAi trigger comprises SEQ ID No 374 or SEQ ID No. 379.

In some embodiments, an F12 RNAi trigger further includes a targeting group, linking group, delivery polymer and/or other non-nucleotide group covalently linked to the 3′ and/or 5′ end of either the sense strand and/or the antisense strand. In some embodiments, an F12 RNAi trigger can contain a targeting group, linking group, delivery polymer, or other non-nucleotide group covalently linked to the 3′ and/or 5′ end of the sense strand. In some embodiments a targeting group, linking group, delivery polymer, or other non-nucleotide group is linked to the 5′ end of an F12 RNAi trigger sense strand. In some embodiments, the targeting group, linking group, and/or delivery vehicle is linked directly or indirectly to the trigger via a linker/linking group. In some embodiments, a targeting group or delivery vehicle is linked to the trigger via a labile, cleavable, or reversible bond or linker. Examples of targeting groups and linking groups are provided in Table 4. Table 4 provides several embodiments of F12 RNAi trigger sense strands having a targeting group or linking group linked to the 5′ or 3′ end.

A targeting group can enhance the pharmacokinetic or biodistribution properties of an RNAi trigger or conjugate to which it is attached to improve cell- or tissue-specific distribution and cell-specific uptake of the conjugate. In some instances, binding of a targeting group to a cell or cell receptor may initiate endocytosis. A targeting group can be monovalent, divalent, trivalent, tetravalent, or have higher valency. Representative targeting groups include, without limitation, compounds with affinity to cell surface molecule, cell receptor ligands, hapten, antibodies, monoclonal antibodies, antibody fragments, and antibody mimics with affinity to cell surface molecules. Simply by way of example, a variety of ligands can be used to target drugs and genes to cells and to specific cellular receptors, including, without limitation, carbohydrates, glycans, saccharides (including, but not limited to: galactose, galactose derivatives (such as, for example, N-acetyl-galactosamine), mannose, and mannose derivatives), vitamins, folate, biotin, aptamers, and peptides (including, but not limited to: RGD-containing peptides, insulin, EGF, and transferrin). In some embodiments, a targeting group can be linked to an RNAi trigger using a linker, such as a PEG linker or one, two, or three abasic and/or ribitol groups.

In some embodiments, any of the F12 RNAi triggers listed in Table 3 which contain a 3′ or 5′ targeting group or linking group, may alternatively contain no 3′ or 5′ targeting group or linking group, or may contain a different 3′ or 5′ targeting group or linking group including, but not limited to, those depicted in Table 4. In some embodiments, an F12 RNAi trigger can include a hydrophobic group such as a cholesterol or a targeting group (e.g. a galactose cluster).

In some embodiments, a targeting group can include or consist of a hydrophobic group. In some embodiments, the hydrophobic group contains at least 20 carbon atoms. Hydrophobic groups can be hydrocarbons (e.g., containing only carbon and hydrogen atoms). However, substitutions or heteroatoms that maintain hydrophobicity, for example fluorine, are permitted. Hydrophobic groups useful as targeting groups include, without limitation, alkyl group, alkenyl group, alkynyl group, aryl group, aralkyl group, aralkenyl group, and aralkynyl group, each of which may be linear, branched, or cyclic, cholesterol, cholesteryl derivative, sterol, steroid, and steroid derivative. Examples of suitable hydrophobic groups include, without limiation: cholesterol, cholesteryl derivatives, dicholesterol, tocopherol, ditocopherol, didecyl, didodecyl, dioctadecyl, didodecyl, dioctadecyl, isoprenoid, and choleamide.

In some embodiments, a targeting group can include or consist of one or more galactose derivatives or galactose clusters. As used herein, the term galactose derivative includes both galactose and derivatives of galactose having affinity for the asialoglycoprotein receptor that is equal to or greater than that of galactose. Glactose derivatives include, but are not limited to: galactose, galactosamine, N-formylgalactosamine, N-acetyl-galactosamine, N-propionyl-galactosamine, N-n-butanoyl-galactosamine, and N-iso-butanoylgalactos-amine (see for example: Iobst, S. T. and Drickamer, K. J.B.C. 1996, 271, 6686). Galactose derivatives and galactose clusters that are useful for in vivo targeting or oligonucleotides and other molecules to the liver are well known in the art (see, for example, Baenziger and Fiete, 1980, Cell, 22, 611-620; Connolly et al., 1982, J. Biol. Chem., 257, 939-945).

As used herein, a galactose cluster comprises a molecule having two to four terminal galactose derivatives. A terminal galactose derivative c attached to a molecule through its C-1 carbon. In some embodiments, the galactose cluster is a galactose derivative trimer, tri-antennary galactose derivative, tri-valent galactose derivative. In some embodiments, the galactose cluster is comprised of N-acetyl-galactosamine (GalNAc). In some embodiments, the galactose cluster comprises a tri-valent N-acetyl-galactosamine.

As used herein, a galactose derivative trimer contains three galactose derivatives, each linked to a central branch point. The galactose derivatives can be attached to the central branch point through the C-1 carbons of the saccharides. In some embodiments, the galactose derivatives are linked to the branch point via linkers or spacers. In some embodiments, the linker or spacer is a flexible hydrophilic spacer, such as a PEG group (see, for example, U.S. Pat. No. 5,885,968; Biessen et al. J. Med. Chem. 1995 Vol. 39 p. 1538-1546). The branch point can be any small molecule which permits attachment of the three galactose derivatives and further permits attachment of the branch point to the RNAi trigger. An example of branch point group is a di-lysine or di-glutamate. Attachment of the branch point to the RNAi trigger can occur through a linker or spacer.

In some embodiments, pharmaceutical compositions for delivering an F12 RNAi trigger to a liver cell in vivo are described. Such pharmaceutical compositions can include, for example, an F12 RNAi trigger conjugated to a galactose cluster. In some embodiments, the galactose cluster is comprised of a galactose derivative trimer, which can be, for example, an N-acetyl-galactosamine trimer.

In some embodiments, an F12 RNAi trigger includes a linking group conjugated to the trigger. The linking group facilitates covalent linkage of the trigger to a targeting group or delivery polymer. The linking group can be linked to the 3′ or the 5′ end of the RNAi trigger sense strand or antisense strand. In some embodiments, the linking group is linked to the RNAi trigger sense strand. In some embodiments, the linking group is conjugated to the 5′ or 3′ end of an RNAi trigger sense strand. In some embodiments a linking group is conjugated to the 5′ end of an RNAi trigger sense strand. Examples of linking groups, include or consist of, but are not limited to: Alk-SMPT-C6, Alk-SS-C6, DBCO-TEG, Me-Alk-SS-C6, and C6-SS-Alk-Me, reactive groups such a primary amines and alkynes, alkyl groups, abasic ribose, ribitol, and/or PEG groups.

A linker or linking group is a connection between two atoms that links one chemical group (such as an RNAi agent) or segment of interest to another chemical group (such as a targeting group or delivery polymer) or segment of interest via one or more covalent bonds. A labile linkage contains a labile bond. A linkage may optionally include a spacer that increases the distance between the two joined atoms. A spacer may further add flexibility and/or length to the linkage. Spacers may include, but are not be limited to, alkyl groups, alkenyl groups, alkynyl groups, aryl groups, aralkyl groups, aralkenyl groups, and aralkynyl groups; each of which can contain one or more heteroatoms, heterocycles, amino acids, nucleotides, and saccharides. Spacer groups are well known in the art and the preceding list is not meant to limit the scope of the description.

Targeting groups and linking groups include or consist of, but are not limited to, the compounds represented by the structures shown in Table 4. In some of the targeting group and linking group structures shown, the RNAi trigger is shown and denoted by Trigger, RNA, R, or R1 or R2 (i.e. Trigger, RNA or R1 or R2 each comprises the RNAi trigger). In some embodiments, the RNAi trigger is linked directly to a targeting group or linking group. In other embodiments, the RNAi trigger is linked to a targeting group or linking group via a linker. For example, with respect to (Alk-C6-Ser), (Alk-PEG5-Ser), and (Alk-PEG13-Ser), one of R1 and R2 comprises the RNAi trigger and the other can be a hydrogen. With respect to linkers (C3), (C12), (Sp9), (Sp18), (Spermine), (C6-SS-C6), one of R1 or R2 comprises the RNAi trigger and the other can be a hydrogen, reactive group, targeting group, linking group, alkyl group, or substituted alkyl group.

TABLE 4 Structures representing, vpdT, targeting groups and linking groups.

vpdT-RNA

(Alk-C6)-Trigger

(Alk-PEG4-C6)-Trigger

(Alk-PEG5-C6)-Trigger or Trigger-(C6-PEG5-Alk)

(Alk-BC9-C6)-Trigger

(Alk-SS-C6)-RNA, (n = 1-10), In some embodiments, n = 4

RNA-(C6-SS-Alk-Me) or ((Me-Alk-SS-C6)-RNA; (n = 1-10), In some embodiments, n = 4.

(Alk-C6-C6)-Trigger or Trigger-(C6-C6-Alk)

(Alk-NHCO-C6)

(Alk-NHCO-SS-C6)

(Alk-C6-Ser)-RNA or RNA-(Ser-C6-Alk), RNA is R1 or R2

(Alk-PEG5-Ser)-RNA, RNA is R1 or R2

(Alk-PEG13-Ser)-RNA, RNA is R1 or R2

(Alk-PEG13-C6)-Trigger

RNA-(C6-SMPT-Alk), n = 1-10, In some embodiments, n = 4

(DBCO-TEG)-Trigger

(BCN)-Trigger

(NH₂-C6)-RNA, n = 1-10, In some embodiments, n = 4.

(NH2-C6)-Trigger or Trigger-(C6-NH2)

(NH2-Ser)-Trigger or Trigger-(Ser-NH2)

(NH2-C7)-Trigger

(Norbornene-C6)-Trigger

(Norbornene-Ser)-Trigger

(TetZ-C6)-Trigger

RNA-(NAG3), x = 1-10, In some embodiments, x = 8.

(NAG3-C6)-Trigger or Trigger-(C6-NAG3)

(C6-C6-NAG3)-Trigger

(C6-C12-NAG3)-Trigger

(C6-PEG4-NAG3)-Trigger

(C11-NAG3)-Trigger

(C11-PEG3-NAG3)-Trigger

RNA-(C11-PEG3-NAG3)

(C11-palm-NAG3)-Trigger

(NAG13)-Trigger

(NAG14)-Trigger

(NAG15)-Trigger

(NAG16)-Trigger

(NAG17)-Trigger

(NAG18)-Trigger

(NAG19)-Trigger

(NAG20)-Trigger

(NAG21)-Trigger

(NAG23)-Trigger

(NAG4)-RNA

((GalNAc-PEG3-ethylene)3 bislysine-PEG3-C7 diol)-Trigger

((GalNAc-PEG3-ethylene)3 bislysine-PEG3-C6)-Trigger

((GalNac-PEG3-methylene)3 bislysine-C6)-Trigger

((GalNac-peg3-methylene)3 bislysine-C7 diol)-Trigger

((GalNac-C6)3 bislysine-C12-C7 diol)-Trigger

(PAZ)-Trigger

(Chol-TEG)-RNA, n = 1-10, In some embodiments, n = 2.

RNA-(TEG-Chol), n = 1-10, In some embodiments, n = 3.

RNA-(C6-SS-C6)(TEG-Chol), n = 1-10, In some embodiments, n = 3.

(Stearyl)-R

(C3)-RNA, RNA is R1 or R2

(C12)-RNA, RNA is R1 or R2

(Sp9)-RNA, RNA is R1 or R2

(Sp18)-RNA, RNA is R1 or R2

(Spermine)-RNA, RNA is R1 or R2

(C6-SS-C6)-RNA, RNA is R1 or R2

(Cy5-C6)-Trigger

In some embodiments, a delivery vehicle may be used to delivery an RNAi trigger to a cell or tissue. A delivery vehicle is a compound that improves delivery of the RNAi trigger to a cell or tissue. A delivery vehicle can include, or consist of, but is not limited to: a polymer, such as an amphipathic polymer, a membrane active polymer, a peptide, a melittin peptide, a melittin-like peptide, a lipid, or a reversibly modified polymer or peptide.

As used herein, the term “sequence” or “nucleotide sequence” refers to a succession or order of nucleobases or nucleotides, described with a succession of letters using the standard nucleotide nomenclature and the key for modified nucleotides described herein.

As used herein, and unless otherwise indicated, the term “complementary,” when used to describe a first nucleotide sequence (e.g., RNAi trigger sense strand or F12 mRNA) in relation to a second nucleotide sequence (e.g. RNAi trigger antisense strand), refers to the ability of an oligonucleotide or polynucleotide comprising the first nucleotide sequence to hybridize (form base pair hydrogen bonds) and form a duplex or double helical structure under certain conditions with an oligonucleotide or polynucleotide comprising the second nucleotide sequence. Complementary sequences include Watson-Crick base pairs or non-Watson-Crick base pairs and include natural or modified nucleotides or nucleotide mimics as long as the above requirements with respect to their ability to hybridize are fulfilled. “Perfectly” or fully complementary” means that all (100%) of the bases in a contiguous sequence of a first polynucleotide will hybridize with the same number of bases in a contiguous sequence of a second polynucleotide. The contiguous sequence may comprise all or a part of a first or second nucleotide sequence. As used herein, “partial complementary” means that in a hybridized pair of nucleobase sequences, at least 70% of the bases in a contiguous sequence of a first polynucleotide will hybridize with the same number of bases in a contiguous sequence of a second polynucleotide. As used herein, “substantial complementary” means that in a hybridized pair of nucleobase sequences, at least 85% of the bases in a contiguous sequence of a first polynucleotide will hybridize with the same number of bases in a contiguous sequence of a second polynucleotide. The terms “complementary”, “fully complementary” and “substantially complementary” as used herein may be used with respect to the base matching between the sense strand and the antisense strand of an RNAi trigger, or between the antisense strand of an RNAi trigger and a sequence of an F12 mRNA.

Sequence identity or complementarity is independent of modification. For the purposes of determining identity or complementarity, for example, a and Af are complementary to U (or T) and identical to A.

In some embodiments, an F12 RNAi trigger can be used to treat a subject having a disease or disorder that would benefit from reducing or inhibiting of expression of F12. In some embodiments, an F12 RNAi trigger can be used to formulate a composition for treating a disease or disorder in a subject that would benefit from reducing or inhibiting of expression of F12. The example, a subject can be administered a therapeutically effective amount of any one or more of the F12 RNAi triggers or compositions described herein. The subject also can be referred to as a patient, and can be a human or animal patient. The described F12 RNAi triggers can be used to provide a method for therapeutic treatment of diseases. Such methods typically include administration of an F12 RNAi trigger described herein to a subject.

In some embodiments, an F12 RNAi trigger can be used to inhibiting expression of F12 in a cell, group of cells, or a tissue, e.g., in a subject. In some embodiments, an F12 RNAi trigger can be used to formulate a composition for inhibiting expression of F12 in a cell, group of cells, or a tissue, e.g., in a subject. In some embodiments, a therapeutically effective amount of one type (or several different types) of F12 RNAi triggers as described herein is administered to a subject, thereby inhibiting expression of F12 in the subject (e.g., an amount effective to inhibit expression of F12 in the subject).

As used herein, the terms “silence,” “reduce,” “inhibit,” “down-regulate,” or “knockdown gene expression,” when referring to an F12 gene, mean that the expression of the gene, as measured by the level of RNA transcribed from the gene or the level of polypeptide, protein, or protein subunit translated from the mRNA in a cell, group of cells, or tissue, in which the F12 gene is transcribed, is reduced when the cell, group of cells, or tissue, is treated with the described F12 RNAi triggers as compared to a second cell, group of cells, or tissue that has or have not been so treated or compared to the same cell, group of cells, or tissue, prior to administration of the F12 RNAi trigger.

In some embodiments, the F12 RNAi triggers described herein are used to treat a subject having a disease or disorder that would benefit from reduction or inhibition in F12 expression. Treatment of a subject that would benefit from a reduction and/or inhibition of F12 gene expression includes therapeutic and/or prophylactic treatment. Representative diseases are those associated with angioedema, including but not limited to: hereditary angioedema (HAE), acquired angioedema (AAE), including but not limited to ACE inhibitor associated angioedema, allergic angioedema, nonhistaminergic angioedema (INAE), idiopathic angioedema, thrombosis, venous thromboembolism (VTE), thrombotic occlusive disease, including but not limited to peri-operative venous occlusive disease prophylaxis, treatment and prevention of venous occlusive disease such as deep venous thrombosis or pulmonary embolism, and treatment or prevention of arterial thromboembolic disease.

In some embodiments, pharmaceutical compositions comprising at least one of the described F12 RNAi triggers are contemplated. These pharmaceutical compositions are useful in the inhibition of the expression of the F12 gene in a cell, a tissue, or an organism. In some embodiments, the described pharmaceutical compositions are used to treat a subject having a disease or disorder that would benefit from reduction or inhibition in F12 expression. In some embodiments, the described pharmaceutical compositions are used to treat a subject at risk of developing a disease or disorder that would benefit from reduction or inhibition in F12 expression. Diseases and/or disorder that would benefit from reduction or inhibition in F12 expression may be selected from the list comprising: angioedema, HAE, AAE, allergic angioedema, INAE, idiopathic angioedema, thrombosis, VTE, thrombotic occlusive disease, venous occlusive disease, and arterial thromboembolic disease. In some embodiments, the subject is a mammal, including, but not limited to, a human patient. In some embodiments, the method comprises administering a composition comprising an F12 RNAi trigger molecule described herein to a mammal to be treated. The pharmaceutical compositions described above may also comprise a one or more pharmaceutically acceptable excipients (including vehicles, carriers, diluents, and/or delivery polymers).

As used herein, a “pharmaceutical composition” comprises a pharmacologically effective amount of at least one RNAi trigger and one or more a pharmaceutically acceptable excipients. Pharmaceutically acceptable excipients (excipients) are substances other than the Active Pharmaceutical ingredient (API, therapeutic product, e.g., RNAi trigger) that have been appropriately evaluated for safety and are intentionally included in the drug delivery system. Excipients do not exert or are not intended to exert a therapeutic effect at the intended dosage. Excipients may act to a) aid in processing of the drug delivery system during manufacture, b) protect, support or enhance stability, bioavailability or patient acceptability of the API, c) assist in product identification, and/or d) enhance any other attribute of the overall safety, effectiveness, of delivery of the API during storage or use. A pharmaceutically acceptable excipient may or may not be an inert substance.

Excipients include, but are not limited to: absorption enhancers, anti-adherents, anti-foaming agents, anti-oxidants, binders, binders, buffering agents, carriers, coating agents, colors, delivery enhancers, dextran, dextrose, diluents, disintegrants, emulsifiers, extenders, fillers, flavors, glidants, humectants, lubricants, oils, polymers, preservatives, saline, salts, solvents, sugars, suspending agents, sustained release matrices, sweeteners, thickening agents, tonicity agents, vehicles, water-repelling agents, and wetting agents.

The pharmaceutical compositions can contain other additional components commonly found in pharmaceutical compositions. Such additional components can include, but are not limited to: anti-pruritics, astringents, local anesthetics, or anti-inflammatory agents (e.g., antihistamine, diphenhydramine, etc.). It is also envisaged that cells, tissues or isolated organs that express or comprise the herein defined RNAi triggers may be used as “pharmaceutical compositions”. As used herein, “pharmacologically effective amount,” “therapeutically effective amount,” or simply “effective amount” refers to that amount of an RNAi trigger to produce the intended pharmacological, therapeutic or preventive result.

In other embodiments, the F12 RNAi triggers are useful for treating, preventing, or managing clinical presentations associated with angioedema, hereditary angioedema (HAE), acquired angioedema (AAE), allergic angioedema, nonhistaminergic angioedema (INAE), idiopathic angioedema, thrombosis, venous thromboembolism (VTE), thrombotic occlusive disease, venous occlusive disease, and arterial thromboembolic disease. Said methods comprise administering to a subject in need of such treatment, prevention or management a therapeutically or prophylactically effective amount of one or more of the F12 RNAi triggers described herein. In some embodiments, the subject is a mammal, including, but not limited to, a human patient. In some embodiments, the method comprises administering a composition comprising an F12 RNAi trigger molecule described herein to a mammal to be treated.

In some embodiments, the described F12 RNAi triggers and methods of using such F12 RNAi triggers are used to treat or prevent at least one symptom in a subject having a disease or disorder that would benefit from reduction or inhibition in F12 expression. The subject is administered a therapeutically effective amount of any one or more of the described RNAi triggers thereby treating the symptom. The subject is administered a prophylactically effective amount of any one or more of the described RNAi triggers thereby preventing the at least one symptom.

In some embodiments, the gene expression level and/or mRNA level of F12 in a subject to whom a described F12 RNAi trigger is administered is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98% relative to the subject prior to being administered the F12 RNAi trigger or to a subject not receiving the F12 RNAi trigger. The gene expression level and/or mRNA level in the subject may be reduced in a cell, group of cells, and/or tissue of the subject. In some embodiments, the protein level of F12 in a subject to whom a described F12 RNAi trigger has been administered is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98% relative to the subject prior to being administered the F12 RNAi trigger or to a subject not receiving the F12 RNAi trigger. The protein level in the subject may be reduced in a cell, group of cells, tissue, blood, and/or other fluid of the subject. A reduction in gene expression, mRNA, or protein levels can be assessed by any methods known in the art. Reduction or decrease in F12 mRNA level and/or protein level are collectively referred to herein as a reduction or decrease in F12 or inhibiting or reducing the expression of F12.

The described F12 RNAi triggers can be combined a second therapeutic or treatment including, but not limited to: a second RNAi trigger or other RNAi agent, a small molecule drug, an antibody, an antibody fragment, and/or a vaccine.

The described RNAi triggers and pharmaceutical compositions comprising F12 RNAi triggers disclosed herein may be packaged or included in a kit, container, pack, or dispenser. The F12 RNAi triggers may be packaged in pre-filled syringes or vials.

“Introducing into a cell”, when referring to an RNAi trigger, means functionally delivering the RNAi trigger into a cell. By functional delivery, it is meant that the RNAi trigger is delivered to the cell and has the expected biological activity, (e.g., sequence-specific inhibition of gene expression).

The route of administration is the path by which an RNAi trigger is brought into contact with the body. In general, methods of administering drugs and nucleic acids for treatment of a subject are well known in the art and can be applied to administration of the compositions described herein. The compounds described herein can be administered via any suitable route in a preparation appropriately tailored to the particular route. Thus, the compounds described herein can be administered by injection, for example, intravenously, intramuscularly, intracutaneously, subcutaneously, or intraperitoneally.

In some embodiments, the F12 RNAi trigger molecules or compositions described herein can be delivered to a cell, group of cells, tissue, or subject using oligonucleotide delivery technologies known in the art. In general, any suitable method recognized in the art for delivering a nucleic acid molecule (in vitro or in vivo) can be adapted for use with an F12 RNAi trigger described herein. For example, delivery can be by local administration, (e.g., direct injection, implantation, or topical administering), systemic administration, or subcutaneous, intravenous, oral, intraperitoneal, or parenteral routes, including intracranial (e.g., intraventricular, intraparenchymal and intrathecal), intramuscular, transdermal, airway (aerosol), nasal, rectal, or topical (including buccal and sublingual) administration, In certain embodiments, the compositions are administered by subcutaneous or intravenous infusion or injection.

In some embodiments, the RNAi triggers can be combined with lipids, nanoparticles, polymers, liposomes, micelles, DPCs or other delivery systems available in the art. The RNAi triggers can also be chemically conjugated to targeting groups, lipids (including, but not limited to cholesterol and cholesteryl derivatives), nanoparticles, polymers, liposomes, micelles, DPCs (se e.g., WO 2000/053722, WO 2008/0022309, WO 2011/104169, and WO 2012/083185, each of which is incorporated herein by reference), or other delivery systems available in the art.

In some embodiments, an RNAi trigger can be conjugated to a delivery polymer. In some embodiments, the delivery polymer is a reversibly masked/modified amphipathic membrane active polyamine.

In some embodiments, an F12 RNAi trigger-targeting group conjugate can be co-administered with a melittin-like peptide (MLP) delivery peptide (e.g., an active excipient). By co-administered it is meant that the F12 RNAi trigger and the delivery peptide are administered to the subject such that both are present in the subject at the same time. The F12 RNAi trigger-targeting group conjugate and the delivery peptide may be administered simultaneously or they may be delivered sequentially. For simultaneous administration, the F12 RNAi trigger-targeting group conjugate and the delivery peptide can be mixed prior to administration. For sequential administration, either the F12 RNAi trigger-group moiety conjugate or the delivery peptide can be administered first.

In some embodiments, pharmaceutical compositions for delivering an F12 RNAi trigger to a liver cell in vivo are described. Such pharmaceutical compositions can include or consist of: a) an F12 RNAi trigger conjugated to a hydrophobic group containing at least 20 carbon atoms (RNAi trigger-conjugate), such as a cholesterol and b) an MLP delivery polymer. The MLP delivery polymer and the RNAi trigger-conjugate can be synthesized separately and may be supplied in separate containers or a single container. In some embodiments, the F12 RNAi trigger is not conjugated to the delivery peptide.

Melittin-like peptide (MLP), as used herein, is a small amphipathic membrane active peptide, comprising about 23 to about 32 amino acids derived from the naturally occurring bee venom peptide, melittin, as described in WO 2012/083185. The naturally occurring melittin contains 26 amino acids and is predominantly hydrophobic on the amino terminal end and predominantly hydrophilic (cationic) on the carboxy terminal end. In some embodiments, the MLP described herein is isolated from a biological source. In other embodiments, the MLP is synthetic. A MLP synthetic polymer can be formulated or manufactured by a chemical process.

As used herein, MLP encompasses the naturally occurring bee venom peptides of the melittin family that can be found in, for example, venom of the species: Apis florea, Apis mellifera, Apis cerana, Apis dorsata, Vespula maculifrons, Vespa magnifica, Vespa velutina, Polistes sp. HQL-2001, and Polistes hebraeus. As used herein, MLP also encompasses synthetic peptides having amino acid sequence identical to or similar to naturally occurring melittin peptides. Examples of MLP amino acid sequences include those provided in Table 5. In some embodiments, MLP comprises: Leu-Ile-Gly-Ala-Ile-Leu-Lys-Val-Leu-Ale-Thr-Gly-Leu-Pro-Thr-Leu-Ile-Ser-Trp-Ile-Lys-Asn-Lys-Arg-Lys-Gln (SEQ ID 2234).

TABLE 5 MLP peptide sequences. SEQ ID NO. Melittin Sequence Name 2228 GIGAILKVLATGLPTLISWIKNKRKQ Apis florea 2229 AIGAILKVLATGLPTLISWIKNKRKQ G1A 2230 CIGAILKVLATGLPTLISWIKNKRKQ G1C 2231 FIGAILKVLATGLPTLISWIKNKRKQ G1F 2232 HIGAILKVLATGLPTLISWIKNKRKQ G1H 2233 IIGAILKVLATGLPTLISWIKNKRKQ G1I 2234 LIGAILKVLATGLPTLISWIKNKRKQ G1L 2235 NleIGAILKVLATGLPTLISWIKNKRKQ G1Nle 2236 VIGAILKVLATGLPTLISWIKNKRKQ G1V 2237 WIGAILKVLATGLPTLISWIKNKRKQ G1W 2238 YIGAILKVLATGLPTLISWIKNKRKQ G1Y 2239 GIGAILKVLACGLPTLISWIKNKRKQ T11C dMel 2240 GIGAILKVLATLLPTLISWIKNKRKQ G12L 2241 GIGAILKVLATWLPTLISWIKNKRKQ G12W 2242 GIGAILKVLATGLPTLISWIKTKRKQ N22T 2243 YIGAILNVLATGLPTLISWIKNKRKQ G1Y, K7N 2244 YIGAILAVLATGLPTLISWIKNKRKQ G1Y, K7A 2245 LIGAILSVLATGLPTLISWIKNKRKQ G1L, K7S 2246 LIGAILRVLATGLPTLISWIKNKRKQ G1L, K7R 2247 LIGAILHVLATGLPTLISWIKNKRKQ G1L, K7H 2248 LIGAILKVLACGLPTLISWIKNKRKQ G1L, T11C 2249 LIGAILKVLATLLPTLISWIKNKRKQ G1L, G12L 2250 YIGAILKVLATGLLTLISWIKNKRKQ G1Y, P14L 2251 LIGAILKVLATGLPCLISWIKNKRKQ G1L, T15C 2252 LIGAILKVLATGLPTLICWIKNKRKQ G1L, S18C 2253 YIGAILKVLATGLPTLISAIKNKRKQ G1Y, W19A 2254 GIGAILKVLACGLPTLISWLKNKRKQ T11C, I20L 2255 YIGAILKVLATGLPTLISWIANKRKQ G1Y, K21A 2256 YIGAILKVLATGLPTLISWIKNARKQ G1Y, K23A 2257 LIGAILKVLATGLPTLISWIKNKAKQ G1L, R24A 2258 YIGAILKVLATGLPTLISWIKNKRAQ G1Y, K25A 2259 YIGAILKVLATGLPTLISWIKNKRKC G1Y, Q26C 2260 LLGAILKVLACGLPTLISWIKNKRKQ G1L, I2L, T11C 2261 LIGALLKVLACGLPTLISWIKNKRKQ G1L, I5L, T11C 2262 YIGAILAVLATGLPTLISWIANKRKQ G1Y, K7A, K21A 2263 YIGAILAVLATGLPTLISWIKNARKQ G1Y, K7A, K23A 2264 LIGAILKVLACGLPTLLSWIKNKRKQ G1L, T11C, I17L 2265 LIGAILKVLACG1PTLICWIKNKRKQ G1L, T11C, S18C 2266 GIGAILKVLACGLPGLIGWIKNKRKQ T11G, T15G, S18G 2267 GIGAILKVLACGLPALIAWIKNKRKQ T11A, T15A, S18A 2268 YIGAILAVLATGLPTLISWIANARKQ G1Y, K7A, K21A, K23A 2269 YIAAILKVLAAALATLISWIKNKRKQ G1Y, G3A, T11A, G12A, P14A 2270 LLGALLKVLATGLPTLLSWLKNKRKQ G1L, I2L, 15L, I17L, I20L 2271 LNleGANleLKVLATGLPTLNleSWNleKNKRKQ G1L, I2Nle, I5Nle, I17Nle, I20Nle 2272 LVGAVLKVLATGLPTLVSWVKNKRKQ G1L, I2V, I5V, I17V, 120V 2273 GLGALLKVLACGLPTLLSWLKNKRKQ I2L, I5L, T11C, I17L, I20L 2274 GNleGANleLKVLACGLPTLNleSWNleKNKRKQ I2Nle, I5Nle, T11C, I17Nle, I20Nle 2275 CEDDLLLGAILKVLATGLPTLISWIKNKRKQ CEDDL-Mel G1L, I2L 2276 CLVVLIVVAILKVLATGLPTLISWIKNKRKQ CLVVL-Mel G1I, I2V, G3V 2277 GIGAVLKVLTTGLPALISWIKRKRQQ Apis mellifera 2278 CLIGAILKVLATGLPTLISWIKNKRKQ C-Mel G1L 2279 CNleIGAILKVLATGLPTLISWIKNKRKQ C-Mel G1Nle 2280 GLIGAILKVLATGLPTLISWIKNKRKQ G-Mel G1L 2281 LLIGAILKVLATGLPTLISWIKNKRKQ L-Mel G1L 2282 KLKLIGAILKVLATGLPTLISWIKNKRKQ KLK-Mel G1L 2283 KLKYIGAILKVLATGLPTLISWIKNKRKQ KLK-Mel G1Y 2284 CKLKLIGAILKVLATGLPTLISWIKNKRKQ CKLK-Mel G1L 2285 CKLKNleIGAILKVLATGLPTLISWIKNKRKQ CKLK-Mel G1Nle 2286 GKLKLIGAILKVLATGLPTLISWIKNKRKQ GKLK-Mel G1L 2287 CPANLIGAILKVLATGLPTLISWIKNKRKQ CPAN-dMel G1L 2288 DEPLRAIGAILKVLATGLPTLISWIKNKRKQ DEPLR-Mel G1A 2289 GIGAILKVLATGLPTLISWIKNKRKQC Mel-Cys 2290 LIGAILKVLATGLPTLISWIKNKRKQC G1L Mel-Cys 2291 NleIGAILKVLATGLPTLISWIKNKRKQC G1Nle Mel-C 2292 LIGAILKVLATGLPTLISWIKNKRKQKLKC G1L Mel-KLKC 2293 YIGAILKVLATGLPTLISWIKNKRKQPLGIAGQC G1Y Mel-PLGIAGQC 2294 LIGAILKVLATGLPTLISWIKNKRKQKKKKK G1L Mel-KKKKK 2295 YIGAILKVLATGLPTLISWIKNKRKQGFKGC G1Y Mel-GFKGC 2296 CFKLIGAILKVLATGLPTLISWIKNKRKQC CFK-G1L Mel-C 2297 FGAILKVLATGLPTLISWIKNKRKQ G1F, I2Δ 2298 LIGAILKVLATGLPTLISWIKNK G1L Mel (1-23) 2299 LIGAVLKVLTTGLPALISWIK G1L, L5V, A10T, T15A Mel (1-23) 2300 LIGAVLKVLTTGLPALISWIKGE G1L, L5V, A10T, T15A, N22G, K23E Mel (1-23) 2301 QKRKNKIWSILTPLGTALVKLIAGIL G1L retroMel 2302 KLKQKRKNKIWSILTPLGTALVKLIAGIL G1L retroMel-KLK 2303 GIGAVLKVLTTGLPALISWISRKKRQQ I5V, A10T, T15A, N22R, R24K, K25R Mel-Q 2304 GIGARLKVLTTGLPRISWIKRKRQQ I5R, A10T, T15R, L16Δ, N22R, K25Q 2305 GIGAILKVLSTGLPALISWIKRKRQE A10S, T15A, N22R, K25Q, Q26E 2306 GIGAVLKVLTTGLPALIGWIKRKRQQ I5V, A10T, T15A, S18G, N22R, K25Q 2307 GIGAVLKVLATGLPALISWIKRKRQQ I5V, T15A, N22R, K25Q 2308 GIGAVLKVLSTGLPALISWIKRKRQQ I5V, A10S, T15A, N22R, K25Q 2309 GIGAILRVLATGLPTLISWIKNKRKQ K7R 2310 GIGAILKVLATGLPTLISWIKRKRKQ N22R 2311 GIGAILKVLATGLPTLISWIKKKKQQ N22K, R24K, K25Q 2312 GIGAILKVLATGLPTLISWIKNKRKQGSKKKK Mel-GSKKKK 2313 KKGIGAILKVLATGLPTLISWIKNKRKQ KK-Mel 2314 GIGAILEVLATGLPTLISWIKNKRKQ K7E Mel 2315 GIGAVLKVLTTGLPALISWIKRKR I5V, T15A, N22R, 25-26Δ 2316 GIGAVLKVLTTGLPALISWIKR I5V, T15A, N22R, 23-26Δ 2317 CIGAVLKVLTTGLPALISWIKRKRQQ G1C, I5L, T15A, N22R 2318 QQRKRKIWSILAPLGTTLVKLVAGIG I5V, A10T, T15A, N22R retroMel 2319 QQRKRKIWSILAPLGTTLVKLVAGIC G1C, I5V, A10T, T15A, N22R retroMel 2320 QQKKKKIWSILAPLGTTLVKLVAGIC G1C, I5V, A10T, T15A, N22R, R24K retroMel 2321 QKRKNKIWSILTPLGTALVKLIAGIG Q25K reverse Mel 2322 QQRKRKIWSILAALGTTLVKLVAGIC G1C, I5V, A10T, P14A, T15A, N22R retroMel dMel = Melittin peptide having D-form amino acids Nle = norluecine

Membrane activity of the MLPs can be reversibly masked to yield MLP delivery polymers. Masking can be accomplished through reversible attachment of masking agents to primary amines of the MLP.

An MLP delivery polymer can include an MLP reversibly modified by reaction of primary amines on the peptide with asialoglycoprotein receptor (ASGPr) ligand-containing masking agents, wherein the reversible modification can be physiologically labile, as described in WO 2012/083185. In some embodiments, the masking agent comprises a neutral hydrophilic disubstituted alkylmaleic anhydride:

wherein R1 comprises an uncharged asialoglycoprotein receptor ligand. In some embodiments, the alkyl group is a methyl or ethyl group. An example of a substituted alkylmaleic anhydride is a 2-propionic-3-alkylmaleic anhydride derivative. A neutral hydrophilic 2-propionic-3-alkylmaleic anhydride derivative can be formed by attachment of a neutral hydrophilic group to a 2-propionic-3-alkylmaleic anhydride through the 2-propionic-3-alkylmaleic anhydride γ-carboxyl group:

wherein R1 includes a neutral ASGPr ligand and n=0 or 1. In some embodiments, the ASGPr ligand can be linked to the anhydride via a short PEG linker.

The ASGPr ligand provides targeting function through affinity for ASGPr. ASGPr ligands contain saccharides having affinity for the ASGPr, including but not limited to: galactose, N-acetyl-galactosamine and galactose derivatives. Galactose derivatives having affinity for the ASGPr are well known in the art.

In some embodiments, a composition is described that includes: N−T and MLP−(L−M)_(x),

wherein N is an F12 RNAi trigger, T comprises a hydrophobic group having 20 or more carbon atoms, such as cholesterol, MLP is a melittin-like peptide, and M contains an ASGPr ligand covalently linked to MLP via a physiologically labile reversible maleamate linkage L. x is an integer greater than 1. More specifically, the value of x is greater than 80%, greater than 90%, or greater than 95% of the number of primary amines on a population MLP. As used herein, MLP−(L−M)_(x) can be referred to as an MLP delivery polymer (e.g., an excipient). In some embodiments, an F12 RNAi trigger-cholesterol conjugate and an MLP delivery polymer can be supplied in the same container. In other embodiments, an F12 RNAi trigger-cholesterol conjugate and an MLP delivery polymer can be supplied in separate containers. An F12 RNAi trigger-cholesterol conjugate and an MLP delivery polymer may be combined prior to administration, co-administered, or administered sequentially.

Cells, tissues, and non-human organisms that include at least one of the RNAi triggers described herein is contemplated. The cell, tissue, or non-human organism is made by delivering the RNAi trigger to the cell, tissue, or non-human organism by any means available in the art. In some embodiments, the cell is a mammalian cell, including, but no limited to, a human cell. The cell, tissue, or non-human organisms are useful for research or as research tools (e.g., drug testing or diagnoses).

The above provided embodiments and items are now illustrated with the following, non-limiting examples.

EXAMPLES Example 1. RNAi Trigger Synthesis

A) Synthesis.

RNAi trigger molecules were synthesized according to phosphoramidite technology on solid phase used in oligonucleotide synthesis. Depending on the scale either a MerMade96E (Bioautomation) or a MerMade12 (Bioautomation) was used. Syntheses were performed on a solid support made of controlled pore glass (CPG, 500 Å or 600 Å, obtained from Prime Synthesis, Aston, Pa., USA). All DNA, 2′-modified RNA, and UNA phosphoramidites were purchased from Thermo Fisher Scientific (Milwaukee, Wis., USA). Specifically, the following 2′-O-Methyl phosphoramidites were used: (5′-O-dimethoxytrityl-N⁶-(benzoyl)-2′-O-methyl-adenosine-3′-O-(2-cyanoethyl-N,N-diisopropy-lamino) phosphoramidite, 5′-O-dimethoxy-trityl-N⁴-(acetyl)-2′-O-methyl-cytidine-3′-O-(2-cyanoethyl-N,N-diisopropylamino) phosphoramidite, (5′-O-dimethoxytrityl-N²-(isobutyryl)-2′-O-methyl-guanosine-3′-O-(2-cyano-ethyl-N,N-diisopropylamino)phosphoramidite, and 5′-O-dimethoxy-trityl-2′-O-methyl-uridine-3′-O-(2-cyanoethyl-N,N-diisopropylamino)phosphoramidite. The 2′-Deoxy-2′-fluoro-phosphor-amidites carried the same protecting groups as the 2′-O-methyl RNA amidites. The following UNA phosphoramidites were used: 5′-(4,4′-Dimethoxytrityl)-N-benzoyl-2′,3′-seco-adenosine, 2′-benzoyl-3′-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite, 5′-(4,4′-Dimethoxytrityl)-N-acetyl-2′,3′-seco-cytosine, 2′-benzoyl-3′-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite, 5′-(4,4′-Dimethoxytrityl)-N-isobutyryl-2′,3′-seco-guanosine, 2′-benzoyl-3′-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite, and 5′-(4,4′-Dimethoxytrityl)-2′,3′-seco-uridine, 2′-benzoyl-3′-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite. All amidites were dissolved in anhydrous acetonitrile (50 mM) and molecular sieves (3 Å) were added. In order to introduce the TEG-Cholesterol at the 5′-end of the oligomers, the 1-Dimethoxytrityloxy-3-O—(N-cholesteryl-3-aminopropyl)-triethyleneglycol-glyceryl-2-O-(2-cyanoethyl)-(N,N,-diisopropyl)-phosphoramidite from Glen Research (Sterling, Va., USA) was employed. The 5′-modifications were introduced without any modification of the synthesis cycle. 5-Benzylthio-1H-tetrazole (BTT, 250 mM in acetonitrile) was used as activator solution. Coupling times were 10 min (RNA), 180 sec (Cholesterol), 90 sec (2′OMe and UNA), and 60 sec (2′F and DNA). In order to introduce phosphorothioate linkages, a 100 mM solution of 3-phenyl 1,2,4-dithiazoline-5-one (POS, obtained from PolyOrg, Inc., Leominster, Mass., USA) in anhydrous Acetonitrile was employed. See Tables 1-3 for specific sequences.

B. Cleavage and Deprotection of Support Bound Oligomer.

After finalization of the solid phase synthesis, the dried solid support was treated with a 1:1 volume solution of 40 wt. % methylamine in water and 28% ammonium hydroxide solution (Aldrich) for two hours at 30° C. The solution was evaporated and the solid residue was reconstituted in water (see below).

C. Purification.

Crude Cholesterol containing oligomers were purified by reverse phase HPLC using a Waters XBridge BEH300 C4 5u Prep column and a Shimadzu LC-8 system. Buffer A was 100 mM TEAA, pH 7.5 and contained 5% Acetonitrile and buffer B was 100 mM TEAA and contained 95% Acetonitrile. UV traces at 260 nm were recorded. Appropriate fractions were then run on size exclusion HPLC using a GE Healthcare XK 16/40 column packed with Sephadex G-25 medium with a running buffer of 100 mM ammonium bicarbonate, pH 6.7 and 20% Acetonitrile. Other crude oligomers were purified by anionic exchange HPLC using a TKSgel SuperQ-5PW 13u column and Shimadzu LC-8 system. Buffer A was 20 mM Tris, 5 mM EDTA, pH 9.0 and contained 20% Acetonitrile and buffer B was the same as buffer A with the addition of 1.5 M sodium chloride. UV traces at 260 nm were recorded. Appropriate fractions were pooled then run on size exclusion HPLC as described for cholesterol containing oligomers.

D. Annealing.

Complementary strands were mixed by combining equimolar solutions (sense and antisense) in 0.2×PBS (Phosphate-Buffered Saline, 1×, Corning, Cellgro) to form the RNAi triggers. This solution was placed into a thermomixer at 70° C., heated to 95° C., held at 95° C. for 5 min, and cooled to room temperature slowly. Some RNAi triggers were lyophilized and stored at −15 to −25° C. Duplex concentration was determined by measuring the solution absorbance on a UV-Vis spectrometer in 0.2×PBS. The solution absorbance at 260 nm was then multiplied by a conversion factor and the dilution factor to determine the duplex concentration. Unless otherwise stated, all conversion factor was 0.037 mg/(mL·cm). For some experiments, a conversion factor was calculated from an experimentally determined extinction coefficient.

Example 2. Melittin-Like-Peptide (MLP) Delivery Polymer

A) Melittin-Like-Peptide (MLP) Synthesis.

All MLPs were made using peptide synthesis techniques standard in the art. Independently of L or D form, the MLP sequence can be reversed (retro).

B) CDM-NAG (N-Acetyl Galactosamine) Synthesis.

To a solution of CDM (300 mg, 0.16 mmol) in 50 mL methylene chloride was added oxalyl chloride (2 g, 10 wt. eq.) and dimethylformamide (5 μl). The reaction was allowed to proceed overnight, after which the excess oxalyl chloride and methylene chloride were removed by rotary evaporation to yield the CDM acid chloride. The acid chloride was dissolved in 1 mL of methylene chloride. To this solution was added 1.1 molar equivalents (aminoethoxy)ethoxy-2-(acetylamino)-2-deoxy-(3-D-galactopyranoside (i.e. amino bisethoxyl-ethyl NAG) and pyridine (200 μl, 1.5 eq) in 10 mL of methylene chloride. The solution was then stirred 1.5 h. The solvent was then removed and the resulting solid was dissolved into 5 mL of water and purified using reverse-phase HPLC using a 0.1% TFA water/acetonitrile gradient.

R1 comprises a neutral ASGPr ligand. In some embodiments, the Masking Agent is uncharged.

n is an integer from 1 to 10. As shown above, a PEG spacer may be positioned between the anhydride group and the ASGPr ligand. In some embodiments, a PEG spacer contains 1-10 ethylene units. Alternatively an alkyl spacer may be used between the anhydride and the N-acetyl-galactosamine (NAG).

n is a integer from 0 to 6.

Other spacers or linkers may be used between the anhydride and the N-acetyl-galactosamine. In some embodiments, the spacer or linker is, a hydrophilic, and neutral or uncharged.

C) Formation of the MLP Delivery Polymer (i.e. Masking).

The MLP was reacted with CDM-NAG masking agent to yield the MLP delivery polymer. The MLP component was first dissolved to a final concentration of 8.5 mg/mL in aqueous HEPES (sodium salt, GMP grade, ˜430 mg/mL). The MLP solution was then cooled to 4° C., and checked for appearance (clear to pale yellow solution free of visible particulate) and for concentration by UV spectrophotometry. CDM-NAG was dissolved in water at 4° C. at a final concentration of ˜75 mg/mL. The solution was checked for appearance (clear to pale yellow solution free of visible particulate) and for concentration by UV spectrophotometry. MLP in solution was mixed with CDM-NAG in solution at a 5:1 (w/w) ratio of CDM-NAG to MLP. The addition rate of CDM-NAG solution was approximately 0.3 L per minute, while stirring. After all CDM-NAG solution had been added to the MLP solution, the mixture was stirred for 30 min. To stabilize the MLP delivery polymer, the pH was increased to 9.0±0.2 by addition of 1 M aqueous sodium hydroxide. Reaction of disubstituted maleic anhydride masking agent with the peptide yielded a compound having the structure represented by:

wherein R is MLP and R1 comprises an ASGPr ligand (e.g. NAG).

Colorimetric trinitrobenzene sulfonic acid (TNBS) assay of remaining free amines was used to determine that MLP was sufficiently masked by CDM-NAG, less than 10% of the total number of MLP amines remained unmodified.

MLP delivery polymer was purified by diafiltration against 10 mM, pH 9.2 carbonate buffer to remove excess CDM-NAG. The diafiltration process exchanged ˜10 volumes of carbonate buffer per volume of masked MLP reaction solution and held at 2-8° C.

Component Quantity (nominal) MLP  30 g/L CDM-NAG^(a)  25 g/L Sodium carbonate 0.3 g/L Sodium bicarbonate 0.6 g/L Water 1000 g/L   ^(a)assumes five (5) CDM-NAG moieties per MLP

The MLP delivery polymer was further formulated with Dextran to 10% w/v and stored at 2 to 8° C. 228 mg MLP delivery polymer, 500 mg 1 kDa dextran, 1.59 mg Na₂CO₃, 2.94 mg NaHCO₃. For some experiments, this solution was lyophilized prior to use.

D) Injection solution. The injection solution was formed by mixing RNAi trigger with the MLP delivery polymer. The lyophilized MLP delivery polymer was dissolved in water and mixed with the RNAi trigger. That solution was then diluted to the correct injection concentration with normal saline.

Example 3. In Vitro Screening of F12 RNAi Triggers

A) Human Cell Background.

Candidate sequences identified as human, non-human primate and mouse cross-reactive by in silico analysis were screened as chemically modified canonical siRNAs in vitro. Thirty-two of the in silico identified potential F12 RNAi triggers were synthesized as canonical siRNAs and screened for efficacy in vitro. For screening purposes, the human F12 cDNA sequence (accession #NM_000505) was synthesized and cloned (DNA 2.0, Menlo Park, Calif.) into a commercially-available reporter-based screening plasmid, psiCHECK2 (Promega, Madison, Wis.) which generated a Renilla luciferase/F12 fusion mRNA. For siRNA efficacy in the human background, Hep3B cells, a human hepatocellular carcinoma line, were plated at ˜10,000 cells per well in 96-well format. Each of the 32 F12 siRNAs was co-transfected at two concentrations, 1 nM and 0.1 nM, with 25 ng F12-psiCHECK2 plasmid DNA per well and 0.2 μL LipoFectamine 2000 per well. Gene knockdown was determined by measuring Renilla luciferase levels normalized to the levels of constitutively-expressed firefly luciferase, also present on the psiCHECK2 plasmid, using the Dual Luciferase Reporter Assay (Promega, Madison, Wis.).

TABLE 6 Efficacy screen results of human/non-human primate/mouse cross-reactive RNAi triggers in human background, as determined by dual-luciferase reporter assay. Relative Rluc-F12 Expression Antisense SEQ Sense SEQ 1 nM 0.1 nM AD Number Strand ID ID strand ID ID Average ± SD Average ± SD AD00459 AM00978-AS 451 AM00913-SS 837 0.871 ± 0.138 0.956 ± 0.096 AD00460 AM00979-AS 452 AM00914-SS 838 0.878 ± 0.040 1.044 ± 0.127 AD00461 AM00980-AS 453 AM00915-SS 839 0.941 ± 0.163 1.003 ± 0.052 AD00462 AM00981-AS 454 AM00916-SS 840 0.515 ± 0.068 0.584 ± 0.117 AD00463 AM00982-AS 455 AM00917-SS 841 0.476 ± 0.014 0.552 ± 0.098 AD00464 AM00983-AS 456 AM00918-SS 842 0.302 ± 0.072 0.442 ± 0.024 AD00465 AM00984-AS 457 AM00919-SS 843 0.428 ± 0.042 0.517 ± 0.037 AD00466 AM00985-AS 458 AM00920-SS 844 0.196 ± 0.016 0.282 ± 0.088 AD00467 AM00986-AS 459 AM00921-SS 845 0.200 ± 0.034 0.303 ± 0.063 AD00468 AM00987-AS 460 AM00922-SS 846 0.255 ± 0.032 0.300 ± 0.042 AD00469 AM00988-AS 461 AM00923-SS 847 0.272 ± 0.060 0.411 ± 0.022 AD00470 AM00989-AS 462 AM00924-SS 848 0.205 ± 0.011 0.328 ± 0.044 AD00471 AM00990-AS 463 AM00925-SS 849 0.524 ± 0.105 0.667 ± 0.040 AD00472 AM00991-AS 464 AM00926-SS 850 0.957 ± 0.062 0.909 ± 0.056 AD00473 AM00992-AS 465 AM00927-SS 851 0.390 ± 0.093 0.502 ± 0.033 AD00474 AM00993-AS 466 AM00928-SS 852 0.247 ± 0.083 0.420 ± 0.045 AD00475 AM00994-AS 467 AM00929-SS 853 1.137 ± 0.029 1.049 ± 0.056 AD00476 AM00995-AS 468 AM00930-SS 854 1.062 ± 0.221 0.873 ± 0.114 AD00477 AM00996-AS 469 AM00931-SS 855 0.657 ± 0.022 0.881 ± 0.107 AD00478 AM00997-AS 470 AM00932-SS 856 0.986 ± 0.118 0.856 ± 0.107 AD00479 AM00998-AS 471 AM00933-SS 857 1.048 ± 0.023 0.920 ± 0.030 AD00480 AM00999-AS 472 AM00934-SS 858 0.579 ± 0.026 0.608 ± 0.123 AD00481 AM01000-AS 473 AM00935-SS 859 0.633 ± 0.081 0.779 ± 0.102 AD00482 AM01001-AS 474 AM00936-SS 860 0.639 ± 0.100 0.708 ± 0.107 AD00483 AM01002-AS 475 AM00937-SS 861 0.761 ± 0.100 0.694 ± 0.102 AD00484 AM01003-AS 476 AM00938-SS 862 1.178 ± 0.074 1.168 ± 0.226 AD00485 AM01004-AS 477 AM00939-SS 863 1.261 ± 0.218 0.964 ± 0.030 AD00486 AM01005-AS 478 AM00940-SS 864 1.155 ± 0.278 1.084 ± 0.073 AD00487 AM01006-AS 479 AM00941-SS 865 1.216 ± 0.081 1.161 ± 0.044 AD00488 AM01007-AS 480 AM00942-SS 866 1.058 ± 0.051 1.112 ± 0.107 AD00489 AM01008-AS 481 AM00943-SS 867 1.152 ± 0.189 0.980 ± 0.077 AD00490 AM01009-AS 482 AM00944-SS 868 1.103 ± 0.273 1.138 ± 0.052

B) Mouse Primary Cell Background.

The same 32 siRNAs were screened for efficacy in a mouse background. Mouse primary hepatocytes were obtained cryopreserved or pre-plated in 96-well plates (TRL Research, Research Triangle Park, N.C.). SiRNAs were transfected at two concentrations, 1 nM and 0.1 nM, for 4 h with 0.6 μL per well of Lipofectamine RNAiMax (Life Technologies, Grand Island, N.Y.), after which fresh medium was supplied. After 24 h cells were lysed for gene expression analysis using the TaqMan Gene Expression Cells-to-CT Kit (Life Technologies). Using mouse-specific TaqMan gene expression assays (Life Technologies), F12 expression relative to the endogenous control, β-actin, was determined by qRT-PCR.

TABLE 7 Efficacy screen results of human/non-human primate/mouse cross-reactive RNAi triggers in mouse background, as determined by qRT-PCR and comparative C_(T) analysis. Relative Mouse F12 Expression 1.0 nM 0.1 nM error error AD Number Average low high Average low high AD00459 0.367 0.019 0.020 0.468 0.091 0.113 AD00460 0.494 0.080 0.096 0.710 0.079 0.089 AD00461 0.353 0.053 0.063 0.673 0.090 0.104 AD00462 0.320 0.072 0.093 0.553 0.034 0.037 AD00463 0.377 0.016 0.017 0.706 0.066 0.073 AD00464 0.232 0.044 0.055 0.418 0.087 0.110 AD00465 0.335 0.033 0.037 0.691 0.092 0.106 AD00466 0.271 0.018 0.019 0.406 0.067 0.080 AD00467 0.070 0.014 0.018 0.204 0.008 0.009 AD00468 0.156 0.031 0.039 0.259 0.038 0.044 AD00469 0.157 0.020 0.024 0.335 0.028 0.031 AD00470 0.228 0.030 0.035 0.320 0.042 0.048 AD00471 0.347 0.031 0.035 0.376 0.082 0.106 AD00472 0.496 0.043 0.048 0.579 0.129 0.166 AD00473 0.257 0.019 0.020 0.518 0.107 0.136 AD00474 0.223 0.021 0.023 0.228 0.033 0.038 AD00475 1.024 0.177 0.214 0.909 0.069 0.075 AD00476 1.110 0.029 0.030 1.160 0.118 0.132 AD00477 0.713 0.034 0.036 0.934 0.042 0.044 AD00478 1.187 0.075 0.080 1.114 0.086 0.093 AD00479 1.168 0.117 0.130 0.889 0.076 0.083 AD00480 0.380 0.078 0.098 0.489 0.049 0.055 AD00481 0.528 0.115 0.147 0.607 0.105 0.128 AD00482 0.359 0.050 0.058 0.367 0.065 0.079 AD00483 0.307 0.021 0.022 0.493 0.105 0.133 AD00484 0.980 0.032 0.033 0.640 0.167 0.226 AD00485 0.218 0.026 0.029 0.179 0.033 0.040 AD00486 0.208 0.006 0.006 0.173 0.019 0.021 AD00487 0.233 0.018 0.019 0.185 0.018 0.020 AD00488 0.223 0.030 0.035 0.267 0.031 0.035 AD00489 0.169 0.023 0.027 0.180 0.014 0.015 AD00490 0.271 0.058 0.075 0.139 0.016 0.018

C) Ec₅₀ Calculation.

Six candidate RNAi triggers were further assessed. Ten-point EC₅₀ curves were generated using the same cells and transfection conditions, as in A) above, with siRNA concentrations ranging from 150 fM to 3 nM. Each of these six F12 RNAi triggers was further modified and synthesized as a corresponding UNA-containing RNAi trigger. All modified RNAi triggers were examined by in vitro knockdown analysis by both 3-concentration analysis (0.02, 0.2 and 2 nM) and ten-point EC₅₀ determination.

TABLE 8 EC₅₀ values (nM) determined in the human background for the indicated RNAi triggers. Duplex ID No. EC₅₀ (nM) AD00466 0.019 AD00903 AM01622-AS 597 AM00920-SS 844 0.049 AD00904 AM01623-AS 598 AM00920-SS 844 0.057 AD00915 AM01621-AS 596 AM01614-SS 983 0.049 AD00916 AM00985-AS 458 AM01614-SS 983 0.189 AD00467 0.133 AD00905 AM01624-AS 599 AM00921-SS 845 0.076 AD00906 AM01625-AS 600 AM00921-SS 845 0.104 AD00468 0.081 AD00907 AM01626-AS 601 AM00922-SS 846 0.143 AD00908 AM01627-AS 602 AM00922-SS 846 0.077 AD00469 0.070 AD00909 AM01629-AS 604 AM00923-SS 847 0.049 AD00910 AM01630-AS 605 AM00923-SS 847 0.037 AD00917 AM01628-AS 603 AM01618-SS 987 0.089 AD00918 AM00988-AS 461 AM01618-SS 987 0.103 AD00470 0.145 AD00911 AM01631-AS 606 AM00924-SS 848 0.982 AD00912 AM01632-AS 607 AM00924-SS 848 0.153 AD00474 0.261 AD00913 AM01633-AS 608 AM00928-SS 852 0.132 AD00914 AM01634-AS 609 AM00928-SS 852 0.175

D) Human/Non-Human Primate-Specific RNAi Triggers.

Additional sequences identified as human and non-human primate, but not mouse, cross-reactive by in silico analysis were additionally screened in human background. The top twelve sequences were screened using the procedure described above, with full 10-point dose response curves and EC₅₀ determination performed for the six most active RNAi triggers.

TABLE 9 Efficacy screen of human/non-human primate-specific RNAi triggers and EC₅₀ values (nM). Relative R_(luc)-F12 Expression 1 nM 0.1 nM SEQ ID pair Average ± SD Average ± SD EC₅₀ (nM) 1940/2053 0.172 ± 0.018 0.314 ± 0.007 0.026 1941/2054 0.218 ± 0.021 0.312 ± 0.029 0.013 1943/2056 0.139 ± 0.016 0.245 ± 0.060 0.027 1944/2054 0.258 ± 0.007 0.314 ± 0.037 1946/2059 0.166 ± 0.016 0.225 ± 0.022 0.017 1947/2060 0.273 ± 0.029 0.382 ± 0.071 1951/2064 0.536 ± 0.011 1.108 ± 0.210 1966/2079 0.745 ± 0.080 0.963 ± 0.051 1971/2084 0.714 ± 0.018 0.853 ± 0.088 1982/2095 0.519 ± 0.065 0.680 ± 0.081 1983/2096 0.454 ± 0.003 0.622 ± 0.071 2013/2126 0.579 ± 0.006 0.778 ± 0.108

Example 4. In Vivo Analysis of RNAi Trigger Efficacy in Wild-Type Mice or Rates

A) Administration and Sample Collection.

In order to evaluate the efficacy of F12 RNAi triggers in vivo, wild-type mice or rats were used. RNAi triggers were dosed either by intravenous (IV) or subcutaneous (SQ) injection. Cholesterol-targeted RNAi triggers were administered to mice or rats using MLP delivery polymer on day 1. Each rodent received an intravenous (IV) injection into the tail vein of 200-250 μL solution containing a dose of RNAi trigger+MLP delivery polymer (1:1 w/w RNAi trigger: MLP delivery polymer in most cases). Alkyne-containing RNAi triggers were administered to mice after conjugation with targeting polymer by either IV or SQ injection. Galactose-cluster containing RNAi triggers were most often dosed SQ, but could also be dosed in combination with MLP delivery polymer. When possible, baseline (pre-treatment) samples were taken from the mice pre-injection between days 7 and injection on day 1. Post injection serum samples were taken from the mice days 4, 8, and weekly up to day 71. In some mice, liver tissue was harvested for RNA isolation on days indicated.

B) Factor 12 Serum Protein Levels.

F12 protein (mF12) levels in serum were monitored by assaying serum from the mice using an ELISA for mF12 (Molecular Innovations) or an internally developed mF12 alphaLISA® (Perkin Elmer) until expression levels returned to baseline. For animals with baseline samples, mF12 level for each animal at a respective time point was divided by the pre-treatment level of expression in that animal to determine the ratio of expression “normalized to pre-treatment”. Expression at a specific time point was then normalized to the saline control group by dividing the “normalized to day pre-treatment” ratio for an individual animal by the mean “normalized to day pre-treatment” ratio of all mice in the saline control group. This resulted in expression for each time point normalized to that in the control group. For samples without baseline samples, expression at a specific bleed date was normalized to the mean of the saline control group for that same date. For all studies, experimental error is given as standard deviation.

Example 5. In Vivo Screening F12 RNAi Triggers and Time Course of F12 Knockdown

Wild-type mice were dosed either IV (cholesterol-conjugated RNAi trigger with delivery polymer) or subcutaneous (SQ) (galactose-cluster-conjugated RNAi trigger), and mF12 levels were monitored as described above. Maximum knockdown (nadir) of mF12 for each RNAi trigger examined is shown in Table 10. Nadir was between days 4-22. Relative serum mF12 levels following administration of RNAi triggers over the time of the experiment is shown for select RNAi triggers tested (see Tables 11, 12, 13, 14, 15 and 16, FIG. 1). A decrease in F12 serum protein level of greater than 98% was obtained following administration of all RNAi triggers tested, with AD00900 showing greatest duration of knockdown (>87% knockdown at day 36). RD10694, a known mouse Factor VII (mF7) RNAi trigger sequence, was used as a control RNAi trigger in these experiments (Table 10).

TABLE 10 Relative serum F12 protein levels in mice following intravenous administration of the indicated F12 RNAi trigger with MLP (delivery polymer) or subcutaneous administration of the indicated F12 RNAi trigger (no delivery polymer). mF12 levels were normalized to pre-treatment and saline control. (F12 RNAi trigger Duplex ID No. with sense strand and antisense strand ID nos.) RNAi Delivery Duplex Antisense SEQ Sense SEQ trigger Polymer Relative ID No. Strand ID ID Strand ID ID (mg/kg) (mg/kg) Factor 12 AD00897 AM00985-AS 458 AM01613-SS 982 8 8 0.007 AD00898 AM00986-AS 459 AM01615-SS 984 8 8 0.007 AD00899 AM00987-AS 460 AM01616-SS 985 8 8 0.009 AD00900 AM00988-AS 461 AM01617-SS 986 8 8 0.007 AD00901 AM00989-AS 462 AM01619-SS 988 8 8 0.020 AD00902 AM00993-AS 466 AM01620-SS 989 8 8 0.012 AD00998 AM01622-AS 597 AM01613-SS 982 2 2 0.284 AD00999 AM01624-AS 599 AM01615-SS 984 2 2 0.175 AD01000 AM01626-AS 601 AM01616-SS 985 2 2 0.052 AD01001 AM01629-AS 604 AM01617-SS 986 2 2 0.048 AD01002 AM01631-AS 606 AM01619-SS 988 2 2 0.253 AD01003 AM01633-AS 608 AM01620-SS 989 2 2 0.132 AD01004 AM01623-AS 598 AM01613-SS 982 2 2 0.136 AD01005 AM01625-AS 600 AM01615-SS 984 2 2 0.464 AD01006 AM01627-AS 602 AM01616-SS 985 2 2 0.268 AD01007 AM01630-AS 605 AM01617-SS 986 2 2 0.127 AD01008 AM01632-AS 607 AM01619-SS 988 2 2 0.263 AD01009 AM01634-AS 609 AM01620-SS 989 2 2 0.228 AD01109 AM01903-AS 610 AM01616-SS 985 0.5 2 0.243 AD01110 AM01904-AS 611 AM01905-SS 990 0.5 2 0.263 AD01111 AM01906-AS 612 AM01617-SS 986 0.5 2 0.159 AD01112 AM01907-AS 613 AM01908-SS 991 0.5 2 0.293 AD01113 AM01909-AS 614 AM01620-SS 989 0.5 2 0.289 AD01114 AM01910-AS 615 AM01911-SS 992 0.5 2 0.645 AD01115 AM01918-AS 619 AM01905-SS 990 0.5 2 0.202 AD01116 AM01919-AS 620 AM01908-SS 991 0.5 2 0.204 AD01117 AM01920-AS 621 AM01911-SS 992 0.5 2 0.266 AD01118 AM01927-AS 625 AM01924-SS 994 0.5 2 0.275 AD01119 AM01928-AS 626 AM01924-SS 994 0.5 2 0.442 AD01120 AM01929-AS 627 AM01924-SS 994 0.5 2 0.374 AD01121 AM01931-AS 629 AM01932-SS 996 0.5 2 0.284 AD01122 AM01915-AS 616 AM01617-SS 986 0.5 2 0.144 AD01123 AM01916-AS 617 AM01908-SS 991 0.5 2 0.226 AD01124 AM01917-AS 618 AM01908-SS 991 0.5 2 0.158 AD01125 AM01921-AS 622 AM01922-SS 993 0.5 2 0.271 AD01126 AM01923-AS 623 AM01924-SS 994 0.5 2 0.247 AD01127 AM01925-AS 624 AM01926-SS 995 0.5 2 0.526 AD01128 AM01930-AS 628 AM01932-SS 996 0.5 2 0.332 AD01181 AM01996-AS 630 AM01995-SS 997 0.5 2 0.100 AD01182 AM01997-AS 631 AM01995-SS 997 0.5 2 0.167 AD01251 AM01629-AS 604 AM02084-SS 1000 0.5 4 0.724 AD01303 AM02165-AS 637 AM02168-SS 1002 2 2 0.233 AD01307 AM02165-AS 637 AM02169-SS 1003 2 2 0.096 AD01312 AM02171-AS 640 AM02173-SS 1004 2 2 0.194 AD01313 AM02172-AS 641 AM02174-SS 1005 2 2 0.173 AD01327 AM02165-AS 637 AM02196-SS 1006 2 2 0.083 AD01367 AM02197-AS 642 AM02269-SS 1014 0.5 2 0.378 AD01368 AM02198-AS 643 AM02270-SS 1015 0.5 2 0.516 AD01369 AM02199-AS 644 AM02271-SS 1016 0.5 2 0.279 AD01370 AM02172-AS 641 AM02272-SS 1017 0.5 2 0.366 AD01371 AM02200-AS 645 AM02273-SS 1018 0.5 2 0.476 AD01372 AM02201-AS 646 AM02274-SS 1019 0.5 2 0.162 AD01373 AM02208-AS 647 AM02275-SS 1020 0.5 2 0.187 AD01394 AM02331-AS 648 AM02330-SS 1023 2 2 0.086 AD01395 AM02332-AS 649 AM02330-SS 1023 2 2 0.089 AD01396 AM02333-AS 650 AM02330-SS 1023 2 2 0.409 AD01397 AM02334-AS 651 AM02330-SS 1023 2 2 0.574 AD01398 AM02335-AS 652 AM02330-SS 1023 2 2 0.063 AD01399 AM02336-AS 653 AM02330-SS 1023 2 2 0.765 AD01400 AM02337-AS 654 AM02330-SS 1023 2 2 0.179 AD01401 AM02338-AS 655 AM02330-SS 1023 2 2 0.083 AD01402 AM02339-AS 656 AM02330-SS 1023 2 2 0.348 AD01403 AM02340-AS 657 AM02330-SS 1023 2 2 0.358 AD01412 AM02348-AS 658 AM02330-SS 1023 2 2 0.145 AD01413 AM02349-AS 659 AM02351-SS 1024 2 2 0.223 AD01414 AM02350-AS 660 AM02352-SS 1025 2 2 0.632 AD01415 AM02354-AS 661 AM02353-SS 1026 2 2 0.696 AD01416 AM02348-AS 658 AM02355-SS 1027 2 2 0.112 AD01417 AM02348-AS 658 AM02356-SS 1028 2 2 0.164 AD01418 AM02348-AS 658 AM02357-SS 1029 2 2 0.723 AD01419 AM02348-AS 658 AM02358-SS 1030 2 2 0.663 AD01420 AM02348-AS 658 AM02359-SS 1031 2 2 0.066 AD01421 AM02348-AS 658 AM02360-SS 1032 2 2 0.145 AD01422 AM02348-AS 658 AM02361-SS 1033 2 2 0.107 AD01423 AM02348-AS 658 AM02362-SS 1034 2 2 0.081 AD01443 AM02395-AS 662 AM02399-SS 1035 2 2 0.161 AD01444 AM02396-AS 663 AM02400-SS 1036 2 2 0.415 AD01445 AM02397-AS 664 AM02401-SS 1037 2 2 0.595 AD01446 AM02398-AS 665 AM02402-SS 1038 2 2 0.599 AD01453 AM02432-AS 666 AM02431-SS 1040 2 2 0.258 AD01454 AM02348-AS 658 AM02431-SS 1040 2 2 0.094 AD01455 AM02433-AS 667 AM02431-SS 1040 2 2 0.268 AD01456 AM02434-AS 668 AM02435-SS 1041 2 2 0.181 AD01457 AM02395-AS 662 AM02436-SS 1042 2 2 0.088 AD01458 AM02437-AS 669 AM02436-SS 1042 2 2 0.244 AD01459 AM02438-AS 670 AM02436-SS 1042 2 2 0.197 AD01460 AM02439-AS 671 AM02440-SS 1043 2 2 0.301 AD01478 AM02201-AS 646 AM02457-SS 1044 10 10 0.566 AD01479 AM02208-AS 647 AM02458-SS 1045 10 10 0.654 AD01484 AM02338-AS 655 AM02359-SS 1031 2 2 0.408 AD01485 AM02338-AS 655 AM02360-SS 1032 2 2 0.254 AD01486 AM02338-AS 655 AM02361-SS 1033 2 2 0.215 AD01487 AM02338-AS 655 AM02362-SS 1034 2 2 0.092 AD01488 AM02335-AS 652 AM02359-SS 1031 2 2 0.259 AD01489 AM02335-AS 652 AM02360-SS 1032 2 2 0.101 AD01490 AM02335-AS 652 AM02361-SS 1033 2 2 0.095 AD01491 AM02335-AS 652 AM02362-SS 1034 2 2 0.525 AD01498 AM02349-AS 659 AM02490-SS 1056 2 2 0.197 AD01499 AM02349-AS 659 AM02491-SS 1057 2 2 0.213 AD01500 AM02487-AS 684 AM02490-SS 1056 2 2 0.077 AD01501 AM02487-AS 684 AM02491-SS 1057 2 2 0.185 AD01502 AM02488-AS 685 AM02490-SS 1056 2 2 0.165 AD01503 AM02488-AS 685 AM02491-SS 1057 2 2 0.140 AD01504 AM02165-AS 637 AM02494-SS 1058 2 2 0.071 AD01505 AM02165-AS 637 AM02495-SS 1059 2 2 0.144 AD01506 AM02492-AS 686 AM02494-SS 1058 2 2 0.040 AD01507 AM02492-AS 686 AM02495-SS 1059 2 2 0.222 AD01508 AM02493-AS 687 AM02494-SS 1058 2 2 0.074 AD01509 AM02493-AS 687 AM02495-SS 1059 2 2 0.132 AD01510 AM02502-AS 688 AM02496-SS 1060 2 2 0.863 AD01511 AM02502-AS 688 AM02497-SS 1061 2 2 0.792 AD01512 AM02503-AS 689 AM02496-SS 1060 2 2 0.827 AD01513 AM02503-AS 689 AM02497-SS 1061 2 2 0.784 AD01514 AM02504-AS 690 AM02498-SS 1062 2 2 0.462 AD01515 AM02504-AS 690 AM02499-SS 1063 2 2 0.386 AD01516 AM02505-AS 691 AM02498-SS 1062 2 2 0.430 AD01517 AM02505-AS 691 AM02499-SS 1063 2 2 0.572 AD01518 AM02506-AS 692 AM02500-SS 1064 2 2 0.059 AD01519 AM02506-AS 692 AM02501-SS 1065 2 2 0.163 AD01520 AM02507-AS 693 AM02500-SS 1064 2 2 0.012 AD01521 AM02507-AS 693 AM02501-SS 1065 2 2 0.028 AD01535 AM02543-AS 694 AM02545-SS 1076 2 2 0.190 AD01536 AM02544-AS 695 AM02545-SS 1076 2 2 0.065 AD01537 AM02464-AS 675 AM02513-SS 1066 10 10 0.588 AD01538 AM02466-AS 676 AM02514-SS 1067 10 10 0.705 AD01539 AM02468-AS 677 AM02515-SS 1068 10 10 0.788 AD01540 AM02470-AS 678 AM02516-SS 1069 10 10 0.661 AD01541 AM02472-AS 679 AM02517-SS 1070 10 10 0.577 AD01542 AM02474-AS 680 AM02518-SS 1071 10 10 0.470 AD01543 AM02476-AS 681 AM02519-SS 1072 10 10 0.774 AD01544 AM02478-AS 682 AM02520-SS 1073 10 10 0.647 AD01545 AM02480-AS 683 AM02521-SS 1074 10 10 0.820 AD01556 AM02543-AS 694 AM02554-SS 1079 2 2 0.174 AD01557 AM02544-AS 695 AM02554-SS 1079 2 2 0.440 AD01558 AM02543-AS 694 AM02555-SS 1080 2 2 0.436 AD01559 AM02544-AS 695 AM02555-SS 1080 2 2 0.090 AD01560 AM02543-AS 694 AM02556-SS 1081 2 2 0.274 AD01561 AM02544-AS 695 AM02556-SS 1081 2 2 0.209 AD01577 AM02631-AS 699 AM02634-SS 1086 2 2 0.790 AD01578 AM02631-AS 699 AM02637-SS 1089 2 2 0.688 AD01579 AM02632-AS 700 AM02635-SS 1087 2 2 0.538 AD01580 AM02632-AS 700 AM02638-SS 1090 2 2 0.663 AD01581 AM02633-AS 701 AM02636-SS 1088 2 2 0.575 AD01582 AM02633-AS 701 AM02639-SS 1091 2 2 0.697 AD01583 AM02640-AS 702 AM02490-SS 1056 2 2 0.126 AD01598 AM02199-AS 644 AM02581-SS 1083 10 10 0.579 AD01599 AM02579-AS 696 AM02271-SS 1016 10 10 1.150 AD01600 AM02200-AS 645 AM02584-SS 1085 10 10 0.825 AD01601 AM02582-AS 697 AM02273-SS 1018 10 10 0.838 AD01602 AM02650-AS 711 AM02652-SS 1094 10 10 0.422 AD01603 AM02172-AS 641 AM02652-SS 1094 10 10 0.567 AD01604 AM02650-AS 711 AM02272-SS 1017 10 10 0.456 AD01968 AM02656-AS 712 AM03117-SS 1176 10 2.5 0.223 AD01969 AM02656-AS 712 AM03118-SS 1177 10 2.5 0.404 AD02066 AM02656-AS 712 AM03181-SS 1198 5 5 0.021 AD02067 AM02656-AS 712 AM03182-SS 1199 5 5 0.030 AD02068 AM02656-AS 712 AM03183-SS 1200 5 5 0.038 AD02639 AM03157-AS 791 AM03398-SS 1228 2 2 0.090 AD02640 AM03157-AS 791 AM03399-SS 1229 2 2 0.165 AD02661 AM03410-AS 820 AM03423-SS 1247 1 1 0.582 AD02668 AM03157-AS 791 AM03432-SS 1252 1 1 0.249 AD02669 AM03157-AS 791 AM03438-SS 1258 1 1 0.239 AD02670 AM03157-AS 791 AM03434-SS 1254 1 1 0.190 AD02671 AM03157-AS 791 AM03439-SS 1259 1 1 0.246 AD02672 AM03157-AS 791 AM03436-SS 1256 1 1 0.305 AD02673 AM03410-AS 820 AM03440-SS 1260 1 1 0.873 AD02765 AM03157-AS 791 AM03571-SS 1276 0.4 4 0.010 AD02766 AM03157-AS 791 AM03573-SS 1278 0.4 4 0.013 AD02767 AM03157-AS 791 AM03575-SS 1280 0.4 4 0.014 AD02768 AM03580-AS 829 AM03577-SS 1282 0.4 4 0.011 AD02769 AM03157-AS 791 AM03579-SS 1284 0.4 4 0.014 AD02770 AM03581-AS 830 AM03579-SS 1284 0.4 4 0.018 AD02771 AM03584-AS 831 AM02500-SS 1064 2 2 0.285 AD02772 AM02507-AS 693 AM03586-SS 1287 2 2 0.700 AD02773 AM03585-AS 832 AM03587-SS 1288 2 2 0.546 AD01393 AM02208-AS 647 AM02328-SS 1021 10 0.671 AD01447 AM02208-AS 647 AM02403-SS 1039 20 0.706 AD01550 AM02172-AS 641 AM02550-SS 1077 10 0.607 AD01605 AM02208-AS 647 AM02653-SS 1095 10 0.689 AD01607 AM02474-AS 680 AM02655-SS 1097 10 0.794 AD01608 AM02656-AS 712 AM02653-SS 1095 10 0.356 AD01610 AM02657-AS 713 AM02655-SS 1097 10 0.637 AD01611 AM02658-AS 714 AM02655-SS 1097 10 0.857 AD01612 AM02659-AS 715 AM02655-SS 1097 10 0.786 AD01613 AM02660-AS 716 AM02655-SS 1097 10 0.843 AD01614 AM02661-AS 717 AM02655-SS 1097 10 0.841 AD01615 AM02662-AS 718 AM02655-SS 1097 10 1.007 AD01616 AM02474-AS 680 AM02663-SS 1098 10 1.149 AD01617 AM02658-AS 714 AM02663-SS 1098 10 0.845 AD01618 AM02659-AS 715 AM02663-SS 1098 10 1.060 AD01619 AM02660-AS 716 AM02663-SS 1098 10 1.056 AD01620 AM02661-AS 717 AM02663-SS 1098 10 0.978 AD01621 AM02662-AS 718 AM02663-SS 1098 10 1.174 AD01622 AM02474-AS 680 AM02664-SS 1099 10 0.980 AD01623 AM02658-AS 714 AM02664-SS 1099 10 0.909 AD01624 AM02659-AS 715 AM02664-SS 1099 10 1.134 AD01627 AM02662-AS 718 AM02664-SS 1099 10 1.135 AD01628 AM02474-AS 680 AM02665-SS 1100 10 0.936 AD01629 AM02658-AS 714 AM02665-SS 1100 10 1.076 AD01630 AM02659-AS 715 AM02665-SS 1100 10 1.107 AD01633 AM02662-AS 718 AM02665-SS 1100 10 1.113 AD01775 AM02474-AS 680 AM02867-SS 1138 10 0.660 AD01776 AM02474-AS 680 AM02868-SS 1139 10 0.619 AD01777 AM02474-AS 680 AM02869-SS 1140 10 0.735 AD01834 AM02953-AS 766 AM02956-SS 1144 10 0.324 AD01838 AM02953-AS 766 AM02956-SS 1144 10 0.355 AD01839 AM02962-AS 767 AM02956-SS 1144 10 0.320 AD01840 AM02963-AS 768 AM02956-SS 1144 10 0.392 AD01841 AM02964-AS 769 AM02956-SS 1144 10 0.463 AD01842 AM02965-AS 770 AM02956-SS 1144 10 0.116 AD01843 AM02966-AS 771 AM02956-SS 1144 10 0.179 AD01844 AM02967-AS 772 AM02956-SS 1144 10 0.179 AD01845 AM02968-AS 773 AM02956-SS 1144 10 0.223 AD01846 AM02969-AS 774 AM02956-SS 1144 10 0.270 AD01847 AM02970-AS 775 AM02956-SS 1144 10 0.193 AD01848 AM02971-AS 776 AM02956-SS 1144 10 0.165 AD01849 AM02953-AS 766 AM02960-SS 1145 10 0.380 AD01850 AM02953-AS 766 AM02960-SS 1145 10 0.482 AD01851 AM02962-AS 767 AM02960-SS 1145 10 0.104 AD01852 AM02963-AS 768 AM02960-SS 1145 10 0.212 AD01853 AM02964-AS 769 AM02960-SS 1145 10 0.119 AD01854 AM02965-AS 770 AM02960-SS 1145 10 0.067 AD01855 AM02966-AS 771 AM02960-SS 1145 10 0.049 AD01856 AM02967-AS 772 AM02960-SS 1145 10 0.034 AD01857 AM02968-AS 773 AM02960-SS 1145 10 0.068 AD01858 AM02969-AS 774 AM02960-SS 1145 10 0.096 AD01859 AM02970-AS 775 AM02960-SS 1145 10 0.057 AD01860 AM02971-AS 776 AM02960-SS 1145 10 0.052 AD01861 AM02953-AS 766 AM02961-SS 1146 10 0.433 AD01862 AM02953-AS 766 AM02961-SS 1146 10 0.332 AD01863 AM02962-AS 767 AM02961-SS 1146 10 0.087 AD01864 AM02963-AS 768 AM02961-SS 1146 10 0.093 AD01865 AM02964-AS 769 AM02961-SS 1146 10 0.048 AD01866 AM02965-AS 770 AM02961-SS 1146 10 0.027 AD01867 AM02966-AS 771 AM02961-SS 1146 10 0.096 AD01868 AM02967-AS 772 AM02961-SS 1146 10 0.044 AD01869 AM02968-AS 773 AM02961-SS 1146 10 0.044 AD01870 AM02969-AS 774 AM02961-SS 1146 10 0.080 AD01871 AM02970-AS 775 AM02961-SS 1146 10 0.050 AD01872 AM02971-AS 776 AM02961-SS 1146 10 0.050 AD01874 AM02656-AS 712 AM02974-SS 1147 10 0.498 AD01942 AM02707-AS 735 AM03071-SS 1164 10 0.826 AD01943 AM02711-AS 739 AM03072-SS 1165 10 0.195 AD01944 AM02714-AS 742 AM03073-SS 1166 10 0.520 AD01945 AM02715-AS 743 AM03074-SS 1167 10 0.781 AD01946 AM03075-AS 781 AM03071-SS 1164 10 0.967 AD01947 AM03076-AS 782 AM03072-SS 1165 10 0.459 AD01948 AM03077-AS 783 AM03073-SS 1166 10 0.727 AD01949 AM03078-AS 784 AM03074-SS 1167 10 0.972 AD01953 AM02656-AS 712 AM03083-SS 1168 5 0.353 AD01954 AM02656-AS 712 AM03084-SS 1169 5 0.449 AD01955 AM02656-AS 712 AM03085-SS 1170 5 0.538 AD01966 AM02656-AS 712 AM03114-SS 1174 5 0.510 AD01967 AM02656-AS 712 AM03115-SS 1175 5 0.481 AD01970 AM03109-AS 785 AM02653-SS 1095 5 0.786 AD01971 AM03110-AS 786 AM02653-SS 1095 5 0.611 AD01972 AM03111-AS 787 AM02653-SS 1095 5 0.665 AD01973 AM02656-AS 712 AM03112-SS 1172 5 0.112 AD01974 AM02656-AS 712 AM03113-SS 1173 5 0.436 AD01975 AM03109-AS 785 AM03112-SS 1172 5 0.444 AD01991 AM02656-AS 712 AM03132-SS 1178 5 0.151 AD01992 AM02656-AS 712 AM03133-SS 1179 5 0.381 AD01993 AM02656-AS 712 AM03135-SS 1180 5 0.149 AD01994 AM02656-AS 712 AM03137-SS 1182 5 0.903 AD01999 AM02656-AS 712 AM03142-SS 1187 5 0.587 AD02000 AM02657-AS 713 AM03143-SS 1188 5 0.673 AD02012 AM02967-AS 772 AM03152-SS 1192 3 0.288 AD02013 AM02967-AS 772 AM03153-SS 1193 3 0.265 AD02014 AM03154-AS 788 AM02961-SS 1146 3 0.125 AD02015 AM03154-AS 788 AM03152-SS 1192 3 0.307 AD02016 AM03154-AS 788 AM03153-SS 1193 3 0.433 AD02017 AM03155-AS 789 AM02961-SS 1146 3 0.118 AD02018 AM03155-AS 789 AM03152-SS 1192 3 0.462 AD02019 AM03155-AS 789 AM03153-SS 1193 3 0.438 AD02020 AM03156-AS 790 AM02961-SS 1146 3 0.100 AD02021 AM03156-AS 790 AM03152-SS 1192 3 0.262 AD02022 AM03156-AS 790 AM03153-SS 1193 3 0.242 AD02023 AM03157-AS 791 AM02961-SS 1146 3 0.070 AD02024 AM03157-AS 791 AM03152-SS 1192 3 0.252 AD02025 AM03157-AS 791 AM03153-SS 1193 3 0.202 AD02045 AM02656-AS 712 AM03177-SS 1194 5 0.644 AD02046 AM02656-AS 712 AM03178-SS 1195 5 0.615 AD02047 AM02656-AS 712 AM03179-SS 1196 5 0.521 AD02056 AM02971-AS 776 AM03209-SS 1201 3 0.103 AD02057 AM03211-AS 800 AM03209-SS 1201 3 0.225 AD02058 AM03211-AS 800 AM02961-SS 1146 3 0.116 AD02059 AM03211-AS 800 AM03210-SS 1202 3 0.104 AD02060 AM02971-AS 776 AM03210-SS 1202 3 0.066 AD02061 AM03212-AS 801 AM02961-SS 1146 3 0.127 AD02062 AM02971-AS 776 AM03213-SS 1203 3 0.043 AD02063 AM03212-AS 801 AM03213-SS 1203 3 0.171 AD02064 AM03215-AS 802 AM03214-SS 1204 5 0.149 AD02065 AM02656-AS 712 AM03217-SS 1205 5 0.195 AD02069 AM02656-AS 712 AM03218-SS 1206 5 0.693 AD02459 AM02966-AS 771 AM03046-SS 1157 5 0.310 AD02460 AM02967-AS 772 AM03327-SS 1207 3 0.232 AD02461 AM02967-AS 772 AM03329-SS 1209 3 0.336 AD02562 AM02967-AS 772 AM03339-SS 1211 2 0.357 AD02564 AM03342-AS 803 AM03072-SS 1165 2 0.867 AD02565 AM03343-AS 804 AM03072-SS 1165 2 1.131 AD02566 AM03344-AS 805 AM03072-SS 1165 2 0.884 AD02567 AM03345-AS 806 AM03072-SS 1165 2 0.839 AD02568 AM03346-AS 807 AM03072-SS 1165 2 1.030 AD02569 AM03347-AS 808 AM03072-SS 1165 2 0.759 AD02570 AM03348-AS 809 AM03072-SS 1165 2 1.025 AD02571 AM03349-AS 810 AM03072-SS 1165 2 1.074 AD02572 AM03350-AS 811 AM03072-SS 1165 2 1.027 AD02573 AM03351-AS 812 AM03072-SS 1165 2 0.820 AD02574 AM03352-AS 813 AM03072-SS 1165 2 0.807 AD02575 AM03353-AS 814 AM03072-SS 1165 2 0.918 AD02576 AM02711-AS 739 AM03354-SS 1212 2 0.447 AD02577 AM02711-AS 739 AM03355-SS 1213 2 0.718 AD02578 AM02711-AS 739 AM03356-SS 1214 2 0.293 AD02579 AM02711-AS 739 AM03357-SS 1215 2 0.322 AD02580 AM02711-AS 739 AM03358-SS 1216 2 0.854 AD02581 AM03359-AS 815 AM03072-SS 1165 2 0.833 AD02582 AM03359-AS 815 AM03354-SS 1212 2 0.503 AD02583 AM03359-AS 815 AM03355-SS 1213 2 0.588 AD02584 AM03359-AS 815 AM03356-SS 1214 2 0.382 AD02585 AM03359-AS 815 AM03357-SS 1215 2 0.488 AD02586 AM03359-AS 815 AM03358-SS 1216 2 0.810 AD02587 AM02714-AS 742 AM03360-SS 1217 2 1.056 AD02588 AM02714-AS 742 AM03361-SS 1218 2 1.023 AD02589 AM02714-AS 742 AM03362-SS 1219 2 1.380 AD02590 AM02714-AS 742 AM03363-SS 1220 2 0.963 AD02591 AM02714-AS 742 AM03364-SS 1221 2 1.111 AD02592 AM03365-AS 816 AM03073-SS 1166 2 1.084 AD02593 AM03365-AS 816 AM03360-SS 1217 2 0.922 AD02594 AM03365-AS 816 AM03361-SS 1218 2 1.197 AD02595 AM03365-AS 816 AM03362-SS 1219 2 1.003 AD02596 AM03365-AS 816 AM03363-SS 1220 2 0.888 AD02597 AM03365-AS 816 AM03364-SS 1221 2 1.073 AD02598 AM03366-AS 817 AM03073-SS 1166 2 1.283 AD02599 AM03366-AS 817 AM03360-SS 1217 2 1.004 AD02600 AM03366-AS 817 AM03361-SS 1218 2 1.074 AD02601 AM03366-AS 817 AM03362-SS 1219 2 1.066 AD02602 AM03366-AS 817 AM03363-SS 1220 2 0.972 AD02603 AM03366-AS 817 AM03364-SS 1221 2 0.918 AD02634 AM02967-AS 772 AM02960-SS 1145 2 0.348 AD02635 AM03154-AS 788 AM02960-SS 1145 3 0.348 AD02636 AM03155-AS 789 AM02960-SS 1145 3 0.247 AD02637 AM03156-AS 790 AM02960-SS 1145 3 0.156 AD02638 AM03157-AS 791 AM02960-SS 1145 3 0.181 AD02642 AM03157-AS 791 AM03402-SS 1232 10 0.033 AD02643 AM03157-AS 791 AM03339-SS 1211 3 0.176 AD02644 AM03157-AS 791 AM03403-SS 1233 3 0.164 AD02645 AM03157-AS 791 AM03404-SS 1234 3 0.264 AD02646 AM03157-AS 791 AM03405-SS 1235 3 0.580 AD02647 AM03157-AS 791 AM03406-SS 1236 3 0.174 AD02648 AM03410-AS 820 AM03407-SS 1237 3 0.614 AD02649 AM03410-AS 820 AM03408-SS 1238 3 0.537 AD02650 AM03410-AS 820 AM03409-SS 1239 3 0.629 AD02651 AM03157-AS 791 AM03411-SS 1240 3 0.299 AD02652 AM03157-AS 791 AM03412-SS 1241 3 0.289 AD02653 AM03157-AS 791 AM03413-SS 1242 3 0.171 AD02654 AM03157-AS 791 AM03414-SS 1243 3 0.226 AD02655 AM03415-AS 821 AM03402-SS 1232 3 0.290 AD02656 AM03416-AS 822 AM03402-SS 1232 3 0.294 AD02657 AM03417-AS 823 AM03402-SS 1232 3 0.134 AD02658 AM03418-AS 824 AM03402-SS 1232 3 0.218 AD02659 AM03419-AS 825 AM03402-SS 1232 3 0.278 AD02665 AM03410-AS 820 AM03428-SS 1248 3 0.241 AD02666 AM03410-AS 820 AM03429-SS 1249 3 0.151 AD02667 AM03410-AS 820 AM03430-SS 1250 3 0.160 AD02688 AM03157-AS 791 AM03456-SS 1261 3 0.304 AD02689 AM03157-AS 791 AM03464-SS 1263 3 0.207 AD02690 AM03157-AS 791 AM03463-SS 1262 3 0.254 AD02700 AM03410-AS 820 AM03476-SS 1264 3 0.335 AD02701 AM03410-AS 820 AM03477-SS 1265 3 0.430 AD02702 AM03410-AS 820 AM03478-SS 1266 3 0.297 AD02703 AM03410-AS 820 AM03479-SS 1267 3 0.308 AD02704 AM03410-AS 820 AM03480-SS 1268 3 0.288 AD02705 AM03410-AS 820 AM03481-SS 1269 3 0.435 AD02706 AM03410-AS 820 AM03482-SS 1270 3 0.915 AD02707 AM03483-AS 826 AM03402-SS 1232 3 0.245 AD02708 AM03484-AS 827 AM03402-SS 1232 3 0.121 AD02709 AM03485-AS 828 AM03402-SS 1232 3 0.974 AD02774 AM03589-AS 833 AM03591-SS 1290 3 0.625 AD02775 AM03590-AS 834 AM03591-SS 1290 3 0.649 AD02776 AM03590-AS 834 AM03592-SS 1291 3 0.565 AD02777 AM03157-AS 791 AM03588-SS 1289 3 0.277 AD02803 AM03157-AS 791 AM03629-SS 1293 3 0.377 AD02804 AM03157-AS 791 AM03630-SS 1294 3 0.337 AD02806 AM03157-AS 791 AM03631-SS 1295 3 0.317 AD02807 AM03157-AS 791 AM03632-SS 1296 3 0.205 AD02808 AM03157-AS 791 AM03633-SS 1297 3 0.519 AD02809 AM03410-AS 820 AM03634-SS 1298 3 0.610 AD02810 AM03157-AS 791 AM03635-SS 1299 3 0.268 AD02811 AM03157-AS 791 AM03636-SS 1300 3 0.242 AD02812 AM03157-AS 791 AM03637-SS 1301 3 0.238 AD02813 AM03410-AS 820 AM03638-SS 1302 3 0.759 AD02814 AM03157-AS 791 AM03639-SS 1303 3 0.223 AD02815 AM03157-AS 791 AM03640-SS 1304 3 0.212 AD02816 AM03157-AS 791 AM03641-SS 1305 3 0.455 AD02817 AM03410-AS 820 AM03642-SS 1306 3 0.524 AD02822 AM03581-AS 830 AM03653-SS 1359 3 0.164 AD02823 AM03157-AS 791 AM03653-SS 1359 3 0.285 AD02824 AM03157-AS 791 AM03654-SS 1360 3 0.152 AD02867 AM03157-AS 791 AM03703-SS 1363 3 0.036 AD02868 AM03157-AS 791 AM03704-SS 1364 3 0.034 AD02872 AM03417-AS 823 AM03413-SS 1242 3 0.170

TABLE 11 Serum F12 protein levels in wild-type mice following administration of 8 mg/kg RNAi trigger with 8 mg/kg MLP delivery polymer. mF12 levels were normalized to pre-treatment and saline control. F12 levels Day day day day day day day treatment −4 4 8 15 22 29 36 Saline 1.000 1.000 ± 0.158 1.000 ± 0.133 1.000 ± 0.239 1.000 ± 0.179 1.000 ± 0.131 1.000 ± 0.303 RD 10694 1.000 1.075 ± 0.032  1.26 ± 0.071 0.778 ± 0.60  0.977 ± 0.037 0.778 ± 0.060 1.030 ± 0.102 (control) AD00897 1.000 0.092 ± 0.006 0.007 ± 0.001 0.007 ± 0.005 0.031 ± 0.015 0.148 ± 0.081 0.639 ± 0.186 AD00898 1.000 0.104 ± 0.013 0.007 ± 0.002 0.024 ± 0.004 0.142 ± 0.039 0.571 ± 0.165 0.907 ± 0.147 AD00899 1.000 0.090 ± 0.004 0.009 ± 0.000 0.041 ± 0.019 0.114 ± 0.070 0.262 ± 0.055 0.580 ± 0.096 AD00900 1.000 0.084 ± 0.012 0.007 ± 0.002 0.014 ± 0.005 0.016 ± 0.003 0.033 ± 0.010 0.123 ± 0.025 AD00901 1.000 0.101 ± 0.014 0.020 ± 0.004 0.043 ± 0.005 0.068 ± 0.019 0.176 ± 0.059 0.491 ± 0.097 AD00902 1.000 0.111 ± 0.022 0.012 ± 0.005 0.022 ± 0.007 0.040 ± 0.024 0.132 ± 0.054 0.441 ± 0.131 F12 levels day day day day day treatment 43 50 57 63 71 Saline 1.000 ± 0.150 1.000 ± 0.076 1.000 ± 0.047 1.000 ± 0.099 1.000 ± 0.100 RD 10694 0.846 ± 0.067 0.832 ± 0.221 0.968 ± 0.070 0.916 ± 0.064 0.936 ± 0.062 (control) AD00897 0.875 ± 0.172 0.873 ± 0.134 0.924 ± 0.107 0.952 ± 0.130 1.013 ± 0.195 AD00898 1.098 ± 0.084 0.997 ± 0.079 1.073 ± 0.051 1.077 ± 0.041 1.059 ± 0.063 AD00899 0.791 ± 0.067 0.905 ± 0.069 0.959 ± 0.053 0.978 ± 0.079 1.059 ± 0.091 AD00900 0.207 ± 0.038 0.331 ± 0.068 0.569 ± 0.104 0.784 ± 0.027 0.961 ± 0.094 AD00901 0.630 ± 0.147 0.566 ± 0.369 0.871 ± 0.119 0.909 ± 0.084 1.083 ± 0.120 AD00902 0.647 ± 0.194 0.778 ± 0.167 0.887 ± 0.139 0.967 ± 0.148 1.055 ± 0.166

TABLE 12 Serum F12 protein levels in C57/B6 mice following administration of 2 mg/kg canonical or UNA-containing RNAi triggers with 2 mg/kg MLP delivery polymer. mF12 levels were normalized to pre-treatment and saline control. Day 3 Day 8 Day 15 Day 22 Day 29 Day 36 Day 43 Day 50 Day 57 saline 1.00 ± 0.09 1.00 ± 0.13 1.00 ± 0.12 1.00 ± 0.07 1.00 ± 0.26 1.00 ± 0.10 1.00 ± 0.20 1.00 ± 0.11 1.00 ± 0.04 RD10694 0.93 ± 0.06 1.03 ± 0.05 0.97 ± 0.05 0.95 ± 0.08 1.44 ± 0.09 1.09 ± 0.58 AD00897 0.17 ± 0.05 0.07 ± 0.00 0.27 ± 0.03 0.67 ± 0.13 1.07 ± 0.27 1.44 ± 0.27 AD00898 0.21 ± 0.01 0.26 ± 0.16 0.66 ± 0.19 0.89 ± 0.06 1.23 ± 0.45 1.14 ± 0.77 AD00899 0.18 ± 0.01 0.10 ± 0.04 0.23 ± 0.08 0.38 ± 0.11 1.09 ± 0.15 1.25 ± 0.61 0.98 ± 0.07 0.92 ± 0.13 0.97 ± 0.22 AD00900 0.21 ± 0.03 0.09 ± 0.04 0.20 ± 0.06 0.35 ± 0.09 1.01 ± 0.21 1.11 ± 0.13 0.87 ± 0.09 0.93 ± 0.03 0.89 ± 0.28 AD00901 0.35 ± 0.03 0.37 ± 0.07 0.55 ± 0.04 0.74 ± 0.03 1.72 ± 0.11 0.65 ± 0.09 AD00902 0.21 ± 0.01 0.10 ± 0.03 0.22 ± 0.04 0.42 ± 0.09 0.84 ± 0.02 1.15 ± 0.34 AD00897 0.28 ± 0.04 0.31 ± 0.11 0.70 ± 0.11 1.00 ± 0.08 1.52 ± 0.48 1.09 ± 0.77 AD00999 0.17 ± 0.03 0.19 ± 0.03 0.71 ± 0.05 0.98 ± 0.02 1.58 ± 0.03 1.53 ± 0.42 AD01000 0.17 ± 0.02 0.05 ± 0.01 0.18 ± 0.03 0.40 ± 0.10 0.66 ± 0.05 0.74 ± 0.12 0.91 ± 0.06 0.92 ± 0.11 1.10 ± 0.13 AD01001 0.16 ± 0.02 0.05 ± 0.02 0.12 ± 0.04 0.23 ± 0.08 0.63 ± 0.17 0.85 ± 0.20 0.73 ± 0.13 0.83 ± 0.25 1.03 ± 0.23 AD01002 0.25 ± 0.04 0.25 ± 0.09 0.38 ± 0.09 0.64 ± 0.08 1.07 ± 0.37 0.96 ± 0.66 AD01003 0.29 ± 0.06 0.13 ± 0.07 0.26 ± 0.10 0.58 ± 0.21 1.27 ± 0.05 1.67 ± 0.13 AD01004 0.29 ± 0.02 0.14 ± 0.02 0.24 ± 0.07 0.52 ± 0.07 0.93 ± 0.19 1.48 ± 0.14 AD01005 0.39 ± 0.06 0.46 ± 0.17 0.89 ± 0.20 1.11 ± 0.08 1.33 ± 0.32 1.16 ± 0.61 AD01006 0.35 ± 0.02 0.27 ± 0.14 0.46 ± 0.25 0.66 ± 0.25 1.27 ± 0.26 1.76 ± 0.17 0.93 ± 0.06 0.93 ± 0.01 0.99 ± 0.29 AD01007 0.27 ± 0.02 0.13 ± 0.01 0.15 ± 0.03 0.22 ± 0.05 0.58 ± 0.10 0.69 ± 0.15 0.61 ± 0.11 0.85 ± 0.04  0.9 ± 0.26 AD01008 0.36 ± 0.04 0.26 ± 0.08 0.35 ± 0.09 0.53 ± 0.14 1.02 ± 0.10 1.10 ± 0.61 AD01109 0.35 ± 0.09 0.23 ± 0.09 0.39 ± 0.17 0.73 ± 0.16 1.10 ± 0.41 1.29 ± 0.23

TABLE 13 Relative serum F12 protein levels in C57/B6 mice following administration of 0.5 mg/kg modified F12 RNAi triggers with 2 mg/kg MLP delivery polymer. mF12 levels were normalized to pre-treatment and saline control. Treatment Day 4 Day 8 Day 15 Day 22 Day 29 Day 36 Day 43 Saline 1.00 ± 0.07 1.00 ± 0.06 1.00 ± 0.39 1.00 ± 0.17 1.00 ± 0.08 1.00 ± 0.07 1.00 ± 0.03 AD01000 0.26 ± 0.07 0.34 ± 0.15 1.25 ± 0.38 0.79 ± 0.14 0.89 ± 0.05 0.95 ± 0.12 AD01001 0.18 ± 0.02 0.17 ± 0.02 0.34 ± 0.05 0.35 ± 0.10 0.62 ± 0.02 0.85 ± 0.05 1.03 ± 0.10 AD01003 0.19 ± 0.01 0.20 ± 0.03 0.62 ± 0.02 0.56 ± 0.16 0.86 ± 0.09 0.97 ± 0.14 AD01007 0.27 ± 0.09 0.15 ± 0.08 0.39 ± 0.06 0.40 ± 0.01 0.76 ± 0.13 0.98 ± 0.26 1.25 ± 0.49 AD01115 0.20 ± 0.12 0.28 ± 0.18 0.95 ± 0.62 0.92 ± 0.48 1.19 ± 0.62 1.32 ± 0.65 AD01116 0.23 ± 0.12 0.20 ± 0.14 0.45 ± 0.33 0.54 ± 0.37 0.74 ± 0.37 1.03 ± 0.52 1.20 ± 0.79 AD01117 0.27 ± 0.03 0.29 ± 0.03 0.73 ± 0.03 0.73 ± 0.03 0.96 ± 0.11 1.09 ± 0.07 AD01118 0.28 ± 0.11 0.27 ± 0.11 0.55 ± 0.22 0.63 ± 0.10 0.84 ± 0.18 1.15 ± 0.29 0.85 ± 0.18 AD01124 0.23 ± 0.09 0.16 ± 0.09 0.38 ± 0.19 0.40 ± 0.18 0.68 ± 0.28 0.98 ± 0.26 1.09 ± 0.38 AD01125 0.27 ± 0.12 0.33 ± 0.12 0.96 ± 0.09 0.85 ± 0.04 1.02 ± 0.10 1.16 ± 0.13 AD01126 0.25 ± 0.02 0.30 ± 0.05 0.73 ± 0.10 0.68 ± 0.06 0.91 ± 0.06 1.12 ± 0.15 1.20 ± 0.07 AD01127 0.55 ± 0.19 0.53 ± 0.25 1.24 ± 0.25 0.85 ± 0.04 1.09 ± 0.14 1.13 ± 0.08

TABLE 14 Relative serum F12 protein levels in C57/B6 mice following administration of 0.5 mg/kg modified F12 RNAi triggers with 2 mg/kg MLP delivery polymer. mF12 levels were normalized to pre-treatment and saline control. Treatment Day 4 Day 8 Day 15 Day 22 Day 29 Day 36 Day 43 Day 53 Saline 1.00 ± 0.12 1.00 ± 0.33 1.00 ± 0.07 1.00 ± 0.08 1.00 ± 0.06 1.00 ± 0.05 1.00 ± 0.07 1.00 ± 0.09 AD01001 0.13 ± 0.03 0.09 ± 0.04 0.20 ± 0.09 0.32 ± 0.11 0.55 ± 0.09 0.73 ± 0.09 0.84 ± 0.12 0.93 ± 0.07 AD01007 0.39 ± 0.25 0.38 ± 0.29 0.59 ± 0.35 0.71 ± 0.37 0.83 ± 0.21 1.11 ± 0.32 0.90 ± 0.12 1.02 ± 0.16 AD01111 0.17 ± 0.01 0.16 ± 0.05 0.37 ± 0.08 0.54 ± 0.16 0.89 ± 0.09 1.02 ± 0.10 0.93 ± 0.06 0.96 ± 0.08 AD01112 0.29 ± 0.21 0.34 ± 0.32 0.63 ± 0.35 0.61 ± 0.13 1.02 ± 0.17 1.12 ± 0.12 1.03 ± 0.13 1.03 ± 0.10 AD01119 0.44 ± 0.10 0.46 ± 0.12 0.64 ± 0.09 1.02 ± 0.11 0.95 ± 0.02 1.00 ± 0.08 0.90 ± 0.08 0.93 ± 0.05 AD01120 0.37 ± 0.18 0.50 ± 0.20 0.75 ± 0.24 0.94 ± 0.12 1.00 ± 0.06 0.96 ± 0.09 0.98 ± 0.09 0.93 ± 0.09 AD01121 0.44 ± 0.11 0.28 ± 0.18 0.50 ± 0.14 0.65 ± 0.12 0.92 ± 0.10 1.02 ± 0.06 0.91 ± 0.10 0.95 ± 0.01 AD01122 0.14 ± 0.04 0.15 ± 0.08 0.29 ± 0.09 0.43 ± 0.05 0.73 ± 0.12 0.90 ± 0.02 0.82 ± 0.08 0.97 ± 0.10 AD01123 0.23 ± 0.04 0.26 ± 0.07 0.48 ± 0.11 0.67 ± 0.10 0.90 ± 0.11 0.91 ± 0.15 0.90 ± 0.06 1.08 ± 0.11 AD01128 0.33 ± 0.11 0.33 ± 0.17 0.42 ± 0.37 0.86 ± 0.38 0.96 ± 0.11 0.98 ± 0.04 0.92 ± 0.09 0.98 ± 0.19

TABLE 15 Relative serum F12 protein levels in C57/B6 mice following administration of 0.5 mg/kg modified F12 RNAi triggers with 2 mg/kg MLP delivery polymer. mF12 levels were normalized to pre-treatment and saline control. Treatment Day 4 Day 8 Day 15 Day 22 Day 29 Day 36 Day 43 Saline 1.00 ± 0.15 1.00 ± 0.13 1.00 ± 0.07 1.00 ± 0.11 1.00 ± 0.10 1.00 ± 0.08 1.00 ± 0.15 AD01000 0.24 ± 0.11 0.29 ± 0.18 0.50 ± 0.20 0.68 ± 0.18 0.95 ± 0.13 0.89 ± 0.06 0.97 ± 0.09 AD01003 0.19 ± 0.04 0.25 ± 0.09 0.43 ± 0.13 0.64 ± 0.11 0.86 ± 0.03 0.86 ± 0.06 1.00 ± 0.12 AD01109 0.24 ± 0.06 0.31 ± 0.16 0.74 ± 0.15 0.79 ± 0.09 0.86 ± 0.12 0.87 ± 0.05 0.92 ± 0.14 AD01110 0.26 ± 0.03 0.34 ± 0.07 0.78 ± 0.01 0.80 ± 0.06 0.94 ± 0.04 0.85 ± 0.09 0.82 ± 0.09 AD01113 0.29 ± 0.10 0.30 ± 0.04 0.71 ± 0.05 0.88 ± 0.11 1.02 ± 0.08 1.02 ± 0.09 0.94 ± 0.08 AD01114 0.64 ± 0.25 0.91 ± 0.32 1.05 ± 0.15 1.02 ± 0.08 0.85 ± 0.06 0.89 ± 0.12 0.94 ± 0.04

TABLE 16 Relative serum F12 protein levels in C57/B6 mice following administration of 0.5 mg/kg modified F12 RNAi triggers with 2 mg/kg MLP delivery polymer. mF12 levels were normalized to pre-treatment and saline control. Day treatment 4 8 15 22 29 36 43 50 57 Saline 1.00 ± 0.13 1.00 ± 0.10 1.00 ± 0.07 1.00 ± 0.08 1.00 ± 0.04 1.00 ± 0.12 1.00 ± 0.09 1.00 ± 0.11 1.00 ± 0.11 AD01001 0.12 ± 0.02 0.08 ± 0.02 0.17 ± 0.05 0.36 ± 0.07 0.46 ± 0.06 0.69 ± 0.15 0.83 ± 0.15 0.89 ± 0.11 1.05 ± 0.28 AD01126 0.34 ± 0.16 0.39 ± 0.16 0.60 ± 0.17 0.88 ± 0.04 0.87 ± 0.22 0.95 ± 0.10 0.94 ± 0.09 0.95 ± 0.11 1.00 ± 0.08 AD01181 0.16 ± 0.03 0.15 ± 0.03 0.29 ± 0.09 0.51 ± 0.09 0.69 ± 0.08 0.69 ± 0.08 0.90 ± 0.10 0.87 ± 0.15 0.97 ± 0.14 AD01007 0.19 ± 0.02 0.16 ± 0.04 0.30 ± 0.07 0.49 ± 0.11 0.64 ± 0.07 0.77 ± 0.07 0.87 ± 0.15 0.92 ± 0.04 0.88 ± 0.11 AD01118 0.22 ± 0.07 0.18 ± 0.09 0.37 ± 0.16 0.52 ± 0.19 0.69 ± 0.17 0.76 ± 0.16 0.90 ± 0.10 0.96 ± 0.11 0.94 ± 0.18 AD01182 0.19 ± 0.04 0.17 ± 0.07 0.31 ± 0.10 0.50 ± 0.15 0.67 ± 0.15 0.86 ± 0.16 0.85 ± 0.18 0.92 ± 0.09 0.90 ± 0.13

Example 6. In Vivo Dose Response of Select F12 RNAi Triggers and Time Course of F12 Knockdown

To further characterize in vivo activity of select RNAi triggers, activity of multiple dose levels were examined in a single experiment. For studies with MLP delivery polymer (IV), both the amount of RNAi trigger dosed and the amount of delivery polymer was adjusted, so that the dose ratio varied. Dosing and mF12 levels were monitored as described above. Relative serum mF12 levels following administration of RNAi triggers over the time of the experiment is shown (see Tables 17 and 18, FIGS. 2 and 3).

Example 7. In Vivo Multiple Dose Studies of Select F12 RNAi Triggers and Time Course of F12 Knockdown

Select triggers were chosen to examine using multiple dose dosing schemes. The most commonly used dosing scheme was three weekly doses and monitoring mF12 levels as described above. This multiple dose dosing scheme was used most often for SQ-delivered triggers. Relative serum mF12 levels following administration of RNAi triggers over time is shown in FIG. 4.

TABLE 17 Serum F12 protein levels in C57/B6 mice following administration of 0.5, 1, or 2 mg/kg UNA-containing RNAi triggers with 2 mg/kg MLP delivery polymer. mF12 levels were normalized to pre-treatment and saline control [trigger] Treatment (mg/kg) Day 4 Day 8 Day 15 Day 22 Day 29 Saline 1.00 ± 0.25 1.00 ± 0.28 1.00 ± 0.13 1.00 ± 0.39 1.00 ± 0.19 AD01000 2 0.14 ± 0.01 0.06 ± 0.04 0.19 ± 0.07 0.67 ± 0.27 0.72 ± 0.17 1 0.18 ± 0.03 0.13 ± 0.08 0.29 ± 0.11 0.74 ± 0.30 0.81 ± 0.05 0.5 0.21 ± 0.06 0.17 ± 0.08 0.38 ± 0.15 0.90 ± 0.10 0.89 ± 0.13 AD01001 2 0.13 ± 0.03 0.03 ± 0.01 0.03 ± 0.01 0.22 ± 0.11 0.29 ± 0.10 1 0.15 ± 0.01 0.06 ± 0.03 0.05 ± 0.02 0.40 ± 0.12 0.54 ± 0.15 0.5 0.18 ± 0.03 0.13 ± 0.06 0.24 ± 0.10 0.55 ± 0.19 0.57 ± 0.12 AD01003 2 0.18 ± 0.03 0.06 ± 0.02 0.19 ± 0.04 0.63 ± 0.13 0.80 ± 0.15 1 0.21 ± 0.03 0.10 ± 0.01 0.28 ± 0.06 0.87 ± 0.15 0.78 ± 0.13 0.5 0.29 ± 0.10 0.19 ± 0.12 0.42 ± 0.21 1.12 ± 0.33 1.11 ± 0.46 Treatment Day 36 Day 43 Day 50 Day 57 Saline 1.00 ± 0.12 1.00 ± 0.31 1.00 ± 0.16 1.00 ± 0.15 AD01000 0.81 ± 0.13 1.16 ± 0.16 0.86 ± 0.15 1.30 ± 0.13 0.81 ± 0.10 1.12 ± 0.24 AD01001 0.52 ± 0.12 0.80 ± 0.17 0.75 ± 0.26 0.93 ± 0.08 0.65 ± 0.13 1.00 ± 0.21 0.90 ± 0.17 0.93 ± 0.14 0.72 ± 0.08 1.02 ± 0.23 0.93 ± 0.16 0.94 ± 0.07 AD01003 0.84 ± 0.17 1.05 ± 0.30 0.95 ± 0.08 1.34 ± 0.19 0.99 ± 0.27 1.34 ± 0.33

TABLE 18 Relative serum F12 protein levels in mice following administration of 2 or 4 mg/kg dose of AD01001 RNAi triggers with 1, 2, 4 or 8 mg/kg of MLP delivery polymer. F12 levels were normalized to pre-treatment and saline control. trigger MLP Day treatment mg/kg mg/kg 4 8 15 22 29 Saline 1.00 ± 0.03 1.00 ± 0.05 1.00 ± 0.03 1.00 ± 0.01 1.00 ± 0.06 AD01001 4 8 0.07 ± 0.01 0.01 ± 0.00 0.01 ± 0.00 0.03 ± 0.01 0.06 ± 0.02 4 4 0.08 ± 0.05 0.05 ± 0.06 0.09 ± 0.14 0.15 ± 0.20 0.24 ± 0.22 4 2 0.09 ± 0.02 0.08 ± 0.03 0.16 ± 0.08 0.28 ± 0.12 0.42 ± 0.14 2 4 0.06 ± 0.01 0.04 ± 0.01 0.05 ± 0.03 0.11 ± 0.06 0.23 ± 0.10 2 2 0.10 ± 0.02 0.07 ± 0.02 0.12 ± 0.05 0.24 ± 0.06 0.39 ± 0.10 2 1 0.27 ± 0.13 0.35 ± 0.16 0.41 ± 0.03 0.72 ± 0.17 0.75 ± 0.12 Day treatment 36 43 50 57 Saline 1.00 ± 0.19 1.00 ± 0.06 1.00 ± 0.19 1.00 ± 0.06 AD01001 0.18 ± 0.05 0.32 ± 0.08 0.54 ± 0.06 0.78 ± 0.12 0.36 ± 0.25 0.52 ± 0.19 0.75 ± 0.14 0.73 ± 0.09 0.65 ± 0.18 0.69 ± 0.09 0.79 ± 0.19 0.79 ± 0.06 0.38 ± 0.12 0.54 ± 0.16 0.76 ± 0.11 0.74 ± 0.04 0.58 ± 0.11 0.75 ± 0.08 0.85 ± 0.11 0.79 ± 0.07 0.93 ± 0.13 0.93 ± 0.16 0.74 ± 0.13 0.79 ± 0.13

Example 8. Liver F12 mRNA Levels

At the time of euthanization, part or all of the mouse liver was transferred to an appropriate volume of TRI Reagent RT (Molecular Research Center, Inc., Cincinnati, Ohio). Total RNA was isolated following the manufacturer's recommended protocol. Briefly, liver sections in TRI Reagent RT were treated with a tissue homogenizer for approximately 30 sec. 1 mL homogenate was added to 50 μL of 4-bromoanisole, mixed, and phases were separated by centrifugation. 0.25-0.5 mL of aqueous phase was removed, precipitated with isopropyl alcohol, and centrifuged. The resultant pellet was washed with 75% ethanol and suspended in 0.3-0.7 mL nuclease-free water.

Total RNA (˜500 ng) was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (Life Technologies, Grand Island, N.Y.). The cDNA was then diluted 1:5 and multiplex RT-qPCR was performed using 5′ exonuclease chemistry with the commercially available FAM-labeled assay for mouse Factor 12 (Assay ID#Mm00491349_m1, Life Technologies), the VIC-labeled endogenous control assay for mouse beta-actin (Life Technologies) and VeriQuest Master Mix (Affymetrix, Santa Clara, Calif.). Gene expression data were analyzed using the comparative CT method of relative quantification (Livak and Schmittgen, 2001) (Tables 19 and 20).

TABLE 19 Relative serum F12 protein levels in mice following administration of canonical or UNA-containing RNAi trigger 1:1 with MLP delivery polymer. Serum F12 levels were normalized to day 1 and saline control. Treatment Day −1 Day 8 Saline 1.00 ± 0.00 1.00 ± 0.38 AD00900 1.00 ± 0.00 0.01 ± 0.00 AD01000 1.00 ± 0.00 0.01 ± 0.00 AD01001 1.00 ± 0.00 0.01 ± 0.00 AD01003 1.00 ± 0.00 0.02 ± 0.01

TABLE 20 Liver mF12 mRNA levels in mice following administration of canonical or UNA-containing RNAi trigger 1:1 wt./wt. with MLP delivery polymer. F12 mRNA level is expressed relative to mouse β-actin mRNA level. Relative Expression Treatment day 8 Low error High error Saline 1.00 −0.09 +0.09 AD00900 0.05 −0.01 +0.01 AD01000 0.04 −0.00 +0.01 AD01001 0.03 −0.00 +0.00 AD01003 0.05 −0.00 +0.00 AD01520 2 0.07 0.01

Example 9. Examination of Pharmacodynamic (PD) Effects of F12 Reduction after Treatment with F12 RNAi Triggers—Carrageenan Induced Paw Edema (CPE) in Rats

To test that reducing F12 levels leads to effects on the kallikrein/kinin system, we tested the effects of pre-treatment with F12 RNAi triggers on an inflammation model (CPE) in rats. Inflammation induced by λ carrageenan is induced by multiple mediators including bradykinin. Wild-type rats were given a single IV dose of either 8 mg/kg RNAi trigger (AD01520) with 8 mg/kg MLP delivery polymer, or saline. After 7 days, carrageenan was injected into the rear paws of saline or RNAi trigger-treated rats, and paw volume was measured over 6 hours. Change in paw volume over time is plotted in FIG. 9. The difference in paw volume changes between saline and F12 RNAi trigger-treated groups are statistically significant (p<0.0001), and are similar to those seen with treatment of kallikrein-targeted antibody (Kenniston J A et al 2014), indicating a reduction of signaling through the kallikrein/kinin system.

Example 10. Examination of Pharmacodynamic (PD) Effects of F12 Reduction after Treatment with F12 RNAi Triggers—Ferric Chloride Challenge

A clinically relevant indicator of physiologic response to F12 knockdown is the thromboembolism model induced by Ferric Chloride treatment. Cholesterol-conjugated canonical RNAi triggers were administered to wild-type mice as described above 7 days prior to Ferric Chloride (FeCl3) Challenge. Prior to FeCl3 challenge, F12 levels were measured. Treatment with 4 mg/kg AD01520 and 4 mg/kg MLP delivery polymer resulted in >99% knockdown of mF12 protein in the serum. Thrombosis is induced by exposure of the carotid artery (CA) to ferric chloride and time to occlusion of blood flow is measured by flow probe for up to 30 minutes. All mice treated with F12 RNAi trigger with MLP delivery polymer did not occlude during the timeframe of the experiment (FIG. 10).

Example 11. Examination of Pharmacodynamic (PD) Effects of F12 Reduction after Treatment with F12 RNAi Triggers—Bleeding Risk

A potential risk of some anticoagulant treatments is an increased risk of bleeding events. A Factor VII (F7)-targeted RNAi trigger was used as a positive bleeding control, as F7 is known as a key component of the extrinsic coagulation pathway.

Wild-type mice were given a single IV dose of 8 mg/kg AD01520 with 8 mg/kg MLP delivery polymer, or 8 mg/kg F7 trigger with 8 mg/kg MLP delivery polymer 7 days prior to challenge. Transverse cut of the tail vein was performed, and time to clotting monitored up to 15 minutes. There was no significant difference in bleeding times between saline and AD01520 treated mice (FIG. 11).

Example 12. Factor 12 (F12) Knockdown in Non-Human Primates Following F12 RNAi Trigger Molecule Delivery with MLP Delivery Polymer

MLP delivery polymer and RNAi trigger were made and combined in a pharmaceutically acceptable buffer as described above. On day 1, two cynomolgus macaque (Macaca fascicularis) primates (both male, 5.0 kg and 8.15 kg, respectively) were co-injected with 2 mg/kg RNAi trigger (AD01001) and 2 mg/kg MLP delivery polymer. For each injection, the RNAi trigger+MLP delivery polymer (2 mg/kg) was injected into the saphenous vein using a 22 to 25 gauge intravenous catheter. At the indicated time points (indicated in Tables 21-23), blood samples were drawn and analyzed for F12 levels, coagulation parameters and toxicity markers. Blood was collected from the femoral vein and primates were fasted overnight before all blood collections. Blood tests for blood urea nitrogen (BUN), alanine transaminase (ALT), aspartate aminotransferase (AST), creatinine, and activated Partial thromboplastin time (aPTT) were performed on an automated chemistry analyzer. F12 protein levels in serum were monitored by assaying serum from the monkeys using an ELISA for human F12 (Molecular Innovations) until F12 expression levels returned to baseline. For normalization, F12 levels for each animal at a respective time point was divided by the pre-treatment level of expression in that animal (in this case at day 1) to determine the ratio of expression “normalized to day 1”. Functional readout of F12 knockdown can also be observed through elongation of the activated partial thromboplastin time (aPTT). No changes in Prothrombin time were observed with treatment.

Significant knockdown of F12 was observed with an average maximum knockdown of 92.5% observed at day 15. An increase in aPTT was observed in both animals with maximal increases over pre-bleed values between 50-56% at days 15 and 22, although aPTT did not exceed “normal” values. No dose-related toxicity was observed in treated animals.

TABLE 21 Serum F12 protein levels in cynomolgus macaque (Macaca fascicularis) primates following administration of 2 mg/kg AD01001 with 2 mg/kg MLP delivery polymer. mF12 levels were normalized to pre-dose. pre- Day animal dose 3 8 15 22 29 36 43 50 57 64 71 78 85 1 1.00 0.59 0.13 0.09 0.13 0.20 0.44 0.60 0.58 0.68 1.50 1.46 1.59 1.63 2 1.00 0.42 0.14 0.06 0.08 0.11 0.22 0.25 0.42 0.51 0.70 0.76 0.91 1.01

TABLE 22 Activated Partial Thromboplastin Time (sec) in cynomolgus macaque (Macaca fascicularis) primates following administration of 2 mg/kg AD01001 with 2 mg/kg MLP delivery polymer. Day animal pre-dose 3 8 15 22 29 36 43 50 57 1 32.2 35.4 44.9 48.6 47.5 39.9 42.9 34.3 38.3. 27 2 29.6 25.0 32.0 42.2 46.3 47.4 42.5 45.0 38.1 29.4

TABLE 23 Urea Nitrogen, Creatinine, Alanine transaminase, and Aspartate aminotransferase levels in cynomolgus macaque (Macaca fascicularis) primates following administration of 2 mg/kg AD01001 with 2 mg/kg MLP delivery polymer. day animal pre-dose 3 8 15 22 29 36 43 50 57 Blood Urea Nitrogen (mg/dL) 1 13 13 12 13 14 13 13 14 14 14 2 18 17 15 17 16 14 18 17 19 18 Creatinine (mg/dL) 1 0.76 0.69 0.76 0.79 0.78 0.77 0.77 0.75 0.69 0.78 2 1.03 1.05 0.04 0.99 0.98 1.00 1.08 1.02 1.03 1.01 Alanine transaminase (U/L) 1 45 45 44 43 42 45 45 44 42 41 2 40 44 45 41 38 47 54 50 49 52 Aspartate aminotransferase (U/L) 1 24 27 22 24 28 24 21 31 27 22 2 25 23 23 22 30 22 21 21 24 22

Example 13. Factor 12 (F12) Knockdown in Non-Human Primates Following F12 RNAi Trigger Molecule Delivery

MLP delivery polymer and RNAi trigger were made and combined in a pharmaceutically acceptable buffer as described above. On day 1, two cynomolgus macaque (Macaca fascicularis) primates were co-injected with either 2 mg/kg AD01001 and 2 mg/kg MLP delivery polymer, or 2 mg/kg AD01520 and 2 mg/kg MLP delivery polymer as described above. Blood samples were drawn and analyzed for F12 levels, coagulation parameters and toxicity markers. Blood was collected from the femoral vein and primates were fasted overnight before all blood collections. Blood tests for blood urea nitrogen (BUN), alanine transaminase (ALT), aspartate aminotransferase (AST), creatinine, and activated Partial thromboplastin time (aPTT) were performed on an automated chemistry analyzer. F12 protein levels in serum were monitored by assaying serum from the monkeys using an ELISA for human F12 (Molecular Innovations) until F12 expression levels returned to baseline. For normalization, F12 levels for each animal at a respective time point was divided by the pre-treatment level of expression in that animal (in this case at day 1) to determine the ratio of expression “normalized to day 1”. Functional readout of F12 knockdown can also be observed through elongation of the activated partial thromboplastin time (aPTT). No changes in prothrombin time (PT) were observed with treatment.

Significant knockdown of F12 was observed with an average maximum knockdown of 89% observed at day 15 (FIG. 5). An increase in aPTT was observed in both animals with maximal increases over pre-bleed values of approximately 70%-80% at days 15 and 22, although aPTT did not exceed “normal” values. No dose-related toxicity was observed in treated animals.

Example 14. Factor 12 (F12) Knockdown in Non-Human Primates Following F12 RNAi Trigger Molecule Delivery

MLP delivery polymer and RNAi trigger were made and combined in a pharmaceutically acceptable buffer as described above. On days 1, 29, 57, 85, two cynomolgus macaque (Macaca fascicularis) primates were co-injected with either 2 mg/kg AD01001 and 2 mg/kg MLP delivery polymer, or 2 mg/kg AD01520 and 2 mg/kg MLP delivery polymer as described above. Blood samples were drawn and analyzed for F12 levels, coagulation parameters and toxicity markers. Blood was collected from the femoral vein and primates were fasted overnight before all blood collections. Blood tests for blood urea nitrogen (BUN), alanine transaminase (ALT), aspartate aminotransferase (AST), creatinine, and both prothrombin time (PT) and activated Partial thromboplastin time (aPTT) were performed on an automated chemistry analyzer. F12 protein levels in serum were monitored by assaying serum from the monkeys using an ELISA for human F12 (Molecular Innovations) until F12 expression levels returned to baseline. For normalization, F12 levels for each animal at a respective time point was divided by the pre-treatment level of expression in that animal (in this case at day 1) to determine the ratio of expression “normalized to day 1”. Functional readout of F12 knockdown can also be observed through elongation of the activated partial thromboplastin time (aPTT). No changes in Prothrombin time were observed with treatment.

Significant knockdown of F12 was observed with an average maximum knockdown between 85-93% observed at day 15, and between 95-98% on subsequent doses (FIG. 6). An increase in aPTT was observed in both animals with maximal increases over pre-bleed values observed when F12 levels are at nadir (FIG. 7). No dose-related toxicity nor increase in PT was observed in treated animals over the time of the experiment.

Example 15. Factor 12 (F12) Knockdown in Non-Human Primates Following F12 RNAi Trigger Molecule Delivery

RNAi trigger was made and combined in a pharmaceutically acceptable buffer as described above for subcutaneous (SQ) injection. On day 1, two cynomolgus macaque (Macaca fascicularis) primates were injected with either 3 mg/kg AD02562, or 10 mg/kg AD02562 subcutaneously. Blood samples were drawn and analyzed for F12 levels, coagulation parameters and toxicity markers as previously described.

Knockdown of F12 was observed with an average maximum knockdown of 60% for the 3 mg/kg dose and 84% for the 10 mg/kg dose, observed between days 22 and day 29 (FIG. 8). No dose-related toxicity nor increase in PT was observed in treated animals over the duration of the experiment.

Example 16. Examples of F12 RNAi Trigger Duplexes

TABLE 24 F12 RNAi triggers identified by Duplex ID No. with corresponding sense and antisense strands. Antisense Sense Strand Antisense Sense Strand Duplex ID Strand ID ID Duplex ID Strand ID ID AD00638 AM01377-AS AM01307-SS AD00873 AM01556-AS AM01513-SS AD00639 AM01378-AS AM01308-SS AD01227 AM02060-AS AM02061-SS AD00640 AM01379-AS AM01309-SS AD01228 AM02062-AS AM02063-SS AD00641 AM01380-AS AM01310-SS AD01269 AM02112-AS AM00923-SS AD00642 AM01381-AS AM01311-SS AD01270 AM02113-AS AM00923-SS AD00643 AM01382-AS AM01312-SS AD01302 AM02164-AS AM02168-SS AD00644 AM01383-AS AM01313-SS AD01304 AM02166-AS AM02168-SS AD00645 AM01384-AS AM01314-SS AD01305 AM02167-AS AM02168-SS AD00646 AM01385-AS AM01315-SS AD01306 AM02164-AS AM02169-SS AD00647 AM01386-AS AM01316-SS AD01308 AM02166-AS AM02169-SS AD00648 AM01387-AS AM01317-SS AD01309 AM02167-AS AM02169-SS AD00649 AM01388-AS AM01318-SS AD01480 AM02165-AS AM02459-SS AD00650 AM01389-AS AM01319-SS AD01481 AM02460-AS AM02459-SS AD00651 AM01390-AS AM01320-SS AD01482 AM02461-AS AM02459-SS AD00652 AM01391-AS AM01321-SS AD01483 AM02462-AS AM02459-SS AD00653 AM01392-AS AM01322-SS AD01551 AM02579-AS AM02581-SS AD00654 AM01393-AS AM01323-SS AD01552 AM02582-AS AM02584-SS AD00655 AM01394-AS AM01324-SS AD01553 AM02585-AS AM02274-SS AD00656 AM01395-AS AM01325-SS AD01584 AM02641-AS AM01617-SS AD00657 AM01396-AS AM01326-SS AD01585 AM02642-AS AM01617-SS AD00658 AM01397-AS AM01327-SS AD01586 AM02643-AS AM01617-SS AD00659 AM01399-AS AM01328-SS AD01587 AM02644-AS AM01617-SS AD00660 AM01400-AS AM01329-SS AD01588 AM02645-AS AM01617-SS AD00661 AM01401-AS AM01330-SS AD01589 AM02646-AS AM01617-SS AD00662 AM01402-AS AM01331-SS AD01590 AM02647-AS AM01617-SS AD00663 AM01403-AS AM01332-SS AD01591 AM02648-AS AM01617-SS AD00664 AM01404-AS AM01333-SS AD01592 AM02645-AS AM02649-SS AD00665 AM01405-AS AM01334-SS AD01593 AM02646-AS AM02649-SS AD00666 AM01406-AS AM01335-SS AD01594 AM02647-AS AM02649-SS AD00667 AM01407-AS AM01336-SS AD01595 AM02648-AS AM02649-SS AD00668 AM01408-AS AM01337-SS AD01596 AM00988-AS AM02649-SS AD00669 AM01409-AS AM01338-SS AD01597 AM01629-AS AM02649-SS AD00670 AM01410-AS AM01339-SS AD01606 AM02208-AS AM02654-SS AD00671 AM01411-AS AM01340-SS AD01609 AM02656-AS AM02654-SS AD00672 AM01412-AS AM01341-SS AD01625 AM02660-AS AM02664-SS AD00673 AM01413-AS AM01342-SS AD01626 AM02661-AS AM02664-SS AD00674 AM01414-AS AM01343-SS AD01631 AM02660-AS AM02665-SS AD00675 AM01415-AS AM01344-SS AD01632 AM02661-AS AM02665-SS AD00676 AM01416-AS AM01345-SS AD01634 AM02657-AS AM02666-SS AD00677 AM01417-AS AM01346-SS AD01660 AM02691-AS AM02723-SS AD00678 AM01418-AS AM01347-SS AD01661 AM02692-AS AM02724-SS AD00679 AM01419-AS AM01348-SS AD01662 AM02693-AS AM02725-SS AD00680 AM01420-AS AM01349-SS AD01663 AM02694-AS AM02726-SS AD00681 AM01421-AS AM01350-SS AD01664 AM02695-AS AM02727-SS AD00682 AM01422-AS AM01351-SS AD01665 AM02696-AS AM02728-SS AD00683 AM01423-AS AM01352-SS AD01666 AM02697-AS AM02729-SS AD00684 AM01424-AS AM01353-SS AD01667 AM02698-AS AM02730-SS AD00685 AM01425-AS AM01354-SS AD01668 AM02699-AS AM02731-SS AD00686 AM01426-AS AM01355-SS AD01669 AM02700-AS AM02732-SS AD00687 AM01427-AS AM01356-SS AD01670 AM02701-AS AM02733-SS AD00688 AM01428-AS AM01357-SS AD01671 AM02702-AS AM02734-SS AD00689 AM01429-AS AM01358-SS AD01672 AM02703-AS AM02735-SS AD00690 AM01430-AS AM01359-SS AD01673 AM02704-AS AM02736-SS AD00691 AM01431-AS AM01360-SS AD01674 AM02705-AS AM02737-SS AD00692 AM01432-AS AM01361-SS AD01675 AM02706-AS AM02738-SS AD00693 AM01433-AS AM01362-SS AD01676 AM02707-AS AM02723-SS AD00694 AM01434-AS AM01363-SS AD01677 AM02708-AS AM02724-SS AD00695 AM01435-AS AM01364-SS AD01678 AM02709-AS AM02725-SS AD00696 AM01436-AS AM01365-SS AD01679 AM02710-AS AM02726-SS AD00697 AM01437-AS AM01366-SS AD01680 AM02711-AS AM02727-SS AD00698 AM01438-AS AM01367-SS AD01681 AM02712-AS AM02728-SS AD00699 AM01439-AS AM01368-SS AD01682 AM02713-AS AM02729-SS AD00700 AM01440-AS AM01369-SS AD01683 AM02714-AS AM02730-SS AD00701 AM01441-AS AM01370-SS AD01684 AM02715-AS AM02731-SS AD00702 AM01442-AS AM01371-SS AD01685 AM02716-AS AM02732-SS AD00703 AM01443-AS AM01372-SS AD01686 AM02717-AS AM02733-SS AD00704 AM01444-AS AM01373-SS AD01687 AM02718-AS AM02734-SS AD00705 AM01445-AS AM01374-SS AD01688 AM02719-AS AM02735-SS AD00706 AM01446-AS AM01375-SS AD01689 AM02720-AS AM02736-SS AD00707 AM01447-AS AM01376-SS AD01690 AM02721-AS AM02737-SS AD00831 AM01514-AS AM01471-SS AD01691 AM02722-AS AM02738-SS AD00832 AM01515-AS AM01472-SS AD01692 AM02707-AS AM02739-SS AD00833 AM01516-AS AM01473-SS AD01693 AM02708-AS AM02740-SS AD00834 AM01517-AS AM01474-SS AD01694 AM02709-AS AM02741-SS AD00835 AM01518-AS AM01475-SS AD01695 AM02710-AS AM02742-SS AD00836 AM01519-AS AM01476-SS AD01696 AM02711-AS AM02743-SS AD00837 AM01520-AS AM01477-SS AD01697 AM02712-AS AM02744-SS AD00838 AM01521-AS AM01478-SS AD01698 AM02713-AS AM02745-SS AD00839 AM01522-AS AM01479-SS AD01699 AM02714-AS AM02746-SS AD00840 AM01523-AS AM01480-SS AD01700 AM02715-AS AM02747-SS AD00841 AM01524-AS AM01481-SS AD01701 AM02716-AS AM02748-SS AD00842 AM01525-AS AM01482-SS AD01702 AM02717-AS AM02749-SS AD00843 AM01526-AS AM01483-SS AD01703 AM02718-AS AM02750-SS AD00844 AM01527-AS AM01484-SS AD01704 AM02719-AS AM02751-SS AD00845 AM01528-AS AM01485-SS AD01705 AM02720-AS AM02752-SS AD00846 AM01529-AS AM01486-SS AD01706 AM02721-AS AM02753-SS AD00847 AM01530-AS AM01487-SS AD01707 AM02722-AS AM02754-SS AD00848 AM01531-AS AM01488-SS AD01781 AM02871-AS AM02500-SS AD00849 AM01532-AS AM01489-SS AD01782 AM02871-AS AM02872-SS AD00850 AM01533-AS AM01490-SS AD01783 AM02507-AS AM02872-SS AD00851 AM01534-AS AM01491-SS AD01833 AM02953-AS AM02955-SS AD00852 AM01535-AS AM01492-SS AD01906 AM02656-AS AM03054-SS AD00853 AM01536-AS AM01493-SS AD01907 AM02656-AS AM03055-SS AD00854 AM01537-AS AM01494-SS AD01908 AM02656-AS AM03057-SS AD00855 AM01538-AS AM01495-SS AD01909 AM02847-AS AM02872-SS AD00856 AM01539-AS AM01496-SS AD01950 AM02656-AS AM03044-SS AD00857 AM01540-AS AM01497-SS AD01951 AM02656-AS AM03032-SS AD00858 AM01541-AS AM01498-SS AD01952 AM02656-AS AM03033-SS AD00859 AM01542-AS AM01499-SS AD01995 AM02656-AS AM03138-SS AD00860 AM01543-AS AM01500-SS AD01996 AM02656-AS AM03139-SS AD00861 AM01544-AS AM01501-SS AD01997 AM02656-AS AM03140-SS AD00862 AM01545-AS AM01502-SS AD01998 AM02656-AS AM03141-SS AD00863 AM01546-AS AM01503-SS AD02048 AM02656-AS AM03180-SS AD00864 AM01547-AS AM01504-SS AD02631 AM03157-AS AM03372-SS AD00865 AM01548-AS AM01505-SS AD02632 AM03157-AS AM03373-SS AD00866 AM01549-AS AM01506-SS AD02633 AM03157-AS AM03374-SS AD00867 AM01550-AS AM01507-SS AD02641 AM03157-AS AM03401-SS AD00868 AM01551-AS AM01508-SS AD02660 AM03410-AS AM03421-SS AD00869 AM01552-AS AM01509-SS AD02742 AM03157-AS AM03540-SS AD00870 AM01553-AS AM01510-SS AD02743 AM03157-AS AM03541-SS AD00871 AM01554-AS AM01511-SS AD02818 AM03644-AS AM03436-SS AD00872 AM01555-AS AM01512-SS AD02980 AM03803-AS AM03653-SS AD02833 AM03662-AS AM03402-SS AD02981 AM03804-AS AM03653-SS AD02834 AM03663-AS AM03402-SS AD02982 AM03805-AS AM03653-SS AD02835 AM03664-AS AM03402-SS AD02983 AM03581-AS AM03778-SS AD02836 AM03665-AS AM03402-SS AD02984 AM03787-AS AM03806-SS AD02837 AM03666-AS AM03402-SS AD02985 AM03581-AS AM03807-SS AD02838 AM03667-AS AM03402-SS AD02986 AM03808-AS AM03653-SS AD02839 AM03157-AS AM03669-SS AD02987 AM03808-AS AM03807-SS AD02840 AM03668-AS AM03402-SS AD02988 AM03809-AS AM03726-SS AD02856 AM03157-AS AM03684-SS AD02989 AM03810-AS AM03726-SS AD02867 AM03157-AS AM03703-SS AD02990 AM03811-AS AM03726-SS AD02868 AM03157-AS AM03704-SS AD02992 AM02711-AS AM03813-SS AD02869 AM03589-AS AM03705-SS AD02993 AM02711-AS AM03814-SS AD02870 AM03590-AS AM03705-SS AD02994 AM02711-AS AM03815-SS AD02871 AM03590-AS AM03706-SS AD02995 AM02711-AS AM03816-SS AD02885 AM02711-AS AM03729-SS AD02996 AM02711-AS AM03817-SS AD02886 AM03359-AS AM03729-SS AD02997 AM02711-AS AM03818-SS AD02887 AM02711-AS AM03730-SS AD02998 AM03809-AS AM03812-SS AD02888 AM03359-AS AM03730-SS AD02999 AM03810-AS AM03812-SS AD02889 AM03732-AS AM03726-SS AD03000 AM03811-AS AM03812-SS AD02890 AM03736-AS AM03726-SS AD03001 AM03809-AS AM03815-SS AD02891 AM03732-AS AM03729-SS AD03002 AM03810-AS AM03815-SS AD02892 AM03736-AS AM03729-SS AD03003 AM03811-AS AM03815-SS AD02893 AM03349-AS AM03726-SS AD03004 AM03809-AS AM03818-SS AD02894 AM03350-AS AM03726-SS AD03005 AM03810-AS AM03818-SS AD02895 AM03351-AS AM03726-SS AD03006 AM03811-AS AM03818-SS AD02896 AM03733-AS AM03726-SS AD03007 AM03819-AS AM03653-SS AD02897 AM03353-AS AM03726-SS AD03008 AM03820-AS AM03653-SS AD02898 AM03734-AS AM03726-SS AD03009 AM03821-AS AM03653-SS AD02899 AM03359-AS AM03727-SS AD03010 AM03822-AS AM03653-SS AD02900 AM03359-AS AM03728-SS AD03014 AM03832-AS AM03726-SS AD02901 AM03735-AS AM03731-SS AD03015 AM03833-AS AM03726-SS AD02902 AM03737-AS AM03731-SS AD03016 AM03832-AS AM03834-SS AD02903 AM03157-AS AM03738-SS AD03017 AM03833-AS AM03834-SS AD02904 AM03157-AS AM03739-SS AD03018 AM02711-AS AM03834-SS AD02905 AM03732-AS AM03730-SS AD03019 AM03581-AS AM03632-SS AD02906 AM03736-AS AM03730-SS AD03020 AM03581-AS AM03836-SS AD02950 AM03581-AS AM03654-SS AD03021 AM03787-AS AM03836-SS AD02951 AM03581-AS AM03775-SS AD03022 AM03581-AS AM03838-SS AD02952 AM03785-AS AM03653-SS AD03023 AM03581-AS AM03840-SS AD02953 AM03786-AS AM03775-SS AD03024 AM03581-AS AM03842-SS AD02954 AM03581-AS AM03776-SS AD03025 AM03581-AS AM03844-SS AD02955 AM03581-As AM03777-SS AD03026 AM03803-AS AM03632-SS AD02956 AM03787-AS AM03776-SS AD03027 AM03804-AS AM03632-SS AD02957 AM03785-AS AM03778-SS AD03028 AM03805-AS AM03632-SS AD02958 AM03581-AS AM03779-SS AD03029 AM03581-AS AM03846-SS AD02959 AM03788-AS AM03653-SS AD03030 AM03581-AS AM03848-SS AD02960 AM03581-AS AM03780-SS AD03031 AM03581-AS AM03850-SS AD02961 AM03789-AS AM03775-SS AD03032 AM03851-AS AM03632-SS AD02962 AM03789-AS AM03781-SS AD03033 AM03852-AS AM03632-SS AD02963 AM03581-AS AM03781-SS AD03034 AM03853-AS AM03632-SS AD02964 AM03790-AS AM03781-SS AD03035 AM03854-AS AM03632-SS AD02965 AM03791-AS AM03775-SS AD03036 AM03851-AS AM03846-SS AD02966 AM03792-AS AM03775-SS AD03037 AM03852-AS AM03846-SS AD02967 AM03793-AS AM03775-SS AD03038 AM03853-AS AM03846-SS AD02968 AM03794-AS AM03775-SS AD03039 AM03854-AS AM03846-SS AD02969 AM03581-AS AM03782-SS AD03040 AM03851-AS AM03848-SS AD02970 AM03581-AS AM03783-SS AD03041 AM03852-AS AM03848-SS AD02971 AM03581-AS AM03784-SS AD03042 AM03853-AS AM03848-SS AD02972 AM03795-AS AM03775-SS AD03043 AM03854-AS AM03848-SS AD02973 AM03796-AS AM03775-SS AD03044 AM03851-AS AM03850-SS AD02974 AM03797-AS AM03775-SS AD03045 AM03852-AS AM03850-SS AD02975 AM03798-AS AM03775-SS AD03046 AM03853-AS AM03850-SS AD02976 AM03799-AS AM03402-SS AD03047 AM03854-AS AM03850-SS AD02977 AM03581-AS AM03800-SS AD03048 AM03855-AS AM03402-SS AD02978 AM03581-AS AM03801-SS AD03076 AM03851-AS AM03886-SS AD02979 AM03581-AS AM03802-SS

Other Embodiments

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims. 

The invention claimed is:
 1. A method for inhibiting Factor XII gene expression in a subject, the method comprising: administering to the subject a therapeutically effective amount of a composition comprising an RNA interference (RNAi) trigger capable of inhibiting the expression of an F12 gene, wherein the RNAi trigger comprises a sense strand and an antisense strand, wherein the antisense strand comprises the nucleotide sequence of nucleotides 2 to 19 (5′ to 3′) of SEQ ID NO: 1417 (GGUCUUUCACUUUCUUGG) and all of the nucleotides of the antisense strand are modified nucleotides, and wherein the sense strand is at least substantially complementary to the antisense strand and all of the nucleotides of the sense strand are modified nucleotides.
 2. The method of claim 1, wherein: (i) the modified nucleotides of the antisense strand of the RNAi trigger are independently selected from the group consisting of: 2′-O-methyl nucleotide and 2′-Fluoro nucleotide; and (ii) the modified nucleotides of the sense strand of the RNAi trigger are independently selected from the group consisting of 2′-O-methyl nucleotide and 2′-Fluoro nucleotide.
 3. The method of claim 1, wherein the sense strand or the antisense strand of the RNAi trigger comprises one or more phosphorothioate internucleotide linkages.
 4. The method of claim 3, wherein the sense strand of the RNAi agent comprises one or two phosphorothioate internucleotide linkages.
 5. The method of claim 3, wherein the antisense strand of the RNAi agent comprises one, two, three, or four phosphorothioate internucleotide linkages.
 6. The method of claim 1, wherein the RNAi agent comprises a targeting group conjugated to the sense strand.
 7. The method of claim 6, wherein the targeting group comprises a cholesterol or cholesteryl derivative.
 8. The method of claim 6, wherein the targeting group comprises an asialoglycoprotein receptor ligand.
 9. The method of claim 8, wherein the asialoglycoprotein receptor ligand comprises a galactose cluster.
 10. The method of claim 9, wherein the galactose cluster comprises an N-acetyl-galactosamine trimer.
 11. The method of claim 1, wherein the sense strand of the RNAi agent comprises the nucleotide sequence of SEQ ID NO: 1385 (CCAAGAAAGUGAAAGACCA).
 12. The method of claim 11, wherein the RNAi trigger comprises ADO 1520 (SEQ ID NO: 1064 and SEQ ID NO:693), AD02023 (SEQ ID NO: 1146 and SEQ ID NO:791), AD00900 (SEQ ID NO:986 and SEQ ID NO:461), AD01001 (SEQ ID NO:986 and SEQ ID NO:604), AD02562 (SEQ ID NO: 1211 and SEQ ID NO:772), AD02639 (SEQ ID NO: 1228 and SEQ ID NO:791), AD02640 (SEQ ID NO: 1229 and SEQ ID NO:791), AD02642 (SEQ ID NO: 1232 and SEQ ID NO:791), AD02708 (SEQ ID NO: 1232 and SEQ ID NO:827), AD02807 (SEQ ID NO: 1296 and SEQ ID NO:791), AD02822 (SEQ ID NO: 1359 and SEQ ID NO:830), AD02867 (SEQ ID NO: 1363 and SEQ ID NO:791), or AD02868 (SEQ ID NO:1364 and SEQ ID NO:791).
 13. The method of claim 12, wherein the composition is administered to the subject by subcutaneous injection or intravenous infusion or injection.
 14. A method for the treatment of diseases or conditions associated with angioedema, including hereditary angioedema and venous thromboembolism, in a human subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a composition comprising an RNA interference (RNAi) trigger capable of inhibiting the expression of an F12 gene, wherein the RNAi trigger comprises a sense strand and an antisense strand, wherein said antisense strand comprises nucleotides 2 to 19 (5′ to 3′) of SEQ ID NO: 1417 (GGUCUUUCACUUUCUUGG) and all of the nucleotides of the antisense strand are modified nucleotides, and wherein the sense strand is at least substantially complementary to the antisense strand and all of the nucleotides of the sense strand are modified nucleotides.
 15. The method of claim 14, wherein: (i) the modified nucleotides of the antisense strand of the RNAi trigger are independently selected from the group consisting of: 2′-O-methyl nucleotide and 2′-Fluoro nucleotide; and (ii) the modified nucleotides of the sense strand of the RNAi trigger are independently selected from the group consisting of: 2′-O-methyl nucleotide and 2′-Fluoro nucleotide.
 16. The method of claim 14, wherein the sense strand or the antisense strand of the RNAi trigger comprises one or more phosphorothioate internucleotide linkages.
 17. The method of claim 16, wherein the sense strand of the RNAi agent comprises one or two phosphorothioate internucleotide linkages.
 18. The method of claim 16, wherein the antisense strand of the RNAi agent comprises one, two, three, or four phosphorothioate internucleotide linkages.
 19. The method of claim 14, wherein the RNAi agent comprises a targeting group conjugated to the sense strand.
 20. The method of claim 19, wherein the targeting group comprises a cholesterol or cholesteryl derivative.
 21. The method of claim 19, wherein the targeting group comprises an asialoglycoprotein receptor ligand.
 22. The method of claim 21, wherein the asialoglycoprotein receptor ligand comprises a galactose cluster.
 23. The method of claim 22, wherein the galactose cluster comprises an N-acetyl-galactosamine trimer.
 24. The method of claim 14, wherein the sense strand of the RNAi agent comprises SEQ ID NO: 1385 (CCAAGAAAGUGAAAGACCA).
 25. The method of claim 24, wherein the RNAi trigger comprises AD01520 (SEQ ID NO: 1064 and SEQ ID NO:693), AD02023 (SEQ ID NO: 1146 and SEQ ID NO:791), AD00900 (SEQ ID NO:986 and SEQ ID NO:461), AD01001 (SEQ ID NO:986 and SEQ ID NO:604), AD02562 (SEQ ID NO: 1211 and SEQ ID NO:772), AD02639 (SEQ ID NO:1228 and SEQ ID NO:791), AD02640 (SEQ ID NO: 1229 and SEQ ID NO:791), AD02642 (SEQ ID NO: 1232 and SEQ ID NO:791), AD02708 (SEQ ID NO: 1232 and SEQ ID NO:827), AD02807 (SEQ ID NO: 1296 and SEQ ID NO:791), AD02822 (SEQ ID NO:1359 and SEQ ID NO:830), AD02867 (SEQ ID NO:1363 and SEQ ID NO:791), or AD02868 (SEQ ID NO:1364 and SEQ ID NO:791).
 26. The method of claim 25, wherein the composition is administered to the subject by subcutaneous injection or intravenous infusion or injection. 